#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Selective functional connectivity abnormality of the transition zone of the inferior parietal lobule in schizophrenia
#Text=Structural and functional alterations in the inferior parietal lobule (IPL) in schizophrenia have been frequently reported; however, the IPL connectivity changes in schizophrenia remain largely unknown.
1-1	0-9	Selective	_
1-2	10-20	functional	_
1-3	21-33	connectivity	_
1-4	34-45	abnormality	_
1-5	46-48	of	_
1-6	49-52	the	_
1-7	53-63	transition	_
1-8	64-68	zone	_
1-9	69-71	of	_
1-10	72-75	the	_
1-11	76-84	inferior	_
1-12	85-93	parietal	_
1-13	94-100	lobule	_
1-14	101-103	in	_
1-15	104-117	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	118-128	Structural	_
1-17	129-132	and	_
1-18	133-143	functional	_
1-19	144-155	alterations	_
1-20	156-158	in	_
1-21	159-162	the	_
1-22	163-171	inferior	_
1-23	172-180	parietal	_
1-24	181-187	lobule	_
1-25	188-189	(	_
1-26	189-192	IPL	_
1-27	192-193	)	_
1-28	194-196	in	_
1-29	197-210	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	211-215	have	_
1-31	216-220	been	_
1-32	221-231	frequently	_
1-33	232-240	reported	_
1-34	240-241	;	_
1-35	242-249	however	_
1-36	249-250	,	_
1-37	251-254	the	_
1-38	255-258	IPL	_
1-39	259-271	connectivity	_
1-40	272-279	changes	_
1-41	280-282	in	_
1-42	283-296	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-43	297-303	remain	_
1-44	304-311	largely	_
1-45	312-319	unknown	_
1-46	319-320	.	_

#Text=Based on heterogeneity of the IPL in structure, connection and function, we hypothesize that the resting-state functional connectivities (rsFCs) of the IPL subregions are differentially affected in schizophrenia.
2-1	321-326	Based	_
2-2	327-329	on	_
2-3	330-343	heterogeneity	_
2-4	344-346	of	_
2-5	347-350	the	_
2-6	351-354	IPL	_
2-7	355-357	in	_
2-8	358-367	structure	_
2-9	367-368	,	_
2-10	369-379	connection	_
2-11	380-383	and	_
2-12	384-392	function	_
2-13	392-393	,	_
2-14	394-396	we	_
2-15	397-408	hypothesize	_
2-16	409-413	that	_
2-17	414-417	the	_
2-18	418-431	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-19	432-442	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-20	443-457	connectivities	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-21	458-459	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-22	459-464	rsFCs	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-23	464-465	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]
2-24	466-468	of	_
2-25	469-472	the	_
2-26	473-476	IPL	_
2-27	477-487	subregions	_
2-28	488-491	are	_
2-29	492-506	differentially	_
2-30	507-515	affected	_
2-31	516-518	in	_
2-32	519-532	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-33	532-533	.	_

#Text=This study included 95 schizophrenia patients and 104 healthy controls.
3-1	534-538	This	_
3-2	539-544	study	_
3-3	545-553	included	_
3-4	554-556	95	_
3-5	557-570	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
3-6	571-579	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
3-7	580-583	and	_
3-8	584-587	104	_
3-9	588-595	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-10	596-604	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-11	604-605	.	_

#Text=The IPL subregions were defined according to a previous in vivo connection-based parcellation study.
4-1	606-609	The	_
4-2	610-613	IPL	_
4-3	614-624	subregions	_
4-4	625-629	were	_
4-5	630-637	defined	_
4-6	638-647	according	_
4-7	648-650	to	_
4-8	651-652	a	_
4-9	653-661	previous	_
4-10	662-664	in	_
4-11	665-669	vivo	_
4-12	670-686	connection-based	_
4-13	687-699	parcellation	_
4-14	700-705	study	_
4-15	705-706	.	_

#Text=We calculated the rsFC of each IPL subregion and compared them between the two groups while controlling for the effects of age, gender, and grey matter volume.
5-1	707-709	We	_
5-2	710-720	calculated	_
5-3	721-724	the	_
5-4	725-729	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-5	730-732	of	_
5-6	733-737	each	_
5-7	738-741	IPL	_
5-8	742-751	subregion	_
5-9	752-755	and	_
5-10	756-764	compared	_
5-11	765-769	them	_
5-12	770-777	between	_
5-13	778-781	the	_
5-14	782-785	two	_
5-15	786-792	groups	_
5-16	793-798	while	_
5-17	799-810	controlling	_
5-18	811-814	for	_
5-19	815-818	the	_
5-20	819-826	effects	_
5-21	827-829	of	_
5-22	830-833	age	_
5-23	833-834	,	_
5-24	835-841	gender	_
5-25	841-842	,	_
5-26	843-846	and	_
5-27	847-851	grey	_
5-28	852-858	matter	_
5-29	859-865	volume	_
5-30	865-866	.	_

#Text=Among the six subregions of the left IPL and the five subregions of the right IPL, only the bilateral PFm (a transition zone of the IPL) subregions exhibited abnormal rsFC in schizophrenia.
6-1	867-872	Among	_
6-2	873-876	the	_
6-3	877-880	six	_
6-4	881-891	subregions	_
6-5	892-894	of	_
6-6	895-898	the	_
6-7	899-903	left	_
6-8	904-907	IPL	_
6-9	908-911	and	_
6-10	912-915	the	_
6-11	916-920	five	_
6-12	921-931	subregions	_
6-13	932-934	of	_
6-14	935-938	the	_
6-15	939-944	right	_
6-16	945-948	IPL	_
6-17	948-949	,	_
6-18	950-954	only	_
6-19	955-958	the	_
6-20	959-968	bilateral	_
6-21	969-972	PFm	_
6-22	973-974	(	_
6-23	974-975	a	_
6-24	976-986	transition	_
6-25	987-991	zone	_
6-26	992-994	of	_
6-27	995-998	the	_
6-28	999-1002	IPL	_
6-29	1002-1003	)	_
6-30	1004-1014	subregions	_
6-31	1015-1024	exhibited	_
6-32	1025-1033	abnormal	_
6-33	1034-1038	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
6-34	1039-1041	in	_
6-35	1042-1055	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-36	1055-1056	.	_

#Text=Specifically, the left PFm showed increased rsFC with the bilateral lingual gyri in schizophrenia patients than in healthy controls.
7-1	1057-1069	Specifically	_
7-2	1069-1070	,	_
7-3	1071-1074	the	_
7-4	1075-1079	left	_
7-5	1080-1083	PFm	_
7-6	1084-1090	showed	_
7-7	1091-1100	increased	_
7-8	1101-1105	rsFC	_
7-9	1106-1110	with	_
7-10	1111-1114	the	_
7-11	1115-1124	bilateral	_
7-12	1125-1132	lingual	_
7-13	1133-1137	gyri	_
7-14	1138-1140	in	_
7-15	1141-1154	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
7-16	1155-1163	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
7-17	1164-1168	than	_
7-18	1169-1171	in	_
7-19	1172-1179	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
7-20	1180-1188	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
7-21	1188-1189	.	_

#Text=The right PFm exhibited increased rsFC with the right lingual gyrus and inferior occipital gyrus, and bilateral mid-cingulate and sensorimotor cortices in schizophrenia patients.
8-1	1190-1193	The	_
8-2	1194-1199	right	_
8-3	1200-1203	PFm	_
8-4	1204-1213	exhibited	_
8-5	1214-1223	increased	_
8-6	1224-1228	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
8-7	1229-1233	with	_
8-8	1234-1237	the	_
8-9	1238-1243	right	_
8-10	1244-1251	lingual	_
8-11	1252-1257	gyrus	_
8-12	1258-1261	and	_
8-13	1262-1270	inferior	_
8-14	1271-1280	occipital	_
8-15	1281-1286	gyrus	_
8-16	1286-1287	,	_
8-17	1288-1291	and	_
8-18	1292-1301	bilateral	_
8-19	1302-1315	mid-cingulate	_
8-20	1316-1319	and	_
8-21	1320-1332	sensorimotor	_
8-22	1333-1341	cortices	_
8-23	1342-1344	in	_
8-24	1345-1358	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
8-25	1359-1367	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
8-26	1367-1368	.	_

#Text=These findings suggest a selective rsFC abnormality in the IPL subregions in schizophrenia, characterized by the increased rsFC between the PFm subregion of the IPL and the visual and sensorimotor areas.
9-1	1369-1374	These	_
9-2	1375-1383	findings	_
9-3	1384-1391	suggest	_
9-4	1392-1393	a	_
9-5	1394-1403	selective	_
9-6	1404-1408	rsFC	_
9-7	1409-1420	abnormality	_
9-8	1421-1423	in	_
9-9	1424-1427	the	_
9-10	1428-1431	IPL	_
9-11	1432-1442	subregions	_
9-12	1443-1445	in	_
9-13	1446-1459	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-14	1459-1460	,	_
9-15	1461-1474	characterized	_
9-16	1475-1477	by	_
9-17	1478-1481	the	_
9-18	1482-1491	increased	_
9-19	1492-1496	rsFC	_
9-20	1497-1504	between	_
9-21	1505-1508	the	_
9-22	1509-1512	PFm	_
9-23	1513-1522	subregion	_
9-24	1523-1525	of	_
9-25	1526-1529	the	_
9-26	1530-1533	IPL	_
9-27	1534-1537	and	_
9-28	1538-1541	the	_
9-29	1542-1548	visual	_
9-30	1549-1552	and	_
9-31	1553-1565	sensorimotor	_
9-32	1566-1571	areas	_
9-33	1571-1572	.	_

#Text=Highlights
#Text=Investigation of the subregional-level rsFC changes of the IPL in schizophrenia
#Text=The PFm is only IPL subregion with significant rsFC changes in schizophrenia.
10-1	1573-1583	Highlights	_
10-2	1584-1597	Investigation	_
10-3	1598-1600	of	_
10-4	1601-1604	the	_
10-5	1605-1622	subregional-level	_
10-6	1623-1627	rsFC	_
10-7	1628-1635	changes	_
10-8	1636-1638	of	_
10-9	1639-1642	the	_
10-10	1643-1646	IPL	_
10-11	1647-1649	in	_
10-12	1650-1663	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-13	1664-1667	The	_
10-14	1668-1671	PFm	_
10-15	1672-1674	is	_
10-16	1675-1679	only	_
10-17	1680-1683	IPL	_
10-18	1684-1693	subregion	_
10-19	1694-1698	with	_
10-20	1699-1710	significant	_
10-21	1711-1715	rsFC	_
10-22	1716-1723	changes	_
10-23	1724-1726	in	_
10-24	1727-1740	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-25	1740-1741	.	_

#Text=Suggesting a selective rsFC abnormality in the IPL subregions in schizophrenia
#Text=Introduction
#Text=The resting-state functional connectivity (rsFC) has been proposed as a measure of the coherence of the blood-oxygen-level-dependent (BOLD) signal fluctuations between any two spatially remote brain regions.
11-1	1742-1752	Suggesting	_
11-2	1753-1754	a	_
11-3	1755-1764	selective	_
11-4	1765-1769	rsFC	_
11-5	1770-1781	abnormality	_
11-6	1782-1784	in	_
11-7	1785-1788	the	_
11-8	1789-1792	IPL	_
11-9	1793-1803	subregions	_
11-10	1804-1806	in	_
11-11	1807-1820	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-12	1821-1833	Introduction	_
11-13	1834-1837	The	_
11-14	1838-1851	resting-state	_
11-15	1852-1862	functional	_
11-16	1863-1875	connectivity	_
11-17	1876-1877	(	_
11-18	1877-1881	rsFC	_
11-19	1881-1882	)	_
11-20	1883-1886	has	_
11-21	1887-1891	been	_
11-22	1892-1900	proposed	_
11-23	1901-1903	as	_
11-24	1904-1905	a	_
11-25	1906-1913	measure	_
11-26	1914-1916	of	_
11-27	1917-1920	the	_
11-28	1921-1930	coherence	_
11-29	1931-1933	of	_
11-30	1934-1937	the	_
11-31	1938-1966	blood-oxygen-level-dependent	_
11-32	1967-1968	(	_
11-33	1968-1972	BOLD	_
11-34	1972-1973	)	_
11-35	1974-1980	signal	_
11-36	1981-1993	fluctuations	_
11-37	1994-2001	between	_
11-38	2002-2005	any	_
11-39	2006-2009	two	_
11-40	2010-2019	spatially	_
11-41	2020-2026	remote	_
11-42	2027-2032	brain	_
11-43	2033-2040	regions	_
11-44	2040-2041	.	_

#Text=Prior studies have revealed extensive rsFC abnormalities in schizophrenia; and proposed that schizophrenia may be considered as a disorder of connectivity.
12-1	2042-2047	Prior	_
12-2	2048-2055	studies	_
12-3	2056-2060	have	_
12-4	2061-2069	revealed	_
12-5	2070-2079	extensive	_
12-6	2080-2084	rsFC	_
12-7	2085-2098	abnormalities	_
12-8	2099-2101	in	_
12-9	2102-2115	schizophrenia	_
12-10	2115-2116	;	_
12-11	2117-2120	and	_
12-12	2121-2129	proposed	_
12-13	2130-2134	that	_
12-14	2135-2148	schizophrenia	_
12-15	2149-2152	may	_
12-16	2153-2155	be	_
12-17	2156-2166	considered	_
12-18	2167-2169	as	_
12-19	2170-2171	a	_
12-20	2172-2180	disorder	_
12-21	2181-2183	of	_
12-22	2184-2196	connectivity	_
12-23	2196-2197	.	_

#Text=However, much previous attention has been paid on the rsFC changes of the prefrontal cortex, hippocampus, thalamus, and cingulate cortex in schizophrenia, leaving the rsFC changes of the inferior parietal lobule (IPL) in schizophrenia remaining largely unknown.
13-1	2198-2205	However	_
13-2	2205-2206	,	_
13-3	2207-2211	much	_
13-4	2212-2220	previous	_
13-5	2221-2230	attention	_
13-6	2231-2234	has	_
13-7	2235-2239	been	_
13-8	2240-2244	paid	_
13-9	2245-2247	on	_
13-10	2248-2251	the	_
13-11	2252-2256	rsFC	_
13-12	2257-2264	changes	_
13-13	2265-2267	of	_
13-14	2268-2271	the	_
13-15	2272-2282	prefrontal	_
13-16	2283-2289	cortex	_
13-17	2289-2290	,	_
13-18	2291-2302	hippocampus	_
13-19	2302-2303	,	_
13-20	2304-2312	thalamus	_
13-21	2312-2313	,	_
13-22	2314-2317	and	_
13-23	2318-2327	cingulate	_
13-24	2328-2334	cortex	_
13-25	2335-2337	in	_
13-26	2338-2351	schizophrenia	_
13-27	2351-2352	,	_
13-28	2353-2360	leaving	_
13-29	2361-2364	the	_
13-30	2365-2369	rsFC	_
13-31	2370-2377	changes	_
13-32	2378-2380	of	_
13-33	2381-2384	the	_
13-34	2385-2393	inferior	_
13-35	2394-2402	parietal	_
13-36	2403-2409	lobule	_
13-37	2410-2411	(	_
13-38	2411-2414	IPL	_
13-39	2414-2415	)	_
13-40	2416-2418	in	_
13-41	2419-2432	schizophrenia	_
13-42	2433-2442	remaining	_
13-43	2443-2450	largely	_
13-44	2451-2458	unknown	_
13-45	2458-2459	.	_

#Text=The IPL, also known as Geschwind's territory, involves in sensorimotor integration, semantic processing, mathematical cognition, body image, concept of self, and execution, most of which have been reported to be impaired in schizophrenia.
14-1	2460-2463	The	_
14-2	2464-2467	IPL	_
14-3	2467-2468	,	_
14-4	2469-2473	also	_
14-5	2474-2479	known	_
14-6	2480-2482	as	_
14-7	2483-2494	Geschwind's	_
14-8	2495-2504	territory	_
14-9	2504-2505	,	_
14-10	2506-2514	involves	_
14-11	2515-2517	in	_
14-12	2518-2530	sensorimotor	_
14-13	2531-2542	integration	_
14-14	2542-2543	,	_
14-15	2544-2552	semantic	_
14-16	2553-2563	processing	_
14-17	2563-2564	,	_
14-18	2565-2577	mathematical	_
14-19	2578-2587	cognition	_
14-20	2587-2588	,	_
14-21	2589-2593	body	_
14-22	2594-2599	image	_
14-23	2599-2600	,	_
14-24	2601-2608	concept	_
14-25	2609-2611	of	_
14-26	2612-2616	self	_
14-27	2616-2617	,	_
14-28	2618-2621	and	_
14-29	2622-2631	execution	_
14-30	2631-2632	,	_
14-31	2633-2637	most	_
14-32	2638-2640	of	_
14-33	2641-2646	which	_
14-34	2647-2651	have	_
14-35	2652-2656	been	_
14-36	2657-2665	reported	_
14-37	2666-2668	to	_
14-38	2669-2671	be	_
14-39	2672-2680	impaired	_
14-40	2681-2683	in	_
14-41	2684-2697	schizophrenia	_
14-42	2697-2698	.	_

#Text=The IPL lesions, especially in dominant hemisphere, can lead to Gerstmann's syndrome, which is characterized by finger agnosia, right-left confusion, acalculia and agraphia.
15-1	2699-2702	The	_
15-2	2703-2706	IPL	_
15-3	2707-2714	lesions	_
15-4	2714-2715	,	_
15-5	2716-2726	especially	_
15-6	2727-2729	in	_
15-7	2730-2738	dominant	_
15-8	2739-2749	hemisphere	_
15-9	2749-2750	,	_
15-10	2751-2754	can	_
15-11	2755-2759	lead	_
15-12	2760-2762	to	_
15-13	2763-2774	Gerstmann's	_
15-14	2775-2783	syndrome	_
15-15	2783-2784	,	_
15-16	2785-2790	which	_
15-17	2791-2793	is	_
15-18	2794-2807	characterized	_
15-19	2808-2810	by	_
15-20	2811-2817	finger	_
15-21	2818-2825	agnosia	_
15-22	2825-2826	,	_
15-23	2827-2837	right-left	_
15-24	2838-2847	confusion	_
15-25	2847-2848	,	_
15-26	2849-2858	acalculia	_
15-27	2859-2862	and	_
15-28	2863-2871	agraphia	_
15-29	2871-2872	.	_

#Text=Most of these symptoms are frequently reported to be present in schizophrenia patients (even in early stages) and are named as neurological soft signs.
16-1	2873-2877	Most	_
16-2	2878-2880	of	_
16-3	2881-2886	these	_
16-4	2887-2895	symptoms	_
16-5	2896-2899	are	_
16-6	2900-2910	frequently	_
16-7	2911-2919	reported	_
16-8	2920-2922	to	_
16-9	2923-2925	be	_
16-10	2926-2933	present	_
16-11	2934-2936	in	_
16-12	2937-2950	schizophrenia	_
16-13	2951-2959	patients	_
16-14	2960-2961	(	_
16-15	2961-2965	even	_
16-16	2966-2968	in	_
16-17	2969-2974	early	_
16-18	2975-2981	stages	_
16-19	2981-2982	)	_
16-20	2983-2986	and	_
16-21	2987-2990	are	_
16-22	2991-2996	named	_
16-23	2997-2999	as	_
16-24	3000-3012	neurological	_
16-25	3013-3017	soft	_
16-26	3018-3023	signs	_
16-27	3023-3024	.	_

#Text=These studies suggest that the IPL is closely associated with schizophrenia.
17-1	3025-3030	These	_
17-2	3031-3038	studies	_
17-3	3039-3046	suggest	_
17-4	3047-3051	that	_
17-5	3052-3055	the	_
17-6	3056-3059	IPL	_
17-7	3060-3062	is	_
17-8	3063-3070	closely	_
17-9	3071-3081	associated	_
17-10	3082-3086	with	_
17-11	3087-3100	schizophrenia	_
17-12	3100-3101	.	_

#Text=Structural abnormalities of the IPL in schizophrenia, such as grey matter volume (GMV) reduction and cortical thinning, have been frequently reported.
18-1	3102-3112	Structural	_
18-2	3113-3126	abnormalities	_
18-3	3127-3129	of	_
18-4	3130-3133	the	_
18-5	3134-3137	IPL	_
18-6	3138-3140	in	_
18-7	3141-3154	schizophrenia	_
18-8	3154-3155	,	_
18-9	3156-3160	such	_
18-10	3161-3163	as	_
18-11	3164-3168	grey	_
18-12	3169-3175	matter	_
18-13	3176-3182	volume	_
18-14	3183-3184	(	_
18-15	3184-3187	GMV	_
18-16	3187-3188	)	_
18-17	3189-3198	reduction	_
18-18	3199-3202	and	_
18-19	3203-3211	cortical	_
18-20	3212-3220	thinning	_
18-21	3220-3221	,	_
18-22	3222-3226	have	_
18-23	3227-3231	been	_
18-24	3232-3242	frequently	_
18-25	3243-3251	reported	_
18-26	3251-3252	.	_

#Text=Moreover, these structural impairments have been associated with clinical symptoms and duration of illness.
19-1	3253-3261	Moreover	_
19-2	3261-3262	,	_
19-3	3263-3268	these	_
19-4	3269-3279	structural	_
19-5	3280-3291	impairments	_
19-6	3292-3296	have	_
19-7	3297-3301	been	_
19-8	3302-3312	associated	_
19-9	3313-3317	with	_
19-10	3318-3326	clinical	_
19-11	3327-3335	symptoms	_
19-12	3336-3339	and	_
19-13	3340-3348	duration	_
19-14	3349-3351	of	_
19-15	3352-3359	illness	_
19-16	3359-3360	.	_

#Text=Similarly, the functional abnormalities of the IPL have also been revealed in patients with schizophrenia.
20-1	3361-3370	Similarly	_
20-2	3370-3371	,	_
20-3	3372-3375	the	_
20-4	3376-3386	functional	_
20-5	3387-3400	abnormalities	_
20-6	3401-3403	of	_
20-7	3404-3407	the	_
20-8	3408-3411	IPL	_
20-9	3412-3416	have	_
20-10	3417-3421	also	_
20-11	3422-3426	been	_
20-12	3427-3435	revealed	_
20-13	3436-3438	in	_
20-14	3439-3447	patients	_
20-15	3448-3452	with	_
20-16	3453-3466	schizophrenia	_
20-17	3466-3467	.	_

#Text=On the basis of these findings, we hypothesize that the rsFC of the IPL may be also altered in schizophrenia.
21-1	3468-3470	On	_
21-2	3471-3474	the	_
21-3	3475-3480	basis	_
21-4	3481-3483	of	_
21-5	3484-3489	these	_
21-6	3490-3498	findings	_
21-7	3498-3499	,	_
21-8	3500-3502	we	_
21-9	3503-3514	hypothesize	_
21-10	3515-3519	that	_
21-11	3520-3523	the	_
21-12	3524-3528	rsFC	_
21-13	3529-3531	of	_
21-14	3532-3535	the	_
21-15	3536-3539	IPL	_
21-16	3540-3543	may	_
21-17	3544-3546	be	_
21-18	3547-3551	also	_
21-19	3552-3559	altered	_
21-20	3560-3562	in	_
21-21	3563-3576	schizophrenia	_
21-22	3576-3577	.	_

#Text=The IPL is a heterogeneous brain region in cytoarchitecture, connection and function.
22-1	3578-3581	The	_
22-2	3582-3585	IPL	_
22-3	3586-3588	is	_
22-4	3589-3590	a	_
22-5	3591-3604	heterogeneous	_
22-6	3605-3610	brain	_
22-7	3611-3617	region	_
22-8	3618-3620	in	_
22-9	3621-3637	cytoarchitecture	_
22-10	3637-3638	,	_
22-11	3639-3649	connection	_
22-12	3650-3653	and	_
22-13	3654-3662	function	_
22-14	3662-3663	.	_

#Text=On the basis of regional cytoarchitecture, Brodmann has roughly categorized the IPL into the supramarginal gyrus (SMG, BA40) and the angular gyrus (AG, BA39).
23-1	3664-3666	On	_
23-2	3667-3670	the	_
23-3	3671-3676	basis	_
23-4	3677-3679	of	_
23-5	3680-3688	regional	_
23-6	3689-3705	cytoarchitecture	_
23-7	3705-3706	,	_
23-8	3707-3715	Brodmann	_
23-9	3716-3719	has	_
23-10	3720-3727	roughly	_
23-11	3728-3739	categorized	_
23-12	3740-3743	the	_
23-13	3744-3747	IPL	_
23-14	3748-3752	into	_
23-15	3753-3756	the	_
23-16	3757-3770	supramarginal	_
23-17	3771-3776	gyrus	_
23-18	3777-3778	(	_
23-19	3778-3781	SMG	_
23-20	3781-3782	,	_
23-21	3783-3787	BA40	_
23-22	3787-3788	)	_
23-23	3789-3792	and	_
23-24	3793-3796	the	_
23-25	3797-3804	angular	_
23-26	3805-3810	gyrus	_
23-27	3811-3812	(	_
23-28	3812-3814	AG	_
23-29	3814-3815	,	_
23-30	3816-3820	BA39	_
23-31	3820-3821	)	_
23-32	3821-3822	.	_

#Text=A subsequent study further parcellates the IPL into seven subregions: five in the SMG and two in the AG.
24-1	3823-3824	A	_
24-2	3825-3835	subsequent	_
24-3	3836-3841	study	_
24-4	3842-3849	further	_
24-5	3850-3861	parcellates	_
24-6	3862-3865	the	_
24-7	3866-3869	IPL	_
24-8	3870-3874	into	_
24-9	3875-3880	seven	_
24-10	3881-3891	subregions	_
24-11	3891-3892	:	_
24-12	3893-3897	five	_
24-13	3898-3900	in	_
24-14	3901-3904	the	_
24-15	3905-3908	SMG	_
24-16	3909-3912	and	_
24-17	3913-3916	two	_
24-18	3917-3919	in	_
24-19	3920-3923	the	_
24-20	3924-3926	AG	_
24-21	3926-3927	.	_

#Text=However, these cytoarchitecture-based parcellation cannot be easily applied into in vivo imaging studies because of misregistration between cytoarchitectonic and imaging data.
25-1	3928-3935	However	_
25-2	3935-3936	,	_
25-3	3937-3942	these	_
25-4	3943-3965	cytoarchitecture-based	_
25-5	3966-3978	parcellation	_
25-6	3979-3985	cannot	_
25-7	3986-3988	be	_
25-8	3989-3995	easily	_
25-9	3996-4003	applied	_
25-10	4004-4008	into	_
25-11	4009-4011	in	_
25-12	4012-4016	vivo	_
25-13	4017-4024	imaging	_
25-14	4025-4032	studies	_
25-15	4033-4040	because	_
25-16	4041-4043	of	_
25-17	4044-4059	misregistration	_
25-18	4060-4067	between	_
25-19	4068-4085	cytoarchitectonic	_
25-20	4086-4089	and	_
25-21	4090-4097	imaging	_
25-22	4098-4102	data	_
25-23	4102-4103	.	_

#Text=Based on connection properties derived from diffusion MRI, the IPL has been in vivo subdivided into several subregions similar to the cytoarchitectonic parcellation.
26-1	4104-4109	Based	_
26-2	4110-4112	on	_
26-3	4113-4123	connection	_
26-4	4124-4134	properties	_
26-5	4135-4142	derived	_
26-6	4143-4147	from	_
26-7	4148-4157	diffusion	_
26-8	4158-4161	MRI	_
26-9	4161-4162	,	_
26-10	4163-4166	the	_
26-11	4167-4170	IPL	_
26-12	4171-4174	has	_
26-13	4175-4179	been	_
26-14	4180-4182	in	_
26-15	4183-4187	vivo	_
26-16	4188-4198	subdivided	_
26-17	4199-4203	into	_
26-18	4204-4211	several	_
26-19	4212-4222	subregions	_
26-20	4223-4230	similar	_
26-21	4231-4233	to	_
26-22	4234-4237	the	_
26-23	4238-4255	cytoarchitectonic	_
26-24	4256-4268	parcellation	_
26-25	4268-4269	.	_

#Text=Each subregion shows its specific anatomical and functional connectivity patterns.
27-1	4270-4274	Each	_
27-2	4275-4284	subregion	_
27-3	4285-4290	shows	_
27-4	4291-4294	its	_
27-5	4295-4303	specific	_
27-6	4304-4314	anatomical	_
27-7	4315-4318	and	_
27-8	4319-4329	functional	_
27-9	4330-4342	connectivity	_
27-10	4343-4351	patterns	_
27-11	4351-4352	.	_

#Text=More importantly, these connection-based parcellation schemes can be easily applied to in vivo rsFC studies.
28-1	4353-4357	More	_
28-2	4358-4369	importantly	_
28-3	4369-4370	,	_
28-4	4371-4376	these	_
28-5	4377-4393	connection-based	_
28-6	4394-4406	parcellation	_
28-7	4407-4414	schemes	_
28-8	4415-4418	can	_
28-9	4419-4421	be	_
28-10	4422-4428	easily	_
28-11	4429-4436	applied	_
28-12	4437-4439	to	_
28-13	4440-4442	in	_
28-14	4443-4447	vivo	_
28-15	4448-4452	rsFC	_
28-16	4453-4460	studies	_
28-17	4460-4461	.	_

#Text=The differential involvement of the IPL in schizophrenia has been shown in GMV analysis.
29-1	4462-4465	The	_
29-2	4466-4478	differential	_
29-3	4479-4490	involvement	_
29-4	4491-4493	of	_
29-5	4494-4497	the	_
29-6	4498-4501	IPL	_
29-7	4502-4504	in	_
29-8	4505-4518	schizophrenia	_
29-9	4519-4522	has	_
29-10	4523-4527	been	_
29-11	4528-4533	shown	_
29-12	4534-4536	in	_
29-13	4537-4540	GMV	_
29-14	4541-4549	analysis	_
29-15	4549-4550	.	_

#Text=The SMG shows more significant GMV reduction than the remainder part of the IPL in schizophrenia.
30-1	4551-4554	The	_
30-2	4555-4558	SMG	_
30-3	4559-4564	shows	_
30-4	4565-4569	more	_
30-5	4570-4581	significant	_
30-6	4582-4585	GMV	_
30-7	4586-4595	reduction	_
30-8	4596-4600	than	_
30-9	4601-4604	the	_
30-10	4605-4614	remainder	_
30-11	4615-4619	part	_
30-12	4620-4622	of	_
30-13	4623-4626	the	_
30-14	4627-4630	IPL	_
30-15	4631-4633	in	_
30-16	4634-4647	schizophrenia	_
30-17	4647-4648	.	_

#Text=However, it remains unknown which IPL subregions have rsFC changes in schizophrenia; the information may further improve our understanding on the role of the IPL in schizophrenia.
31-1	4649-4656	However	_
31-2	4656-4657	,	_
31-3	4658-4660	it	_
31-4	4661-4668	remains	_
31-5	4669-4676	unknown	_
31-6	4677-4682	which	_
31-7	4683-4686	IPL	_
31-8	4687-4697	subregions	_
31-9	4698-4702	have	_
31-10	4703-4707	rsFC	_
31-11	4708-4715	changes	_
31-12	4716-4718	in	_
31-13	4719-4732	schizophrenia	_
31-14	4732-4733	;	_
31-15	4734-4737	the	_
31-16	4738-4749	information	_
31-17	4750-4753	may	_
31-18	4754-4761	further	_
31-19	4762-4769	improve	_
31-20	4770-4773	our	_
31-21	4774-4787	understanding	_
31-22	4788-4790	on	_
31-23	4791-4794	the	_
31-24	4795-4799	role	_
31-25	4800-4802	of	_
31-26	4803-4806	the	_
31-27	4807-4810	IPL	_
31-28	4811-4813	in	_
31-29	4814-4827	schizophrenia	_
31-30	4827-4828	.	_

#Text=The aim of this study was to identify the specific alterations in the rsFCs of the IPL subregions in schizophrenia.
32-1	4829-4832	The	_
32-2	4833-4836	aim	_
32-3	4837-4839	of	_
32-4	4840-4844	this	_
32-5	4845-4850	study	_
32-6	4851-4854	was	_
32-7	4855-4857	to	_
32-8	4858-4866	identify	_
32-9	4867-4870	the	_
32-10	4871-4879	specific	_
32-11	4880-4891	alterations	_
32-12	4892-4894	in	_
32-13	4895-4898	the	_
32-14	4899-4904	rsFCs	_
32-15	4905-4907	of	_
32-16	4908-4911	the	_
32-17	4912-4915	IPL	_
32-18	4916-4926	subregions	_
32-19	4927-4929	in	_
32-20	4930-4943	schizophrenia	_
32-21	4943-4944	.	_

#Text=Materials and methods
#Text=Participants
#Text=A total of 102 schizophrenia patients and 104 healthy subjects were recruited for this study.
33-1	4945-4954	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
33-2	4955-4958	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
33-3	4959-4966	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
33-4	4967-4979	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-5	4980-4981	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-6	4982-4987	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-7	4988-4990	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-8	4991-4994	102	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-9	4995-5008	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]
33-10	5009-5017	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]
33-11	5018-5021	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-12	5022-5025	104	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-13	5026-5033	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
33-14	5034-5042	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
33-15	5043-5047	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-16	5048-5057	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-17	5058-5061	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-18	5062-5066	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-19	5067-5072	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-20	5072-5073	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Diagnoses for patients were confirmed using the Structured Clinical Interview for DSM-IV.
34-1	5074-5083	Diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-2	5084-5087	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-3	5088-5096	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-4	5097-5101	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-5	5102-5111	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-6	5112-5117	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-7	5118-5121	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-8	5122-5132	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-9	5133-5141	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-10	5142-5151	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-11	5152-5155	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-12	5156-5162	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
34-13	5162-5163	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Inclusion criteria were age (16–60 years) and right-handedness.
35-1	5164-5173	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-2	5174-5182	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-3	5183-5187	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-4	5188-5191	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-5	5192-5193	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-6	5193-5195	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-7	5195-5196	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-8	5196-5198	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-9	5198-5199	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-10	5199-5204	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-11	5204-5205	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-12	5206-5209	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-13	5210-5226	right-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
35-14	5226-5227	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Exclusion criteria included MRI contraindications, poor image quality, presence of a systemic medical illness (i.e., cardiovascular disease, diabetes) or CNS disorder (i.e., stroke, epilepsy), history of head trauma, and substance abuse within the last 3 months or lifetime history of substance abuse or dependence.
36-1	5228-5237	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-2	5238-5246	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-3	5247-5255	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-4	5256-5259	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-5	5260-5277	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-6	5277-5278	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-7	5279-5283	poor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-8	5284-5289	image	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-9	5290-5297	quality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-10	5297-5298	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-11	5299-5307	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-12	5308-5310	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-13	5311-5312	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-14	5313-5321	systemic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-15	5322-5329	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-16	5330-5337	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-17	5338-5339	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-18	5339-5342	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-19	5342-5343	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-20	5343-5344	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-21	5345-5359	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-22	5360-5367	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-23	5367-5368	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-24	5369-5377	diabetes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-25	5377-5378	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-26	5379-5381	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-27	5382-5385	CNS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-28	5386-5394	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-29	5395-5396	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-30	5396-5399	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-31	5399-5400	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-32	5400-5401	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-33	5402-5408	stroke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-34	5408-5409	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-35	5410-5418	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-36	5418-5419	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-37	5419-5420	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-38	5421-5428	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-39	5429-5431	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-40	5432-5436	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-41	5437-5443	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-42	5443-5444	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-43	5445-5448	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-44	5449-5458	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-45	5459-5464	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-46	5465-5471	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-47	5472-5475	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-48	5476-5480	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-49	5481-5482	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-50	5482-5483	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-51	5483-5489	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-52	5490-5492	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-53	5493-5501	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-54	5502-5509	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-55	5510-5512	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-56	5513-5522	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-57	5523-5528	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-58	5529-5531	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-59	5532-5542	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-60	5542-5543	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Additional exclusion criteria for healthy subjects were history of any Axis I or II disorders and a psychotic disorder and first-degree relative with a psychotic disorder.
37-1	5544-5554	Additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-2	5555-5564	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-3	5565-5573	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-4	5574-5577	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-5	5578-5585	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-6	5586-5594	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-7	5595-5599	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-8	5600-5607	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-9	5608-5610	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-10	5611-5614	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-11	5615-5619	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-12	5620-5621	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-13	5622-5624	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-14	5625-5627	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-15	5628-5637	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-16	5638-5641	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-17	5642-5643	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-18	5644-5653	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-19	5654-5662	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-20	5663-5666	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-21	5667-5679	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-22	5680-5688	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-23	5689-5693	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-24	5694-5695	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-25	5696-5705	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-26	5706-5714	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
37-27	5714-5715	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=After excluding seven patients with excessive head motion (translational or rotational motion parameters more than 2 mm or 2°), 95 schizophrenia patients and 104 healthy subjects were finally included in further analysis.
38-1	5716-5721	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-2	5722-5731	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-3	5732-5737	seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-4	5738-5746	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-5	5747-5751	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-6	5752-5761	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-7	5762-5766	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-8	5767-5773	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-9	5774-5775	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-10	5775-5788	translational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-11	5789-5791	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-12	5792-5802	rotational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-13	5803-5809	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-14	5810-5820	parameters	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-15	5821-5825	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-16	5826-5830	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-17	5831-5832	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-18	5832-5833	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-19	5833-5835	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-20	5836-5838	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-21	5839-5840	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-22	5840-5841	°	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-23	5841-5842	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-24	5842-5843	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-25	5844-5846	95	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-26	5847-5860	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]
38-27	5861-5869	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]
38-28	5870-5873	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-29	5874-5877	104	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-30	5878-5885	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
38-31	5886-5894	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
38-32	5895-5899	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-33	5900-5907	finally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-34	5908-5916	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-35	5917-5919	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-36	5920-5927	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-37	5928-5936	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
38-38	5936-5937	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Clinical symptoms were quantified with the Positive and Negative Syndrome Scale (PANSS).
39-1	5938-5946	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-2	5947-5955	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-3	5956-5960	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-4	5961-5971	quantified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-5	5972-5976	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-6	5977-5980	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
39-7	5981-5989	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-8	5990-5993	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-9	5994-6002	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-10	6003-6011	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-11	6012-6017	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-12	6018-6019	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-13	6019-6024	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-14	6024-6025	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]
39-15	6025-6026	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=This study was approved by the Medical Research Ethics Committee at Tianjin Medical University General Hospital.
40-1	6027-6031	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-2	6032-6037	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-3	6038-6041	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-4	6042-6050	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-5	6051-6053	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-6	6054-6057	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-7	6058-6065	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-8	6066-6074	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-9	6075-6081	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-10	6082-6091	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-11	6092-6094	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-12	6095-6102	Tianjin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-13	6103-6110	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-14	6111-6121	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-15	6122-6129	General	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-16	6130-6138	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
40-17	6138-6139	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=All participants were clearly informed about the whole study, and written informed consent was obtained from each participant.
41-1	6140-6143	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-2	6144-6156	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-3	6157-6161	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-4	6162-6169	clearly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-5	6170-6178	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-6	6179-6184	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-7	6185-6188	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-8	6189-6194	whole	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-9	6195-6200	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-10	6200-6201	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-11	6202-6205	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-12	6206-6213	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-13	6214-6222	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-14	6223-6230	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-15	6231-6234	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-16	6235-6243	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-17	6244-6248	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-18	6249-6253	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-19	6254-6265	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
41-20	6265-6266	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]

#Text=Imaging data acquisition
#Text=MRI was performed using a 3.0-Tesla MR system (Discovery MR750, General Electric, Milwaukee, WI, USA).
42-1	6267-6274	Imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]
42-2	6275-6279	data	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]
42-3	6280-6291	acquisition	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]
42-4	6292-6295	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[16]
42-5	6296-6299	was	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]
42-6	6300-6309	performed	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]
42-7	6310-6315	using	_
42-8	6316-6317	a	_
42-9	6318-6321	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]
42-10	6321-6322	-	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]
42-11	6322-6327	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]
42-12	6328-6330	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]
42-13	6331-6337	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]
42-14	6338-6339	(	_
42-15	6339-6348	Discovery	_
42-16	6349-6354	MR750	_
42-17	6354-6355	,	_
42-18	6356-6363	General	_
42-19	6364-6372	Electric	_
42-20	6372-6373	,	_
42-21	6374-6383	Milwaukee	_
42-22	6383-6384	,	_
42-23	6385-6387	WI	_
42-24	6387-6388	,	_
42-25	6389-6392	USA	_
42-26	6392-6393	)	_
42-27	6393-6394	.	_

#Text=Tight but comfortable foam padding was used to minimize head motion, and earplugs were used to reduce scanner noise.
43-1	6395-6400	Tight	_
43-2	6401-6404	but	_
43-3	6405-6416	comfortable	_
43-4	6417-6421	foam	_
43-5	6422-6429	padding	_
43-6	6430-6433	was	_
43-7	6434-6438	used	_
43-8	6439-6441	to	_
43-9	6442-6450	minimize	_
43-10	6451-6455	head	_
43-11	6456-6462	motion	_
43-12	6462-6463	,	_
43-13	6464-6467	and	_
43-14	6468-6476	earplugs	_
43-15	6477-6481	were	_
43-16	6482-6486	used	_
43-17	6487-6489	to	_
43-18	6490-6496	reduce	_
43-19	6497-6504	scanner	_
43-20	6505-6510	noise	_
43-21	6510-6511	.	_

#Text=Sagittal 3D T1-weighted images were acquired by a brain volume sequence with the following parameters: repetition time (TR) = 8.2 ms; echo time (TE) = 3.2 ms; inversion time = 450 ms; flip angle (FA) = 12°; field of view (FOV) = 256 mm × 256 mm; matrix = 256 × 256; slice thickness = 1 mm, no gap; and 188 sagittal slices.
44-1	6512-6520	Sagittal	_
44-2	6521-6523	3D	_
44-3	6524-6526	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
44-4	6526-6527	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
44-5	6527-6535	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
44-6	6536-6542	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
44-7	6543-6547	were	_
44-8	6548-6556	acquired	_
44-9	6557-6559	by	_
44-10	6560-6561	a	_
44-11	6562-6567	brain	_
44-12	6568-6574	volume	_
44-13	6575-6583	sequence	_
44-14	6584-6588	with	_
44-15	6589-6592	the	_
44-16	6593-6602	following	_
44-17	6603-6613	parameters	_
44-18	6613-6614	:	_
44-19	6615-6625	repetition	_
44-20	6626-6630	time	_
44-21	6631-6632	(	_
44-22	6632-6634	TR	_
44-23	6634-6635	)	_
44-24	6635-6636	 	_
44-25	6636-6637	=	_
44-26	6637-6638	 	_
44-27	6638-6641	8.2	_
44-28	6641-6642	 	_
44-29	6642-6644	ms	_
44-30	6644-6645	;	_
44-31	6646-6650	echo	_
44-32	6651-6655	time	_
44-33	6656-6657	(	_
44-34	6657-6659	TE	_
44-35	6659-6660	)	_
44-36	6660-6661	 	_
44-37	6661-6662	=	_
44-38	6662-6663	 	_
44-39	6663-6666	3.2	_
44-40	6666-6667	 	_
44-41	6667-6669	ms	_
44-42	6669-6670	;	_
44-43	6671-6680	inversion	_
44-44	6681-6685	time	_
44-45	6685-6686	 	_
44-46	6686-6687	=	_
44-47	6687-6688	 	_
44-48	6688-6691	450	_
44-49	6691-6692	 	_
44-50	6692-6694	ms	_
44-51	6694-6695	;	_
44-52	6696-6700	flip	_
44-53	6701-6706	angle	_
44-54	6707-6708	(	_
44-55	6708-6710	FA	_
44-56	6710-6711	)	_
44-57	6711-6712	 	_
44-58	6712-6713	=	_
44-59	6713-6714	 	_
44-60	6714-6716	12	_
44-61	6716-6717	°	_
44-62	6717-6718	;	_
44-63	6719-6724	field	_
44-64	6725-6727	of	_
44-65	6728-6732	view	_
44-66	6733-6734	(	_
44-67	6734-6737	FOV	_
44-68	6737-6738	)	_
44-69	6738-6739	 	_
44-70	6739-6740	=	_
44-71	6740-6741	 	_
44-72	6741-6744	256	_
44-73	6744-6745	 	_
44-74	6745-6747	mm	_
44-75	6747-6748	 	_
44-76	6748-6749	×	_
44-77	6749-6750	 	_
44-78	6750-6753	256	_
44-79	6753-6754	 	_
44-80	6754-6756	mm	_
44-81	6756-6757	;	_
44-82	6758-6764	matrix	_
44-83	6764-6765	 	_
44-84	6765-6766	=	_
44-85	6766-6767	 	_
44-86	6767-6770	256	_
44-87	6770-6771	 	_
44-88	6771-6772	×	_
44-89	6772-6773	 	_
44-90	6773-6776	256	_
44-91	6776-6777	;	_
44-92	6778-6783	slice	_
44-93	6784-6793	thickness	_
44-94	6793-6794	 	_
44-95	6794-6795	=	_
44-96	6795-6796	 	_
44-97	6796-6797	1	_
44-98	6797-6798	 	_
44-99	6798-6800	mm	_
44-100	6800-6801	,	_
44-101	6802-6804	no	_
44-102	6805-6808	gap	_
44-103	6808-6809	;	_
44-104	6810-6813	and	_
44-105	6814-6817	188	_
44-106	6818-6826	sagittal	_
44-107	6827-6833	slices	_
44-108	6833-6834	.	_

#Text=The resting-state functional MRI (rs-fMRI) data were acquired using a gradient-echo single-short echo planar imaging sequence with the following parameters: TR/TE = 2000/45 ms; FOV = 220 mm × 220 mm; matrix = 64 × 64; FA = 90°; slice thickness = 4 mm; gap = 0.5 mm; 32 interleaved transverse slices; and 180 volumes.
45-1	6835-6838	The	_
45-2	6839-6852	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-3	6853-6863	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-4	6864-6867	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-5	6868-6869	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-6	6869-6876	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-7	6876-6877	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-8	6878-6882	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[19]
45-9	6883-6887	were	_
45-10	6888-6896	acquired	_
45-11	6897-6902	using	_
45-12	6903-6904	a	_
45-13	6905-6918	gradient-echo	_
45-14	6919-6931	single-short	_
45-15	6932-6936	echo	_
45-16	6937-6943	planar	_
45-17	6944-6951	imaging	_
45-18	6952-6960	sequence	_
45-19	6961-6965	with	_
45-20	6966-6969	the	_
45-21	6970-6979	following	_
45-22	6980-6990	parameters	_
45-23	6990-6991	:	_
45-24	6992-6994	TR	_
45-25	6994-6995	/	_
45-26	6995-6997	TE	_
45-27	6997-6998	 	_
45-28	6998-6999	=	_
45-29	6999-7000	 	_
45-30	7000-7004	2000	_
45-31	7004-7005	/	_
45-32	7005-7007	45	_
45-33	7007-7008	 	_
45-34	7008-7010	ms	_
45-35	7010-7011	;	_
45-36	7012-7015	FOV	_
45-37	7015-7016	 	_
45-38	7016-7017	=	_
45-39	7017-7018	 	_
45-40	7018-7021	220	_
45-41	7021-7022	 	_
45-42	7022-7024	mm	_
45-43	7024-7025	 	_
45-44	7025-7026	×	_
45-45	7026-7027	 	_
45-46	7027-7030	220	_
45-47	7030-7031	 	_
45-48	7031-7033	mm	_
45-49	7033-7034	;	_
45-50	7035-7041	matrix	_
45-51	7041-7042	 	_
45-52	7042-7043	=	_
45-53	7043-7044	 	_
45-54	7044-7046	64	_
45-55	7046-7047	 	_
45-56	7047-7048	×	_
45-57	7048-7049	 	_
45-58	7049-7051	64	_
45-59	7051-7052	;	_
45-60	7053-7055	FA	_
45-61	7055-7056	 	_
45-62	7056-7057	=	_
45-63	7057-7058	 	_
45-64	7058-7060	90	_
45-65	7060-7061	°	_
45-66	7061-7062	;	_
45-67	7063-7068	slice	_
45-68	7069-7078	thickness	_
45-69	7078-7079	 	_
45-70	7079-7080	=	_
45-71	7080-7081	 	_
45-72	7081-7082	4	_
45-73	7082-7083	 	_
45-74	7083-7085	mm	_
45-75	7085-7086	;	_
45-76	7087-7090	gap	_
45-77	7090-7091	 	_
45-78	7091-7092	=	_
45-79	7092-7093	 	_
45-80	7093-7096	0.5	_
45-81	7096-7097	 	_
45-82	7097-7099	mm	_
45-83	7099-7100	;	_
45-84	7101-7103	32	_
45-85	7104-7115	interleaved	_
45-86	7116-7126	transverse	_
45-87	7127-7133	slices	_
45-88	7133-7134	;	_
45-89	7135-7138	and	_
45-90	7139-7142	180	_
45-91	7143-7150	volumes	_
45-92	7150-7151	.	_

#Text=During rs-fMRI scans, all subjects were instructed to keep their eyes closed, to relax and move as little as possible, to think of nothing in particular, and not to fall asleep.
46-1	7152-7158	During	_
46-2	7159-7166	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-3	7167-7172	scans	_
46-4	7172-7173	,	_
46-5	7174-7177	all	_
46-6	7178-7186	subjects	_
46-7	7187-7191	were	_
46-8	7192-7202	instructed	_
46-9	7203-7205	to	_
46-10	7206-7210	keep	_
46-11	7211-7216	their	_
46-12	7217-7221	eyes	_
46-13	7222-7228	closed	_
46-14	7228-7229	,	_
46-15	7230-7232	to	_
46-16	7233-7238	relax	_
46-17	7239-7242	and	_
46-18	7243-7247	move	_
46-19	7248-7250	as	_
46-20	7251-7257	little	_
46-21	7258-7260	as	_
46-22	7261-7269	possible	_
46-23	7269-7270	,	_
46-24	7271-7273	to	_
46-25	7274-7279	think	_
46-26	7280-7282	of	_
46-27	7283-7290	nothing	_
46-28	7291-7293	in	_
46-29	7294-7304	particular	_
46-30	7304-7305	,	_
46-31	7306-7309	and	_
46-32	7310-7313	not	_
46-33	7314-7316	to	_
46-34	7317-7321	fall	_
46-35	7322-7328	asleep	_
46-36	7328-7329	.	_

#Text=Definition of the IPL subregions
#Text=Here, the naming of the IPL subregions was based on previous studies on cytoarchitecture.
47-1	7330-7340	Definition	_
47-2	7341-7343	of	_
47-3	7344-7347	the	_
47-4	7348-7351	IPL	_
47-5	7352-7362	subregions	_
47-6	7363-7367	Here	_
47-7	7367-7368	,	_
47-8	7369-7372	the	_
47-9	7373-7379	naming	_
47-10	7380-7382	of	_
47-11	7383-7386	the	_
47-12	7387-7390	IPL	_
47-13	7391-7401	subregions	_
47-14	7402-7405	was	_
47-15	7406-7411	based	_
47-16	7412-7414	on	_
47-17	7415-7423	previous	_
47-18	7424-7431	studies	_
47-19	7432-7434	on	_
47-20	7435-7451	cytoarchitecture	_
47-21	7451-7452	.	_

#Text=The IPL contains PF and PG, where P represents the parietal cortex, PF is the number F subregion of the parietal cortex corresponding to the SMG (BA 40), and PG is the number G subregion of the parietal cortex corresponding to the AG (BA 39).
48-1	7453-7456	The	_
48-2	7457-7460	IPL	_
48-3	7461-7469	contains	_
48-4	7470-7472	PF	_
48-5	7473-7476	and	_
48-6	7477-7479	PG	_
48-7	7479-7480	,	_
48-8	7481-7486	where	_
48-9	7487-7488	P	_
48-10	7489-7499	represents	_
48-11	7500-7503	the	_
48-12	7504-7512	parietal	_
48-13	7513-7519	cortex	_
48-14	7519-7520	,	_
48-15	7521-7523	PF	_
48-16	7524-7526	is	_
48-17	7527-7530	the	_
48-18	7531-7537	number	_
48-19	7538-7539	F	_
48-20	7540-7549	subregion	_
48-21	7550-7552	of	_
48-22	7553-7556	the	_
48-23	7557-7565	parietal	_
48-24	7566-7572	cortex	_
48-25	7573-7586	corresponding	_
48-26	7587-7589	to	_
48-27	7590-7593	the	_
48-28	7594-7597	SMG	_
48-29	7598-7599	(	_
48-30	7599-7601	BA	_
48-31	7602-7604	40	_
48-32	7604-7605	)	_
48-33	7605-7606	,	_
48-34	7607-7610	and	_
48-35	7611-7613	PG	_
48-36	7614-7616	is	_
48-37	7617-7620	the	_
48-38	7621-7627	number	_
48-39	7628-7629	G	_
48-40	7630-7639	subregion	_
48-41	7640-7642	of	_
48-42	7643-7646	the	_
48-43	7647-7655	parietal	_
48-44	7656-7662	cortex	_
48-45	7663-7676	corresponding	_
48-46	7677-7679	to	_
48-47	7680-7683	the	_
48-48	7684-7686	AG	_
48-49	7687-7688	(	_
48-50	7688-7690	BA	_
48-51	7691-7693	39	_
48-52	7693-7694	)	_
48-53	7694-7695	.	_

#Text=Based on local variations in cytoarchitecture, four additional subregions are identified in PF: PFop, the opercular part of PF; PFt, the part of PF with a thin cortical ribbon; PFm, the magnocellular part of PF; PFcm, the magnocellular and columnar part of PF, and PG is subdivided into PGa and PGp, representing the anterior and posterior parts of PG, respectively.
49-1	7696-7701	Based	_
49-2	7702-7704	on	_
49-3	7705-7710	local	_
49-4	7711-7721	variations	_
49-5	7722-7724	in	_
49-6	7725-7741	cytoarchitecture	_
49-7	7741-7742	,	_
49-8	7743-7747	four	_
49-9	7748-7758	additional	_
49-10	7759-7769	subregions	_
49-11	7770-7773	are	_
49-12	7774-7784	identified	_
49-13	7785-7787	in	_
49-14	7788-7790	PF	_
49-15	7790-7791	:	_
49-16	7792-7796	PFop	_
49-17	7796-7797	,	_
49-18	7798-7801	the	_
49-19	7802-7811	opercular	_
49-20	7812-7816	part	_
49-21	7817-7819	of	_
49-22	7820-7822	PF	_
49-23	7822-7823	;	_
49-24	7824-7827	PFt	_
49-25	7827-7828	,	_
49-26	7829-7832	the	_
49-27	7833-7837	part	_
49-28	7838-7840	of	_
49-29	7841-7843	PF	_
49-30	7844-7848	with	_
49-31	7849-7850	a	_
49-32	7851-7855	thin	_
49-33	7856-7864	cortical	_
49-34	7865-7871	ribbon	_
49-35	7871-7872	;	_
49-36	7873-7876	PFm	_
49-37	7876-7877	,	_
49-38	7878-7881	the	_
49-39	7882-7895	magnocellular	_
49-40	7896-7900	part	_
49-41	7901-7903	of	_
49-42	7904-7906	PF	_
49-43	7906-7907	;	_
49-44	7908-7912	PFcm	_
49-45	7912-7913	,	_
49-46	7914-7917	the	_
49-47	7918-7931	magnocellular	_
49-48	7932-7935	and	_
49-49	7936-7944	columnar	_
49-50	7945-7949	part	_
49-51	7950-7952	of	_
49-52	7953-7955	PF	_
49-53	7955-7956	,	_
49-54	7957-7960	and	_
49-55	7961-7963	PG	_
49-56	7964-7966	is	_
49-57	7967-7977	subdivided	_
49-58	7978-7982	into	_
49-59	7983-7986	PGa	_
49-60	7987-7990	and	_
49-61	7991-7994	PGp	_
49-62	7994-7995	,	_
49-63	7996-8008	representing	_
49-64	8009-8012	the	_
49-65	8013-8021	anterior	_
49-66	8022-8025	and	_
49-67	8026-8035	posterior	_
49-68	8036-8041	parts	_
49-69	8042-8044	of	_
49-70	8045-8047	PG	_
49-71	8047-8048	,	_
49-72	8049-8061	respectively	_
49-73	8061-8062	.	_

#Text=PFm has been named as the transition zone of the IPL because it is located between PF and PG and has common cytoarchitectural features with PF and PG.
50-1	8063-8066	PFm	_
50-2	8067-8070	has	_
50-3	8071-8075	been	_
50-4	8076-8081	named	_
50-5	8082-8084	as	_
50-6	8085-8088	the	_
50-7	8089-8099	transition	_
50-8	8100-8104	zone	_
50-9	8105-8107	of	_
50-10	8108-8111	the	_
50-11	8112-8115	IPL	_
50-12	8116-8123	because	_
50-13	8124-8126	it	_
50-14	8127-8129	is	_
50-15	8130-8137	located	_
50-16	8138-8145	between	_
50-17	8146-8148	PF	_
50-18	8149-8152	and	_
50-19	8153-8155	PG	_
50-20	8156-8159	and	_
50-21	8160-8163	has	_
50-22	8164-8170	common	_
50-23	8171-8188	cytoarchitectural	_
50-24	8189-8197	features	_
50-25	8198-8202	with	_
50-26	8203-8205	PF	_
50-27	8206-8209	and	_
50-28	8210-8212	PG	_
50-29	8212-8213	.	_

#Text=The IPL subregions were defined according to a connection-based parcellation study using diffusion MRI data.
51-1	8214-8217	The	_
51-2	8218-8221	IPL	_
51-3	8222-8232	subregions	_
51-4	8233-8237	were	_
51-5	8238-8245	defined	_
51-6	8246-8255	according	_
51-7	8256-8258	to	_
51-8	8259-8260	a	_
51-9	8261-8277	connection-based	_
51-10	8278-8290	parcellation	_
51-11	8291-8296	study	_
51-12	8297-8302	using	_
51-13	8303-8312	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[20]
51-14	8313-8316	MRI	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[20]
51-15	8317-8321	data	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging[20]
51-16	8321-8322	.	_

#Text=As shown in Fig. 1, the left IPL was parcellated into six subregions including PFt, PFop, PF + PFcm, PFm, PGa and PGp, whereas the right IPL was parcellated into five subregions, i.e., PFop, PF + PFt, PFm, PGa and PGp.
52-1	8323-8325	As	_
52-2	8326-8331	shown	_
52-3	8332-8334	in	_
52-4	8335-8338	Fig	_
52-5	8338-8339	.	_
52-6	8340-8341	1	_
52-7	8341-8342	,	_
52-8	8343-8346	the	_
52-9	8347-8351	left	_
52-10	8352-8355	IPL	_
52-11	8356-8359	was	_
52-12	8360-8371	parcellated	_
52-13	8372-8376	into	_
52-14	8377-8380	six	_
52-15	8381-8391	subregions	_
52-16	8392-8401	including	_
52-17	8402-8405	PFt	_
52-18	8405-8406	,	_
52-19	8407-8411	PFop	_
52-20	8411-8412	,	_
52-21	8413-8415	PF	_
52-22	8415-8416	 	_
52-23	8416-8417	+	_
52-24	8417-8418	 	_
52-25	8418-8422	PFcm	_
52-26	8422-8423	,	_
52-27	8424-8427	PFm	_
52-28	8427-8428	,	_
52-29	8429-8432	PGa	_
52-30	8433-8436	and	_
52-31	8437-8440	PGp	_
52-32	8440-8441	,	_
52-33	8442-8449	whereas	_
52-34	8450-8453	the	_
52-35	8454-8459	right	_
52-36	8460-8463	IPL	_
52-37	8464-8467	was	_
52-38	8468-8479	parcellated	_
52-39	8480-8484	into	_
52-40	8485-8489	five	_
52-41	8490-8500	subregions	_
52-42	8500-8501	,	_
52-43	8502-8505	i.e	_
52-44	8505-8506	.	_
52-45	8506-8507	,	_
52-46	8508-8512	PFop	_
52-47	8512-8513	,	_
52-48	8514-8516	PF	_
52-49	8516-8517	 	_
52-50	8517-8518	+	_
52-51	8518-8519	 	_
52-52	8519-8522	PFt	_
52-53	8522-8523	,	_
52-54	8524-8527	PFm	_
52-55	8527-8528	,	_
52-56	8529-8532	PGa	_
52-57	8533-8536	and	_
52-58	8537-8540	PGp	_
52-59	8540-8541	.	_

#Text=These subregions have shown their specific rsFC patterns, and thus this parcellation scheme is especially suitable for investigating subregion-specific rsFC changes of the IPL in schizophrenia.
#Text=rs-fMRI Data preprocessing
#Text=The rs-fMRI data were preprocessed using SPM8.
53-1	8542-8547	These	_
53-2	8548-8558	subregions	_
53-3	8559-8563	have	_
53-4	8564-8569	shown	_
53-5	8570-8575	their	_
53-6	8576-8584	specific	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[21]
53-7	8585-8589	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[21]
53-8	8590-8598	patterns	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[21]
53-9	8598-8599	,	_
53-10	8600-8603	and	_
53-11	8604-8608	thus	_
53-12	8609-8613	this	_
53-13	8614-8626	parcellation	_
53-14	8627-8633	scheme	_
53-15	8634-8636	is	_
53-16	8637-8647	especially	_
53-17	8648-8656	suitable	_
53-18	8657-8660	for	_
53-19	8661-8674	investigating	_
53-20	8675-8693	subregion-specific	_
53-21	8694-8698	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
53-22	8699-8706	changes	_
53-23	8707-8709	of	_
53-24	8710-8713	the	_
53-25	8714-8717	IPL	_
53-26	8718-8720	in	_
53-27	8721-8734	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
53-28	8734-8735	.	_
53-29	8736-8743	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
53-30	8744-8748	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
53-31	8749-8762	preprocessing	_
53-32	8763-8766	The	_
53-33	8767-8774	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
53-34	8775-8779	data	_
53-35	8780-8784	were	_
53-36	8785-8797	preprocessed	_
53-37	8798-8803	using	_
53-38	8804-8808	SPM8	_
53-39	8808-8809	.	_

#Text=The first 10 volumes for each subject were discarded to allow the signal to reach equilibrium and the participants to adapt to the scanning noise.
54-1	8810-8813	The	_
54-2	8814-8819	first	_
54-3	8820-8822	10	_
54-4	8823-8830	volumes	_
54-5	8831-8834	for	_
54-6	8835-8839	each	_
54-7	8840-8847	subject	_
54-8	8848-8852	were	_
54-9	8853-8862	discarded	_
54-10	8863-8865	to	_
54-11	8866-8871	allow	_
54-12	8872-8875	the	_
54-13	8876-8882	signal	_
54-14	8883-8885	to	_
54-15	8886-8891	reach	_
54-16	8892-8903	equilibrium	_
54-17	8904-8907	and	_
54-18	8908-8911	the	_
54-19	8912-8924	participants	_
54-20	8925-8927	to	_
54-21	8928-8933	adapt	_
54-22	8934-8936	to	_
54-23	8937-8940	the	_
54-24	8941-8949	scanning	_
54-25	8950-8955	noise	_
54-26	8955-8956	.	_

#Text=The remaining volumes were then corrected for the acquisition time delay between slices.
55-1	8957-8960	The	_
55-2	8961-8970	remaining	_
55-3	8971-8978	volumes	_
55-4	8979-8983	were	_
55-5	8984-8988	then	_
55-6	8989-8998	corrected	_
55-7	8999-9002	for	_
55-8	9003-9006	the	_
55-9	9007-9018	acquisition	_
55-10	9019-9023	time	_
55-11	9024-9029	delay	_
55-12	9030-9037	between	_
55-13	9038-9044	slices	_
55-14	9044-9045	.	_

#Text=On the basis of head motion, seven patients' fMRI data were excluded from further analysis because their translational or rotational motion parameters were greater than 2 mm or 2°.
56-1	9046-9048	On	_
56-2	9049-9052	the	_
56-3	9053-9058	basis	_
56-4	9059-9061	of	_
56-5	9062-9066	head	_
56-6	9067-9073	motion	_
56-7	9073-9074	,	_
56-8	9075-9080	seven	_
56-9	9081-9089	patients	_
56-10	9089-9090	'	_
56-11	9091-9095	fMRI	_
56-12	9096-9100	data	_
56-13	9101-9105	were	_
56-14	9106-9114	excluded	_
56-15	9115-9119	from	_
56-16	9120-9127	further	_
56-17	9128-9136	analysis	_
56-18	9137-9144	because	_
56-19	9145-9150	their	_
56-20	9151-9164	translational	_
56-21	9165-9167	or	_
56-22	9168-9178	rotational	_
56-23	9179-9185	motion	_
56-24	9186-9196	parameters	_
56-25	9197-9201	were	_
56-26	9202-9209	greater	_
56-27	9210-9214	than	_
56-28	9215-9216	2	_
56-29	9216-9217	 	_
56-30	9217-9219	mm	_
56-31	9220-9222	or	_
56-32	9223-9224	2	_
56-33	9224-9225	°	_
56-34	9225-9226	.	_

#Text=We also calculated framewise displacement (FD), which indexes volume-to-volume changes in head position.
57-1	9227-9229	We	_
57-2	9230-9234	also	_
57-3	9235-9245	calculated	_
57-4	9246-9255	framewise	_
57-5	9256-9268	displacement	_
57-6	9269-9270	(	_
57-7	9270-9272	FD	_
57-8	9272-9273	)	_
57-9	9273-9274	,	_
57-10	9275-9280	which	_
57-11	9281-9288	indexes	_
57-12	9289-9305	volume-to-volume	_
57-13	9306-9313	changes	_
57-14	9314-9316	in	_
57-15	9317-9321	head	_
57-16	9322-9330	position	_
57-17	9330-9331	.	_

#Text=Because recent studies have reported that signal spike caused by head motion significantly contaminated the final rs-fMRI results even after regressing out the realignment parameters, we removed spike volumes with the FD > 0.5.
58-1	9332-9339	Because	_
58-2	9340-9346	recent	_
58-3	9347-9354	studies	_
58-4	9355-9359	have	_
58-5	9360-9368	reported	_
58-6	9369-9373	that	_
58-7	9374-9380	signal	_
58-8	9381-9386	spike	_
58-9	9387-9393	caused	_
58-10	9394-9396	by	_
58-11	9397-9401	head	_
58-12	9402-9408	motion	_
58-13	9409-9422	significantly	_
58-14	9423-9435	contaminated	_
58-15	9436-9439	the	_
58-16	9440-9445	final	_
58-17	9446-9453	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
58-18	9454-9461	results	_
58-19	9462-9466	even	_
58-20	9467-9472	after	_
58-21	9473-9483	regressing	_
58-22	9484-9487	out	_
58-23	9488-9491	the	_
58-24	9492-9503	realignment	_
58-25	9504-9514	parameters	_
58-26	9514-9515	,	_
58-27	9516-9518	we	_
58-28	9519-9526	removed	_
58-29	9527-9532	spike	_
58-30	9533-9540	volumes	_
58-31	9541-9545	with	_
58-32	9546-9549	the	_
58-33	9550-9552	FD	_
58-34	9552-9553	 	_
58-35	9553-9554	>	_
58-36	9554-9555	 	_
58-37	9555-9558	0.5	_
58-38	9558-9559	.	_

#Text=Several nuisance covariates (six motion parameters and average BOLD signals of the ventricular and white matter) were regressed out from the data.
59-1	9560-9567	Several	_
59-2	9568-9576	nuisance	_
59-3	9577-9587	covariates	_
59-4	9588-9589	(	_
59-5	9589-9592	six	_
59-6	9593-9599	motion	_
59-7	9600-9610	parameters	_
59-8	9611-9614	and	_
59-9	9615-9622	average	_
59-10	9623-9627	BOLD	_
59-11	9628-9635	signals	_
59-12	9636-9638	of	_
59-13	9639-9642	the	_
59-14	9643-9654	ventricular	_
59-15	9655-9658	and	_
59-16	9659-9664	white	_
59-17	9665-9671	matter	_
59-18	9671-9672	)	_
59-19	9673-9677	were	_
59-20	9678-9687	regressed	_
59-21	9688-9691	out	_
59-22	9692-9696	from	_
59-23	9697-9700	the	_
59-24	9701-9705	data	_
59-25	9705-9706	.	_

#Text=The datasets were band-pass filtered with a frequency range of 0.01 to 0.08 Hz to reduce low-frequency drift and high-frequency noise.
60-1	9707-9710	The	_
60-2	9711-9719	datasets	_
60-3	9720-9724	were	_
60-4	9725-9734	band-pass	_
60-5	9735-9743	filtered	_
60-6	9744-9748	with	_
60-7	9749-9750	a	_
60-8	9751-9760	frequency	_
60-9	9761-9766	range	_
60-10	9767-9769	of	_
60-11	9770-9774	0.01	_
60-12	9775-9777	to	_
60-13	9778-9782	0.08	_
60-14	9782-9783	 	_
60-15	9783-9785	Hz	_
60-16	9786-9788	to	_
60-17	9789-9795	reduce	_
60-18	9796-9809	low-frequency	_
60-19	9810-9815	drift	_
60-20	9816-9819	and	_
60-21	9820-9834	high-frequency	_
60-22	9835-9840	noise	_
60-23	9840-9841	.	_

#Text=Individual structural images were linearly coregistered to the mean functional image; then, the transformed structural images were segmented into GM, white matter, and cerebrospinal fluid.
61-1	9842-9852	Individual	_
61-2	9853-9863	structural	_
61-3	9864-9870	images	_
61-4	9871-9875	were	_
61-5	9876-9884	linearly	_
61-6	9885-9897	coregistered	_
61-7	9898-9900	to	_
61-8	9901-9904	the	_
61-9	9905-9909	mean	_
61-10	9910-9920	functional	_
61-11	9921-9926	image	_
61-12	9926-9927	;	_
61-13	9928-9932	then	_
61-14	9932-9933	,	_
61-15	9934-9937	the	_
61-16	9938-9949	transformed	_
61-17	9950-9960	structural	_
61-18	9961-9967	images	_
61-19	9968-9972	were	_
61-20	9973-9982	segmented	_
61-21	9983-9987	into	_
61-22	9988-9990	GM	_
61-23	9990-9991	,	_
61-24	9992-9997	white	_
61-25	9998-10004	matter	_
61-26	10004-10005	,	_
61-27	10006-10009	and	_
61-28	10010-10023	cerebrospinal	_
61-29	10024-10029	fluid	_
61-30	10029-10030	.	_

#Text=The GM maps were linearly coregistered to the tissue probability maps in the Montreal Neurological Institute (MNI) space.
62-1	10031-10034	The	_
62-2	10035-10037	GM	_
62-3	10038-10042	maps	_
62-4	10043-10047	were	_
62-5	10048-10056	linearly	_
62-6	10057-10069	coregistered	_
62-7	10070-10072	to	_
62-8	10073-10076	the	_
62-9	10077-10083	tissue	_
62-10	10084-10095	probability	_
62-11	10096-10100	maps	_
62-12	10101-10103	in	_
62-13	10104-10107	the	_
62-14	10108-10116	Montreal	_
62-15	10117-10129	Neurological	_
62-16	10130-10139	Institute	_
62-17	10140-10141	(	_
62-18	10141-10144	MNI	_
62-19	10144-10145	)	_
62-20	10146-10151	space	_
62-21	10151-10152	.	_

#Text=Finally the motion-corrected functional volumes were spatially normalized to the MNI space using the parameters estimated during linear coregistration.
63-1	10153-10160	Finally	_
63-2	10161-10164	the	_
63-3	10165-10181	motion-corrected	_
63-4	10182-10192	functional	_
63-5	10193-10200	volumes	_
63-6	10201-10205	were	_
63-7	10206-10215	spatially	_
63-8	10216-10226	normalized	_
63-9	10227-10229	to	_
63-10	10230-10233	the	_
63-11	10234-10237	MNI	_
63-12	10238-10243	space	_
63-13	10244-10249	using	_
63-14	10250-10253	the	_
63-15	10254-10264	parameters	_
63-16	10265-10274	estimated	_
63-17	10275-10281	during	_
63-18	10282-10288	linear	_
63-19	10289-10303	coregistration	_
63-20	10303-10304	.	_

#Text=The functional images were resampled into a 3 × 3 × 3 mm3 voxel.
64-1	10305-10308	The	_
64-2	10309-10319	functional	_
64-3	10320-10326	images	_
64-4	10327-10331	were	_
64-5	10332-10341	resampled	_
64-6	10342-10346	into	_
64-7	10347-10348	a	_
64-8	10349-10350	3	_
64-9	10350-10351	 	_
64-10	10351-10352	×	_
64-11	10352-10353	 	_
64-12	10353-10354	3	_
64-13	10354-10355	 	_
64-14	10355-10356	×	_
64-15	10356-10357	 	_
64-16	10357-10358	3	_
64-17	10358-10359	 	_
64-18	10359-10362	mm3	_
64-19	10363-10368	voxel	_
64-20	10368-10369	.	_

#Text=After normalization, all datasets were smoothed with a Gaussian kernel of 6 × 6 × 6 mm3 full-width at half maximum.
#Text=rsFC Analysis
#Text=For individual datasets, Pearson's correlation coefficients between the mean timecourses of each IPL subregion and timecourses of each voxel in other parts of the brain grey matter were computed and converted to z values using Fisher's r-to-z transformation to improve the normality.
65-1	10370-10375	After	_
65-2	10376-10389	normalization	_
65-3	10389-10390	,	_
65-4	10391-10394	all	_
65-5	10395-10403	datasets	_
65-6	10404-10408	were	_
65-7	10409-10417	smoothed	_
65-8	10418-10422	with	_
65-9	10423-10424	a	_
65-10	10425-10433	Gaussian	_
65-11	10434-10440	kernel	_
65-12	10441-10443	of	_
65-13	10444-10445	6	_
65-14	10445-10446	 	_
65-15	10446-10447	×	_
65-16	10447-10448	 	_
65-17	10448-10449	6	_
65-18	10449-10450	 	_
65-19	10450-10451	×	_
65-20	10451-10452	 	_
65-21	10452-10453	6	_
65-22	10453-10454	 	_
65-23	10454-10457	mm3	_
65-24	10458-10468	full-width	_
65-25	10469-10471	at	_
65-26	10472-10476	half	_
65-27	10477-10484	maximum	_
65-28	10484-10485	.	_
65-29	10486-10490	rsFC	_
65-30	10491-10499	Analysis	_
65-31	10500-10503	For	_
65-32	10504-10514	individual	_
65-33	10515-10523	datasets	_
65-34	10523-10524	,	_
65-35	10525-10534	Pearson's	_
65-36	10535-10546	correlation	_
65-37	10547-10559	coefficients	_
65-38	10560-10567	between	_
65-39	10568-10571	the	_
65-40	10572-10576	mean	_
65-41	10577-10588	timecourses	_
65-42	10589-10591	of	_
65-43	10592-10596	each	_
65-44	10597-10600	IPL	_
65-45	10601-10610	subregion	_
65-46	10611-10614	and	_
65-47	10615-10626	timecourses	_
65-48	10627-10629	of	_
65-49	10630-10634	each	_
65-50	10635-10640	voxel	_
65-51	10641-10643	in	_
65-52	10644-10649	other	_
65-53	10650-10655	parts	_
65-54	10656-10658	of	_
65-55	10659-10662	the	_
65-56	10663-10668	brain	_
65-57	10669-10673	grey	_
65-58	10674-10680	matter	_
65-59	10681-10685	were	_
65-60	10686-10694	computed	_
65-61	10695-10698	and	_
65-62	10699-10708	converted	_
65-63	10709-10711	to	_
65-64	10712-10713	z	_
65-65	10714-10720	values	_
65-66	10721-10726	using	_
65-67	10727-10735	Fisher's	_
65-68	10736-10742	r-to-z	_
65-69	10743-10757	transformation	_
65-70	10758-10760	to	_
65-71	10761-10768	improve	_
65-72	10769-10772	the	_
65-73	10773-10782	normality	_
65-74	10782-10783	.	_

#Text=For each group, individuals' z values were then entered into a random-effect one-sample t-test in a voxel-wise manner to identify brain regions that showed significant positive correlations with each IPL subregion.
66-1	10784-10787	For	_
66-2	10788-10792	each	_
66-3	10793-10798	group	_
66-4	10798-10799	,	_
66-5	10800-10811	individuals	_
66-6	10811-10812	'	_
66-7	10813-10814	z	_
66-8	10815-10821	values	_
66-9	10822-10826	were	_
66-10	10827-10831	then	_
66-11	10832-10839	entered	_
66-12	10840-10844	into	_
66-13	10845-10846	a	_
66-14	10847-10860	random-effect	_
66-15	10861-10871	one-sample	_
66-16	10872-10878	t-test	_
66-17	10879-10881	in	_
66-18	10882-10883	a	_
66-19	10884-10894	voxel-wise	_
66-20	10895-10901	manner	_
66-21	10902-10904	to	_
66-22	10905-10913	identify	_
66-23	10914-10919	brain	_
66-24	10920-10927	regions	_
66-25	10928-10932	that	_
66-26	10933-10939	showed	_
66-27	10940-10951	significant	_
66-28	10952-10960	positive	_
66-29	10961-10973	correlations	_
66-30	10974-10978	with	_
66-31	10979-10983	each	_
66-32	10984-10987	IPL	_
66-33	10988-10997	subregion	_
66-34	10997-10998	.	_

#Text=Then for each IPL subregion, voxels that showed significant positive correlations with the subregion in any of the two groups were merged into a mask.
67-1	10999-11003	Then	_
67-2	11004-11007	for	_
67-3	11008-11012	each	_
67-4	11013-11016	IPL	_
67-5	11017-11026	subregion	_
67-6	11026-11027	,	_
67-7	11028-11034	voxels	_
67-8	11035-11039	that	_
67-9	11040-11046	showed	_
67-10	11047-11058	significant	_
67-11	11059-11067	positive	_
67-12	11068-11080	correlations	_
67-13	11081-11085	with	_
67-14	11086-11089	the	_
67-15	11090-11099	subregion	_
67-16	11100-11102	in	_
67-17	11103-11106	any	_
67-18	11107-11109	of	_
67-19	11110-11113	the	_
67-20	11114-11117	two	_
67-21	11118-11124	groups	_
67-22	11125-11129	were	_
67-23	11130-11136	merged	_
67-24	11137-11141	into	_
67-25	11142-11143	a	_
67-26	11144-11148	mask	_
67-27	11148-11149	.	_

#Text=Then, general linear model was performed within the mask of each IPL subregion to quantitatively compare intergroup differences in rsFC of this IPL subregion while controlling for the effects of age and gender.
68-1	11150-11154	Then	_
68-2	11154-11155	,	_
68-3	11156-11163	general	_
68-4	11164-11170	linear	_
68-5	11171-11176	model	_
68-6	11177-11180	was	_
68-7	11181-11190	performed	_
68-8	11191-11197	within	_
68-9	11198-11201	the	_
68-10	11202-11206	mask	_
68-11	11207-11209	of	_
68-12	11210-11214	each	_
68-13	11215-11218	IPL	_
68-14	11219-11228	subregion	_
68-15	11229-11231	to	_
68-16	11232-11246	quantitatively	_
68-17	11247-11254	compare	_
68-18	11255-11265	intergroup	_
68-19	11266-11277	differences	_
68-20	11278-11280	in	_
68-21	11281-11285	rsFC	_
68-22	11286-11288	of	_
68-23	11289-11293	this	_
68-24	11294-11297	IPL	_
68-25	11298-11307	subregion	_
68-26	11308-11313	while	_
68-27	11314-11325	controlling	_
68-28	11326-11329	for	_
68-29	11330-11333	the	_
68-30	11334-11341	effects	_
68-31	11342-11344	of	_
68-32	11345-11348	age	_
68-33	11349-11352	and	_
68-34	11353-11359	gender	_
68-35	11359-11360	.	_

#Text=Because several previous studies reported decreased GMV in the IPL in schizophrenia, we also added the GMV of each subregion as an additional covariate of no interest in the rsFC analyses of the IPL subregions.
69-1	11361-11368	Because	_
69-2	11369-11376	several	_
69-3	11377-11385	previous	_
69-4	11386-11393	studies	_
69-5	11394-11402	reported	_
69-6	11403-11412	decreased	_
69-7	11413-11416	GMV	_
69-8	11417-11419	in	_
69-9	11420-11423	the	_
69-10	11424-11427	IPL	_
69-11	11428-11430	in	_
69-12	11431-11444	schizophrenia	_
69-13	11444-11445	,	_
69-14	11446-11448	we	_
69-15	11449-11453	also	_
69-16	11454-11459	added	_
69-17	11460-11463	the	_
69-18	11464-11467	GMV	_
69-19	11468-11470	of	_
69-20	11471-11475	each	_
69-21	11476-11485	subregion	_
69-22	11486-11488	as	_
69-23	11489-11491	an	_
69-24	11492-11502	additional	_
69-25	11503-11512	covariate	_
69-26	11513-11515	of	_
69-27	11516-11518	no	_
69-28	11519-11527	interest	_
69-29	11528-11530	in	_
69-30	11531-11534	the	_
69-31	11535-11539	rsFC	_
69-32	11540-11548	analyses	_
69-33	11549-11551	of	_
69-34	11552-11555	the	_
69-35	11556-11559	IPL	_
69-36	11560-11570	subregions	_
69-37	11570-11571	.	_

#Text=The detailed description of GMV calculation is shown in the Supplementary materials.
70-1	11572-11575	The	_
70-2	11576-11584	detailed	_
70-3	11585-11596	description	_
70-4	11597-11599	of	_
70-5	11600-11603	GMV	_
70-6	11604-11615	calculation	_
70-7	11616-11618	is	_
70-8	11619-11624	shown	_
70-9	11625-11627	in	_
70-10	11628-11631	the	_
70-11	11632-11645	Supplementary	_
70-12	11646-11655	materials	_
70-13	11655-11656	.	_

#Text=Multiple comparisons for these rsFC analyses were corrected using the false discovery rate (FDR) method.
71-1	11657-11665	Multiple	_
71-2	11666-11677	comparisons	_
71-3	11678-11681	for	_
71-4	11682-11687	these	_
71-5	11688-11692	rsFC	_
71-6	11693-11701	analyses	_
71-7	11702-11706	were	_
71-8	11707-11716	corrected	_
71-9	11717-11722	using	_
71-10	11723-11726	the	_
71-11	11727-11732	false	_
71-12	11733-11742	discovery	_
71-13	11743-11747	rate	_
71-14	11748-11749	(	_
71-15	11749-11752	FDR	_
71-16	11752-11753	)	_
71-17	11754-11760	method	_
71-18	11760-11761	.	_

#Text=Because 11 regions were analyzed, we further controlled for these additional comparisons using a corrected threshold of P < 0.05/11 = 0.0045 (FDR corrected, two-tailed).
72-1	11762-11769	Because	_
72-2	11770-11772	11	_
72-3	11773-11780	regions	_
72-4	11781-11785	were	_
72-5	11786-11794	analyzed	_
72-6	11794-11795	,	_
72-7	11796-11798	we	_
72-8	11799-11806	further	_
72-9	11807-11817	controlled	_
72-10	11818-11821	for	_
72-11	11822-11827	these	_
72-12	11828-11838	additional	_
72-13	11839-11850	comparisons	_
72-14	11851-11856	using	_
72-15	11857-11858	a	_
72-16	11859-11868	corrected	_
72-17	11869-11878	threshold	_
72-18	11879-11881	of	_
72-19	11882-11883	P	_
72-20	11883-11884	 	_
72-21	11884-11885	<	_
72-22	11885-11886	 	_
72-23	11886-11890	0.05	_
72-24	11890-11891	/	_
72-25	11891-11893	11	_
72-26	11893-11894	 	_
72-27	11894-11895	=	_
72-28	11895-11896	 	_
72-29	11896-11902	0.0045	_
72-30	11903-11904	(	_
72-31	11904-11907	FDR	_
72-32	11908-11917	corrected	_
72-33	11917-11918	,	_
72-34	11919-11929	two-tailed	_
72-35	11929-11930	)	_
72-36	11930-11931	.	_

#Text=Moreover, we also used a relatively lenient threshold (FDR corrected, P < 0.01, two-tailed) to reduce type II error.
73-1	11932-11940	Moreover	_
73-2	11940-11941	,	_
73-3	11942-11944	we	_
73-4	11945-11949	also	_
73-5	11950-11954	used	_
73-6	11955-11956	a	_
73-7	11957-11967	relatively	_
73-8	11968-11975	lenient	_
73-9	11976-11985	threshold	_
73-10	11986-11987	(	_
73-11	11987-11990	FDR	_
73-12	11991-12000	corrected	_
73-13	12000-12001	,	_
73-14	12002-12003	P	_
73-15	12003-12004	 	_
73-16	12004-12005	<	_
73-17	12005-12006	 	_
73-18	12006-12010	0.01	_
73-19	12010-12011	,	_
73-20	12012-12022	two-tailed	_
73-21	12022-12023	)	_
73-22	12024-12026	to	_
73-23	12027-12033	reduce	_
73-24	12034-12038	type	_
73-25	12039-12041	II	_
73-26	12042-12047	error	_
73-27	12047-12048	.	_

#Text=Validation analysis
#Text=To test whether the resulted rsFC map of each IPL subregion reflects its own unique variance, we recalculated rsFC maps using one first-level model per subject including the preprocessed BOLD timecourses of all IPL subregions.
74-1	12049-12059	Validation	_
74-2	12060-12068	analysis	_
74-3	12069-12071	To	_
74-4	12072-12076	test	_
74-5	12077-12084	whether	_
74-6	12085-12088	the	_
74-7	12089-12097	resulted	_
74-8	12098-12102	rsFC	_
74-9	12103-12106	map	_
74-10	12107-12109	of	_
74-11	12110-12114	each	_
74-12	12115-12118	IPL	_
74-13	12119-12128	subregion	_
74-14	12129-12137	reflects	_
74-15	12138-12141	its	_
74-16	12142-12145	own	_
74-17	12146-12152	unique	_
74-18	12153-12161	variance	_
74-19	12161-12162	,	_
74-20	12163-12165	we	_
74-21	12166-12178	recalculated	_
74-22	12179-12183	rsFC	_
74-23	12184-12188	maps	_
74-24	12189-12194	using	_
74-25	12195-12198	one	_
74-26	12199-12210	first-level	_
74-27	12211-12216	model	_
74-28	12217-12220	per	_
74-29	12221-12228	subject	_
74-30	12229-12238	including	_
74-31	12239-12242	the	_
74-32	12243-12255	preprocessed	_
74-33	12256-12260	BOLD	_
74-34	12261-12272	timecourses	_
74-35	12273-12275	of	_
74-36	12276-12279	all	_
74-37	12280-12283	IPL	_
74-38	12284-12294	subregions	_
74-39	12294-12295	.	_

#Text=For each hemisphere of each subject, the timecourses of each IPL subregion was orthogonalized with respect to each of the other IPL subregions using the Gram-Schmidt process, to ensure that the timecourses for each IPL subregion reflected its unique variance.
75-1	12296-12299	For	_
75-2	12300-12304	each	_
75-3	12305-12315	hemisphere	_
75-4	12316-12318	of	_
75-5	12319-12323	each	_
75-6	12324-12331	subject	_
75-7	12331-12332	,	_
75-8	12333-12336	the	_
75-9	12337-12348	timecourses	_
75-10	12349-12351	of	_
75-11	12352-12356	each	_
75-12	12357-12360	IPL	_
75-13	12361-12370	subregion	_
75-14	12371-12374	was	_
75-15	12375-12389	orthogonalized	_
75-16	12390-12394	with	_
75-17	12395-12402	respect	_
75-18	12403-12405	to	_
75-19	12406-12410	each	_
75-20	12411-12413	of	_
75-21	12414-12417	the	_
75-22	12418-12423	other	_
75-23	12424-12427	IPL	_
75-24	12428-12438	subregions	_
75-25	12439-12444	using	_
75-26	12445-12448	the	_
75-27	12449-12461	Gram-Schmidt	_
75-28	12462-12469	process	_
75-29	12469-12470	,	_
75-30	12471-12473	to	_
75-31	12474-12480	ensure	_
75-32	12481-12485	that	_
75-33	12486-12489	the	_
75-34	12490-12501	timecourses	_
75-35	12502-12505	for	_
75-36	12506-12510	each	_
75-37	12511-12514	IPL	_
75-38	12515-12524	subregion	_
75-39	12525-12534	reflected	_
75-40	12535-12538	its	_
75-41	12539-12545	unique	_
75-42	12546-12554	variance	_
75-43	12554-12555	.	_

#Text=And then the orthogonalized timecourses of all IPL subregions in the same hemisphere were considered as independent predictors in one multiple regression model to calculate the functional connectivity (i.e., the beta value of the timecourses) between each IPL subregion and each of other voxels of the whole brain, which simultaneously generated the rsFC maps of all IPL subregions in a subject.
76-1	12556-12559	And	_
76-2	12560-12564	then	_
76-3	12565-12568	the	_
76-4	12569-12583	orthogonalized	_
76-5	12584-12595	timecourses	_
76-6	12596-12598	of	_
76-7	12599-12602	all	_
76-8	12603-12606	IPL	_
76-9	12607-12617	subregions	_
76-10	12618-12620	in	_
76-11	12621-12624	the	_
76-12	12625-12629	same	_
76-13	12630-12640	hemisphere	_
76-14	12641-12645	were	_
76-15	12646-12656	considered	_
76-16	12657-12659	as	_
76-17	12660-12671	independent	_
76-18	12672-12682	predictors	_
76-19	12683-12685	in	_
76-20	12686-12689	one	_
76-21	12690-12698	multiple	_
76-22	12699-12709	regression	_
76-23	12710-12715	model	_
76-24	12716-12718	to	_
76-25	12719-12728	calculate	_
76-26	12729-12732	the	_
76-27	12733-12743	functional	_
76-28	12744-12756	connectivity	_
76-29	12757-12758	(	_
76-30	12758-12761	i.e	_
76-31	12761-12762	.	_
76-32	12762-12763	,	_
76-33	12764-12767	the	_
76-34	12768-12772	beta	_
76-35	12773-12778	value	_
76-36	12779-12781	of	_
76-37	12782-12785	the	_
76-38	12786-12797	timecourses	_
76-39	12797-12798	)	_
76-40	12799-12806	between	_
76-41	12807-12811	each	_
76-42	12812-12815	IPL	_
76-43	12816-12825	subregion	_
76-44	12826-12829	and	_
76-45	12830-12834	each	_
76-46	12835-12837	of	_
76-47	12838-12843	other	_
76-48	12844-12850	voxels	_
76-49	12851-12853	of	_
76-50	12854-12857	the	_
76-51	12858-12863	whole	_
76-52	12864-12869	brain	_
76-53	12869-12870	,	_
76-54	12871-12876	which	_
76-55	12877-12891	simultaneously	_
76-56	12892-12901	generated	_
76-57	12902-12905	the	_
76-58	12906-12910	rsFC	_
76-59	12911-12915	maps	_
76-60	12916-12918	of	_
76-61	12919-12922	all	_
76-62	12923-12926	IPL	_
76-63	12927-12937	subregions	_
76-64	12938-12940	in	_
76-65	12941-12942	a	_
76-66	12943-12950	subject	_
76-67	12950-12951	.	_

#Text=Because global signal regression is still controversial, the global signal was not regressed out from the data.
77-1	12952-12959	Because	_
77-2	12960-12966	global	_
77-3	12967-12973	signal	_
77-4	12974-12984	regression	_
77-5	12985-12987	is	_
77-6	12988-12993	still	_
77-7	12994-13007	controversial	_
77-8	13007-13008	,	_
77-9	13009-13012	the	_
77-10	13013-13019	global	_
77-11	13020-13026	signal	_
77-12	13027-13030	was	_
77-13	13031-13034	not	_
77-14	13035-13044	regressed	_
77-15	13045-13048	out	_
77-16	13049-13053	from	_
77-17	13054-13057	the	_
77-18	13058-13062	data	_
77-19	13062-13063	.	_

#Text=The rsFC map of each IPL subregion in each group was calculated using general linear model based on the rsFC map of this subregion in each subject (FDR corrected, P < 0.01, two-tailed).
78-1	13064-13067	The	_
78-2	13068-13072	rsFC	_
78-3	13073-13076	map	_
78-4	13077-13079	of	_
78-5	13080-13084	each	_
78-6	13085-13088	IPL	_
78-7	13089-13098	subregion	_
78-8	13099-13101	in	_
78-9	13102-13106	each	_
78-10	13107-13112	group	_
78-11	13113-13116	was	_
78-12	13117-13127	calculated	_
78-13	13128-13133	using	_
78-14	13134-13141	general	_
78-15	13142-13148	linear	_
78-16	13149-13154	model	_
78-17	13155-13160	based	_
78-18	13161-13163	on	_
78-19	13164-13167	the	_
78-20	13168-13172	rsFC	_
78-21	13173-13176	map	_
78-22	13177-13179	of	_
78-23	13180-13184	this	_
78-24	13185-13194	subregion	_
78-25	13195-13197	in	_
78-26	13198-13202	each	_
78-27	13203-13210	subject	_
78-28	13211-13212	(	_
78-29	13212-13215	FDR	_
78-30	13216-13225	corrected	_
78-31	13225-13226	,	_
78-32	13227-13228	P	_
78-33	13228-13229	 	_
78-34	13229-13230	<	_
78-35	13230-13231	 	_
78-36	13231-13235	0.01	_
78-37	13235-13236	,	_
78-38	13237-13247	two-tailed	_
78-39	13247-13248	)	_
78-40	13248-13249	.	_

#Text=We defined the positive rsFC map of each IPL subregion of each group derived from multiple first-level models with each investigating one region's connectivity as Mask A and that derived from one first-level model per subject as Mask B.
79-1	13250-13252	We	_
79-2	13253-13260	defined	_
79-3	13261-13264	the	_
79-4	13265-13273	positive	_
79-5	13274-13278	rsFC	_
79-6	13279-13282	map	_
79-7	13283-13285	of	_
79-8	13286-13290	each	_
79-9	13291-13294	IPL	_
79-10	13295-13304	subregion	_
79-11	13305-13307	of	_
79-12	13308-13312	each	_
79-13	13313-13318	group	_
79-14	13319-13326	derived	_
79-15	13327-13331	from	_
79-16	13332-13340	multiple	_
79-17	13341-13352	first-level	_
79-18	13353-13359	models	_
79-19	13360-13364	with	_
79-20	13365-13369	each	_
79-21	13370-13383	investigating	_
79-22	13384-13387	one	_
79-23	13388-13396	region's	_
79-24	13397-13409	connectivity	_
79-25	13410-13412	as	_
79-26	13413-13417	Mask	_
79-27	13418-13419	A	_
79-28	13420-13423	and	_
79-29	13424-13428	that	_
79-30	13429-13436	derived	_
79-31	13437-13441	from	_
79-32	13442-13445	one	_
79-33	13446-13457	first-level	_
79-34	13458-13463	model	_
79-35	13464-13467	per	_
79-36	13468-13475	subject	_
79-37	13476-13478	as	_
79-38	13479-13483	Mask	_
79-39	13484-13485	B	_
79-40	13485-13486	.	_

#Text=For each IPL subregion of each group, we projected the Mask A onto the Mask B to compare the spatial differences between the group-level rsFC maps of each IPL subregion derived from the two methods.
80-1	13487-13490	For	_
80-2	13491-13495	each	_
80-3	13496-13499	IPL	_
80-4	13500-13509	subregion	_
80-5	13510-13512	of	_
80-6	13513-13517	each	_
80-7	13518-13523	group	_
80-8	13523-13524	,	_
80-9	13525-13527	we	_
80-10	13528-13537	projected	_
80-11	13538-13541	the	_
80-12	13542-13546	Mask	_
80-13	13547-13548	A	_
80-14	13549-13553	onto	_
80-15	13554-13557	the	_
80-16	13558-13562	Mask	_
80-17	13563-13564	B	_
80-18	13565-13567	to	_
80-19	13568-13575	compare	_
80-20	13576-13579	the	_
80-21	13580-13587	spatial	_
80-22	13588-13599	differences	_
80-23	13600-13607	between	_
80-24	13608-13611	the	_
80-25	13612-13623	group-level	_
80-26	13624-13628	rsFC	_
80-27	13629-13633	maps	_
80-28	13634-13636	of	_
80-29	13637-13641	each	_
80-30	13642-13645	IPL	_
80-31	13646-13655	subregion	_
80-32	13656-13663	derived	_
80-33	13664-13668	from	_
80-34	13669-13672	the	_
80-35	13673-13676	two	_
80-36	13677-13684	methods	_
80-37	13684-13685	.	_

#Text=The spatial overlapping ratios of the rsFC maps of each IPL subregion derived from the two methods were calculated by the following equation: Overlapping ratio = (Mask A ∩ Mask B) / (Mask A ∪ Mask B).
81-1	13686-13689	The	_
81-2	13690-13697	spatial	_
81-3	13698-13709	overlapping	_
81-4	13710-13716	ratios	_
81-5	13717-13719	of	_
81-6	13720-13723	the	_
81-7	13724-13728	rsFC	_
81-8	13729-13733	maps	_
81-9	13734-13736	of	_
81-10	13737-13741	each	_
81-11	13742-13745	IPL	_
81-12	13746-13755	subregion	_
81-13	13756-13763	derived	_
81-14	13764-13768	from	_
81-15	13769-13772	the	_
81-16	13773-13776	two	_
81-17	13777-13784	methods	_
81-18	13785-13789	were	_
81-19	13790-13800	calculated	_
81-20	13801-13803	by	_
81-21	13804-13807	the	_
81-22	13808-13817	following	_
81-23	13818-13826	equation	_
81-24	13826-13827	:	_
81-25	13828-13839	Overlapping	_
81-26	13840-13845	ratio	_
81-27	13845-13846	 	_
81-28	13846-13847	=	_
81-29	13847-13848	 	_
81-30	13848-13849	(	_
81-31	13849-13853	Mask	_
81-32	13854-13855	A	_
81-33	13855-13856	 	_
81-34	13856-13857	∩	_
81-35	13857-13858	 	_
81-36	13858-13862	Mask	_
81-37	13863-13864	B	_
81-38	13864-13865	)	_
81-39	13865-13866	 	_
81-40	13866-13867	/	_
81-41	13867-13868	 	_
81-42	13868-13869	(	_
81-43	13869-13873	Mask	_
81-44	13874-13875	A	_
81-45	13875-13876	 	_
81-46	13876-13877	∪	_
81-47	13877-13878	 	_
81-48	13878-13882	Mask	_
81-49	13883-13884	B	_
81-50	13884-13885	)	_
81-51	13885-13886	.	_

#Text=Effect of antipsychotic treatments on rsFC changes in schizophrenia
#Text=Although most schizophrenia patients (n = 86) have received antipsychotic treatments, there were drug naïve patients (n = 9).
82-1	13887-13893	Effect	_
82-2	13894-13896	of	_
82-3	13897-13910	antipsychotic	_
82-4	13911-13921	treatments	_
82-5	13922-13924	on	_
82-6	13925-13929	rsFC	_
82-7	13930-13937	changes	_
82-8	13938-13940	in	_
82-9	13941-13954	schizophrenia	_
82-10	13955-13963	Although	_
82-11	13964-13968	most	_
82-12	13969-13982	schizophrenia	_
82-13	13983-13991	patients	_
82-14	13992-13993	(	_
82-15	13993-13994	n	_
82-16	13994-13995	 	_
82-17	13995-13996	=	_
82-18	13996-13997	 	_
82-19	13997-13999	86	_
82-20	13999-14000	)	_
82-21	14001-14005	have	_
82-22	14006-14014	received	_
82-23	14015-14028	antipsychotic	_
82-24	14029-14039	treatments	_
82-25	14039-14040	,	_
82-26	14041-14046	there	_
82-27	14047-14051	were	_
82-28	14052-14056	drug	_
82-29	14057-14062	naïve	_
82-30	14063-14071	patients	_
82-31	14072-14073	(	_
82-32	14073-14074	n	_
82-33	14074-14075	 	_
82-34	14075-14076	=	_
82-35	14076-14077	 	_
82-36	14077-14078	9	_
82-37	14078-14079	)	_
82-38	14079-14080	.	_

#Text=To explore the effect of antipsychotic treatments on rsFC changes in schizophrenia, we extracted rsFCs of the IPL subregions exhibiting significant intergroup difference from each patient and used two sample t-test to compare these rsFCs between the 9 drug-naïve patients and the 86 patients with antipsychotic treatments (P < 0.05, uncorrected).
83-1	14081-14083	To	_
83-2	14084-14091	explore	_
83-3	14092-14095	the	_
83-4	14096-14102	effect	_
83-5	14103-14105	of	_
83-6	14106-14119	antipsychotic	_
83-7	14120-14130	treatments	_
83-8	14131-14133	on	_
83-9	14134-14138	rsFC	_
83-10	14139-14146	changes	_
83-11	14147-14149	in	_
83-12	14150-14163	schizophrenia	_
83-13	14163-14164	,	_
83-14	14165-14167	we	_
83-15	14168-14177	extracted	_
83-16	14178-14183	rsFCs	_
83-17	14184-14186	of	_
83-18	14187-14190	the	_
83-19	14191-14194	IPL	_
83-20	14195-14205	subregions	_
83-21	14206-14216	exhibiting	_
83-22	14217-14228	significant	_
83-23	14229-14239	intergroup	_
83-24	14240-14250	difference	_
83-25	14251-14255	from	_
83-26	14256-14260	each	_
83-27	14261-14268	patient	_
83-28	14269-14272	and	_
83-29	14273-14277	used	_
83-30	14278-14281	two	_
83-31	14282-14288	sample	_
83-32	14289-14295	t-test	_
83-33	14296-14298	to	_
83-34	14299-14306	compare	_
83-35	14307-14312	these	_
83-36	14313-14318	rsFCs	_
83-37	14319-14326	between	_
83-38	14327-14330	the	_
83-39	14331-14332	9	_
83-40	14333-14343	drug-naïve	_
83-41	14344-14352	patients	_
83-42	14353-14356	and	_
83-43	14357-14360	the	_
83-44	14361-14363	86	_
83-45	14364-14372	patients	_
83-46	14373-14377	with	_
83-47	14378-14391	antipsychotic	_
83-48	14392-14402	treatments	_
83-49	14403-14404	(	_
83-50	14404-14405	P	_
83-51	14405-14406	 	_
83-52	14406-14407	<	_
83-53	14407-14408	 	_
83-54	14408-14412	0.05	_
83-55	14412-14413	,	_
83-56	14414-14425	uncorrected	_
83-57	14425-14426	)	_
83-58	14426-14427	.	_

#Text=Correlations with clinical parameters
#Text=To test potential correlations between the rsFCs of the IPL subregions with significant intergroup differences and the clinical variables, we extracted these rsFCs and calculated Spearman's correlation coefficients between these imaging measures and clinical parameters (i.e., PANSS scores, illness duration, and antipsychotic dosage).
84-1	14428-14440	Correlations	_
84-2	14441-14445	with	_
84-3	14446-14454	clinical	_
84-4	14455-14465	parameters	_
84-5	14466-14468	To	_
84-6	14469-14473	test	_
84-7	14474-14483	potential	_
84-8	14484-14496	correlations	_
84-9	14497-14504	between	_
84-10	14505-14508	the	_
84-11	14509-14514	rsFCs	_
84-12	14515-14517	of	_
84-13	14518-14521	the	_
84-14	14522-14525	IPL	_
84-15	14526-14536	subregions	_
84-16	14537-14541	with	_
84-17	14542-14553	significant	_
84-18	14554-14564	intergroup	_
84-19	14565-14576	differences	_
84-20	14577-14580	and	_
84-21	14581-14584	the	_
84-22	14585-14593	clinical	_
84-23	14594-14603	variables	_
84-24	14603-14604	,	_
84-25	14605-14607	we	_
84-26	14608-14617	extracted	_
84-27	14618-14623	these	_
84-28	14624-14629	rsFCs	_
84-29	14630-14633	and	_
84-30	14634-14644	calculated	_
84-31	14645-14655	Spearman's	_
84-32	14656-14667	correlation	_
84-33	14668-14680	coefficients	_
84-34	14681-14688	between	_
84-35	14689-14694	these	_
84-36	14695-14702	imaging	_
84-37	14703-14711	measures	_
84-38	14712-14715	and	_
84-39	14716-14724	clinical	_
84-40	14725-14735	parameters	_
84-41	14736-14737	(	_
84-42	14737-14740	i.e	_
84-43	14740-14741	.	_
84-44	14741-14742	,	_
84-45	14743-14748	PANSS	_
84-46	14749-14755	scores	_
84-47	14755-14756	,	_
84-48	14757-14764	illness	_
84-49	14765-14773	duration	_
84-50	14773-14774	,	_
84-51	14775-14778	and	_
84-52	14779-14792	antipsychotic	_
84-53	14793-14799	dosage	_
84-54	14799-14800	)	_
84-55	14800-14801	.	_

#Text=For these correlation analyses, the threshold of significance was set at P < 0.05, uncorrected.
85-1	14802-14805	For	_
85-2	14806-14811	these	_
85-3	14812-14823	correlation	_
85-4	14824-14832	analyses	_
85-5	14832-14833	,	_
85-6	14834-14837	the	_
85-7	14838-14847	threshold	_
85-8	14848-14850	of	_
85-9	14851-14863	significance	_
85-10	14864-14867	was	_
85-11	14868-14871	set	_
85-12	14872-14874	at	_
85-13	14875-14876	P	_
85-14	14876-14877	 	_
85-15	14877-14878	<	_
85-16	14878-14879	 	_
85-17	14879-14883	0.05	_
85-18	14883-14884	,	_
85-19	14885-14896	uncorrected	_
85-20	14896-14897	.	_

#Text=Results
#Text=Demographic and clinical characteristics of subjects
#Text=We finally included 95 schizophrenia patients (53 males; age: 34.1 ± 9.2 years) and 104 healthy controls (46 males; age: 33.8 ± 10.9 years).
86-1	14898-14905	Results	_
86-2	14906-14917	Demographic	_
86-3	14918-14921	and	_
86-4	14922-14930	clinical	_
86-5	14931-14946	characteristics	_
86-6	14947-14949	of	_
86-7	14950-14958	subjects	_
86-8	14959-14961	We	_
86-9	14962-14969	finally	_
86-10	14970-14978	included	_
86-11	14979-14981	95	_
86-12	14982-14995	schizophrenia	_
86-13	14996-15004	patients	_
86-14	15005-15006	(	_
86-15	15006-15008	53	_
86-16	15009-15014	males	_
86-17	15014-15015	;	_
86-18	15016-15019	age	_
86-19	15019-15020	:	_
86-20	15021-15025	34.1	_
86-21	15025-15026	 	_
86-22	15026-15027	±	_
86-23	15027-15028	 	_
86-24	15028-15031	9.2	_
86-25	15031-15032	 	_
86-26	15032-15037	years	_
86-27	15037-15038	)	_
86-28	15039-15042	and	_
86-29	15043-15046	104	_
86-30	15047-15054	healthy	_
86-31	15055-15063	controls	_
86-32	15064-15065	(	_
86-33	15065-15067	46	_
86-34	15068-15073	males	_
86-35	15073-15074	;	_
86-36	15075-15078	age	_
86-37	15078-15079	:	_
86-38	15080-15084	33.8	_
86-39	15084-15085	 	_
86-40	15085-15086	±	_
86-41	15086-15087	 	_
86-42	15087-15091	10.9	_
86-43	15091-15092	 	_
86-44	15092-15097	years	_
86-45	15097-15098	)	_
86-46	15098-15099	.	_

#Text=Their demographic and clinical characteristics were summarized in Table 1.
87-1	15100-15105	Their	_
87-2	15106-15117	demographic	_
87-3	15118-15121	and	_
87-4	15122-15130	clinical	_
87-5	15131-15146	characteristics	_
87-6	15147-15151	were	_
87-7	15152-15162	summarized	_
87-8	15163-15165	in	_
87-9	15166-15171	Table	_
87-10	15172-15173	1	_
87-11	15173-15174	.	_

#Text=There were no significant group differences in sex (χ2 = 2.65, df = 1, P = 0.10) and age (t = 0.22, df = 197, P = 0.83).
88-1	15175-15180	There	_
88-2	15181-15185	were	_
88-3	15186-15188	no	_
88-4	15189-15200	significant	_
88-5	15201-15206	group	_
88-6	15207-15218	differences	_
88-7	15219-15221	in	_
88-8	15222-15225	sex	_
88-9	15226-15227	(	_
88-10	15227-15229	χ2	_
88-11	15229-15230	 	_
88-12	15230-15231	=	_
88-13	15231-15232	 	_
88-14	15232-15236	2.65	_
88-15	15236-15237	,	_
88-16	15238-15240	df	_
88-17	15240-15241	 	_
88-18	15241-15242	=	_
88-19	15242-15243	 	_
88-20	15243-15244	1	_
88-21	15244-15245	,	_
88-22	15246-15247	P	_
88-23	15247-15248	 	_
88-24	15248-15249	=	_
88-25	15249-15250	 	_
88-26	15250-15254	0.10	_
88-27	15254-15255	)	_
88-28	15256-15259	and	_
88-29	15260-15263	age	_
88-30	15264-15265	(	_
88-31	15265-15266	t	_
88-32	15266-15267	 	_
88-33	15267-15268	=	_
88-34	15268-15269	 	_
88-35	15269-15273	0.22	_
88-36	15273-15274	,	_
88-37	15275-15277	df	_
88-38	15277-15278	 	_
88-39	15278-15279	=	_
88-40	15279-15280	 	_
88-41	15280-15283	197	_
88-42	15283-15284	,	_
88-43	15285-15286	P	_
88-44	15286-15287	 	_
88-45	15287-15288	=	_
88-46	15288-15289	 	_
88-47	15289-15293	0.83	_
88-48	15293-15294	)	_
88-49	15294-15295	.	_

#Text=Nine patients had never received any medications, and the remaining 86 patients were receiving one or more atypical antipsychotics when performing the MRI scans.
89-1	15296-15300	Nine	_
89-2	15301-15309	patients	_
89-3	15310-15313	had	_
89-4	15314-15319	never	_
89-5	15320-15328	received	_
89-6	15329-15332	any	_
89-7	15333-15344	medications	_
89-8	15344-15345	,	_
89-9	15346-15349	and	_
89-10	15350-15353	the	_
89-11	15354-15363	remaining	_
89-12	15364-15366	86	_
89-13	15367-15375	patients	_
89-14	15376-15380	were	_
89-15	15381-15390	receiving	_
89-16	15391-15394	one	_
89-17	15395-15397	or	_
89-18	15398-15402	more	_
89-19	15403-15411	atypical	_
89-20	15412-15426	antipsychotics	_
89-21	15427-15431	when	_
89-22	15432-15442	performing	_
89-23	15443-15446	the	_
89-24	15447-15450	MRI	_
89-25	15451-15456	scans	_
89-26	15456-15457	.	_

#Text=GMV differences in the IPL subregions
#Text=Among the 11 IPL subregions, 8 subregions showed significantly reduced GMV in schizophrenia (P < 0.05, Bonferroni corrected) (Fig.
90-1	15458-15461	GMV	_
90-2	15462-15473	differences	_
90-3	15474-15476	in	_
90-4	15477-15480	the	_
90-5	15481-15484	IPL	_
90-6	15485-15495	subregions	_
90-7	15496-15501	Among	_
90-8	15502-15505	the	_
90-9	15506-15508	11	_
90-10	15509-15512	IPL	_
90-11	15513-15523	subregions	_
90-12	15523-15524	,	_
90-13	15525-15526	8	_
90-14	15527-15537	subregions	_
90-15	15538-15544	showed	_
90-16	15545-15558	significantly	_
90-17	15559-15566	reduced	_
90-18	15567-15570	GMV	_
90-19	15571-15573	in	_
90-20	15574-15587	schizophrenia	_
90-21	15588-15589	(	_
90-22	15589-15590	P	_
90-23	15590-15591	 	_
90-24	15591-15592	<	_
90-25	15592-15593	 	_
90-26	15593-15597	0.05	_
90-27	15597-15598	,	_
90-28	15599-15609	Bonferroni	_
90-29	15610-15619	corrected	_
90-30	15619-15620	)	_
90-31	15621-15622	(	_
90-32	15622-15625	Fig	_
90-33	15625-15626	.	_

#Text=S1).
91-1	15627-15629	S1	_
91-2	15629-15630	)	_
91-3	15630-15631	.	_

#Text=The rsFC maps of each IPL subregion
#Text=The rsFC maps of the IPL subregions (P < 0.01, FDR corrected, two-tailed) in both groups are depicted in Fig. 2.
92-1	15632-15635	The	_
92-2	15636-15640	rsFC	_
92-3	15641-15645	maps	_
92-4	15646-15648	of	_
92-5	15649-15653	each	_
92-6	15654-15657	IPL	_
92-7	15658-15667	subregion	_
92-8	15668-15671	The	_
92-9	15672-15676	rsFC	_
92-10	15677-15681	maps	_
92-11	15682-15684	of	_
92-12	15685-15688	the	_
92-13	15689-15692	IPL	_
92-14	15693-15703	subregions	_
92-15	15704-15705	(	_
92-16	15705-15706	P	_
92-17	15706-15707	 	_
92-18	15707-15708	<	_
92-19	15708-15709	 	_
92-20	15709-15713	0.01	_
92-21	15713-15714	,	_
92-22	15715-15718	FDR	_
92-23	15719-15728	corrected	_
92-24	15728-15729	,	_
92-25	15730-15740	two-tailed	_
92-26	15740-15741	)	_
92-27	15742-15744	in	_
92-28	15745-15749	both	_
92-29	15750-15756	groups	_
92-30	15757-15760	are	_
92-31	15761-15769	depicted	_
92-32	15770-15772	in	_
92-33	15773-15776	Fig	_
92-34	15776-15777	.	_
92-35	15778-15779	2	_
92-36	15779-15780	.	_

#Text=In healthy subjects, four types of connectivity patterns were found.
93-1	15781-15783	In	_
93-2	15784-15791	healthy	_
93-3	15792-15800	subjects	_
93-4	15800-15801	,	_
93-5	15802-15806	four	_
93-6	15807-15812	types	_
93-7	15813-15815	of	_
93-8	15816-15828	connectivity	_
93-9	15829-15837	patterns	_
93-10	15838-15842	were	_
93-11	15843-15848	found	_
93-12	15848-15849	.	_

#Text=The left PFt and PFop and the right PF + PFt similarly connected with the sensorimotor, lateral frontal, temporal, parietal, occipital, insular, and anterior portion of the cingulate cortices.
94-1	15850-15853	The	_
94-2	15854-15858	left	_
94-3	15859-15862	PFt	_
94-4	15863-15866	and	_
94-5	15867-15871	PFop	_
94-6	15872-15875	and	_
94-7	15876-15879	the	_
94-8	15880-15885	right	_
94-9	15886-15888	PF	_
94-10	15888-15889	 	_
94-11	15889-15890	+	_
94-12	15890-15891	 	_
94-13	15891-15894	PFt	_
94-14	15895-15904	similarly	_
94-15	15905-15914	connected	_
94-16	15915-15919	with	_
94-17	15920-15923	the	_
94-18	15924-15936	sensorimotor	_
94-19	15936-15937	,	_
94-20	15938-15945	lateral	_
94-21	15946-15953	frontal	_
94-22	15953-15954	,	_
94-23	15955-15963	temporal	_
94-24	15963-15964	,	_
94-25	15965-15973	parietal	_
94-26	15973-15974	,	_
94-27	15975-15984	occipital	_
94-28	15984-15985	,	_
94-29	15986-15993	insular	_
94-30	15993-15994	,	_
94-31	15995-15998	and	_
94-32	15999-16007	anterior	_
94-33	16008-16015	portion	_
94-34	16016-16018	of	_
94-35	16019-16022	the	_
94-36	16023-16032	cingulate	_
94-37	16033-16041	cortices	_
94-38	16041-16042	.	_

#Text=The left PF + PFcm and the right PFop showed similar connectivity patterns except that they less connected with the sensorimotor and occipital cortices.
95-1	16043-16046	The	_
95-2	16047-16051	left	_
95-3	16052-16054	PF	_
95-4	16054-16055	 	_
95-5	16055-16056	+	_
95-6	16056-16057	 	_
95-7	16057-16061	PFcm	_
95-8	16062-16065	and	_
95-9	16066-16069	the	_
95-10	16070-16075	right	_
95-11	16076-16080	PFop	_
95-12	16081-16087	showed	_
95-13	16088-16095	similar	_
95-14	16096-16108	connectivity	_
95-15	16109-16117	patterns	_
95-16	16118-16124	except	_
95-17	16125-16129	that	_
95-18	16130-16134	they	_
95-19	16135-16139	less	_
95-20	16140-16149	connected	_
95-21	16150-16154	with	_
95-22	16155-16158	the	_
95-23	16159-16171	sensorimotor	_
95-24	16172-16175	and	_
95-25	16176-16185	occipital	_
95-26	16186-16194	cortices	_
95-27	16194-16195	.	_

#Text=The left PFm and the bilateral PGa and PGp similarly connected with brain regions of the default-mode network, including the anterior cingulate cortex/medial prefrontal cortex, posterior cingulate cortex/precuneus, lateral parietal cortex, anterior temporal cortex, and lateral prefrontal cortex.
96-1	16196-16199	The	_
96-2	16200-16204	left	_
96-3	16205-16208	PFm	_
96-4	16209-16212	and	_
96-5	16213-16216	the	_
96-6	16217-16226	bilateral	_
96-7	16227-16230	PGa	_
96-8	16231-16234	and	_
96-9	16235-16238	PGp	_
96-10	16239-16248	similarly	_
96-11	16249-16258	connected	_
96-12	16259-16263	with	_
96-13	16264-16269	brain	_
96-14	16270-16277	regions	_
96-15	16278-16280	of	_
96-16	16281-16284	the	_
96-17	16285-16297	default-mode	_
96-18	16298-16305	network	_
96-19	16305-16306	,	_
96-20	16307-16316	including	_
96-21	16317-16320	the	_
96-22	16321-16329	anterior	_
96-23	16330-16339	cingulate	_
96-24	16340-16346	cortex	_
96-25	16346-16347	/	_
96-26	16347-16353	medial	_
96-27	16354-16364	prefrontal	_
96-28	16365-16371	cortex	_
96-29	16371-16372	,	_
96-30	16373-16382	posterior	_
96-31	16383-16392	cingulate	_
96-32	16393-16399	cortex	_
96-33	16399-16400	/	_
96-34	16400-16409	precuneus	_
96-35	16409-16410	,	_
96-36	16411-16418	lateral	_
96-37	16419-16427	parietal	_
96-38	16428-16434	cortex	_
96-39	16434-16435	,	_
96-40	16436-16444	anterior	_
96-41	16445-16453	temporal	_
96-42	16454-16460	cortex	_
96-43	16460-16461	,	_
96-44	16462-16465	and	_
96-45	16466-16473	lateral	_
96-46	16474-16484	prefrontal	_
96-47	16485-16491	cortex	_
96-48	16491-16492	.	_

#Text=The right PFm had a transition connectivity pattern between the latter two types of IPL subregions.
97-1	16493-16496	The	_
97-2	16497-16502	right	_
97-3	16503-16506	PFm	_
97-4	16507-16510	had	_
97-5	16511-16512	a	_
97-6	16513-16523	transition	_
97-7	16524-16536	connectivity	_
97-8	16537-16544	pattern	_
97-9	16545-16552	between	_
97-10	16553-16556	the	_
97-11	16557-16563	latter	_
97-12	16564-16567	two	_
97-13	16568-16573	types	_
97-14	16574-16576	of	_
97-15	16577-16580	IPL	_
97-16	16581-16591	subregions	_
97-17	16591-16592	.	_

#Text=The connectivity patterns of the IPL subregions in schizophrenia patients were very similar with those in healthy controls, except that the right PFop and the bilateal PFm and PGa had more connections with the sensorimotor and occipital cortices in schizophrenia patients than in healthy controls.
98-1	16593-16596	The	_
98-2	16597-16609	connectivity	_
98-3	16610-16618	patterns	_
98-4	16619-16621	of	_
98-5	16622-16625	the	_
98-6	16626-16629	IPL	_
98-7	16630-16640	subregions	_
98-8	16641-16643	in	_
98-9	16644-16657	schizophrenia	_
98-10	16658-16666	patients	_
98-11	16667-16671	were	_
98-12	16672-16676	very	_
98-13	16677-16684	similar	_
98-14	16685-16689	with	_
98-15	16690-16695	those	_
98-16	16696-16698	in	_
98-17	16699-16706	healthy	_
98-18	16707-16715	controls	_
98-19	16715-16716	,	_
98-20	16717-16723	except	_
98-21	16724-16728	that	_
98-22	16729-16732	the	_
98-23	16733-16738	right	_
98-24	16739-16743	PFop	_
98-25	16744-16747	and	_
98-26	16748-16751	the	_
98-27	16752-16760	bilateal	_
98-28	16761-16764	PFm	_
98-29	16765-16768	and	_
98-30	16769-16772	PGa	_
98-31	16773-16776	had	_
98-32	16777-16781	more	_
98-33	16782-16793	connections	_
98-34	16794-16798	with	_
98-35	16799-16802	the	_
98-36	16803-16815	sensorimotor	_
98-37	16816-16819	and	_
98-38	16820-16829	occipital	_
98-39	16830-16838	cortices	_
98-40	16839-16841	in	_
98-41	16842-16855	schizophrenia	_
98-42	16856-16864	patients	_
98-43	16865-16869	than	_
98-44	16870-16872	in	_
98-45	16873-16880	healthy	_
98-46	16881-16889	controls	_
98-47	16889-16890	.	_

#Text=Validation analysis of the group-level rsFC pattern of each IPL subregion
#Text=The rsFC map of each IPL subregion derived from one first-level model per subject (P < 0.01, FDR corrected, two-tailed) is shown in Fig.
99-1	16891-16901	Validation	_
99-2	16902-16910	analysis	_
99-3	16911-16913	of	_
99-4	16914-16917	the	_
99-5	16918-16929	group-level	_
99-6	16930-16934	rsFC	_
99-7	16935-16942	pattern	_
99-8	16943-16945	of	_
99-9	16946-16950	each	_
99-10	16951-16954	IPL	_
99-11	16955-16964	subregion	_
99-12	16965-16968	The	_
99-13	16969-16973	rsFC	_
99-14	16974-16977	map	_
99-15	16978-16980	of	_
99-16	16981-16985	each	_
99-17	16986-16989	IPL	_
99-18	16990-16999	subregion	_
99-19	17000-17007	derived	_
99-20	17008-17012	from	_
99-21	17013-17016	one	_
99-22	17017-17028	first-level	_
99-23	17029-17034	model	_
99-24	17035-17038	per	_
99-25	17039-17046	subject	_
99-26	17047-17048	(	_
99-27	17048-17049	P	_
99-28	17049-17050	 	_
99-29	17050-17051	<	_
99-30	17051-17052	 	_
99-31	17052-17056	0.01	_
99-32	17056-17057	,	_
99-33	17058-17061	FDR	_
99-34	17062-17071	corrected	_
99-35	17071-17072	,	_
99-36	17073-17083	two-tailed	_
99-37	17083-17084	)	_
99-38	17085-17087	is	_
99-39	17088-17093	shown	_
99-40	17094-17096	in	_
99-41	17097-17100	Fig	_
99-42	17100-17101	.	_

#Text=S2.
100-1	17102-17104	S2	_
100-2	17104-17105	.	_

#Text=The rsFC maps derived from the two methods were highly overlapped in spatial distributions (Fig.
101-1	17106-17109	The	_
101-2	17110-17114	rsFC	_
101-3	17115-17119	maps	_
101-4	17120-17127	derived	_
101-5	17128-17132	from	_
101-6	17133-17136	the	_
101-7	17137-17140	two	_
101-8	17141-17148	methods	_
101-9	17149-17153	were	_
101-10	17154-17160	highly	_
101-11	17161-17171	overlapped	_
101-12	17172-17174	in	_
101-13	17175-17182	spatial	_
101-14	17183-17196	distributions	_
101-15	17197-17198	(	_
101-16	17198-17201	Fig	_
101-17	17201-17202	.	_

#Text=S3).
102-1	17203-17205	S3	_
102-2	17205-17206	)	_
102-3	17206-17207	.	_

#Text=As shown in Table S1, the spatial overlapping ratios are ranged from 95.48% to 98.96%.
103-1	17208-17210	As	_
103-2	17211-17216	shown	_
103-3	17217-17219	in	_
103-4	17220-17225	Table	_
103-5	17226-17228	S1	_
103-6	17228-17229	,	_
103-7	17230-17233	the	_
103-8	17234-17241	spatial	_
103-9	17242-17253	overlapping	_
103-10	17254-17260	ratios	_
103-11	17261-17264	are	_
103-12	17265-17271	ranged	_
103-13	17272-17276	from	_
103-14	17277-17283	95.48%	_
103-15	17284-17286	to	_
103-16	17287-17293	98.96%	_
103-17	17293-17294	.	_

#Text=The highly consistency between the two methods for rsFC calculation suggests that the rsFC maps of the IPL subregions derived from multiple first-level models are also reliable.
104-1	17295-17298	The	_
104-2	17299-17305	highly	_
104-3	17306-17317	consistency	_
104-4	17318-17325	between	_
104-5	17326-17329	the	_
104-6	17330-17333	two	_
104-7	17334-17341	methods	_
104-8	17342-17345	for	_
104-9	17346-17350	rsFC	_
104-10	17351-17362	calculation	_
104-11	17363-17371	suggests	_
104-12	17372-17376	that	_
104-13	17377-17380	the	_
104-14	17381-17385	rsFC	_
104-15	17386-17390	maps	_
104-16	17391-17393	of	_
104-17	17394-17397	the	_
104-18	17398-17401	IPL	_
104-19	17402-17412	subregions	_
104-20	17413-17420	derived	_
104-21	17421-17425	from	_
104-22	17426-17434	multiple	_
104-23	17435-17446	first-level	_
104-24	17447-17453	models	_
104-25	17454-17457	are	_
104-26	17458-17462	also	_
104-27	17463-17471	reliable	_
104-28	17471-17472	.	_

#Text=The rsFC differences of each IPL subregion between groups
#Text=Among the 11 IPL subregions, only the right PFm showed significant rsFC differences (P < 0.05/11 = 0.0045, FDR corrected, two-tailed) between the two groups (Fig. 3A).
105-1	17473-17476	The	_
105-2	17477-17481	rsFC	_
105-3	17482-17493	differences	_
105-4	17494-17496	of	_
105-5	17497-17501	each	_
105-6	17502-17505	IPL	_
105-7	17506-17515	subregion	_
105-8	17516-17523	between	_
105-9	17524-17530	groups	_
105-10	17531-17536	Among	_
105-11	17537-17540	the	_
105-12	17541-17543	11	_
105-13	17544-17547	IPL	_
105-14	17548-17558	subregions	_
105-15	17558-17559	,	_
105-16	17560-17564	only	_
105-17	17565-17568	the	_
105-18	17569-17574	right	_
105-19	17575-17578	PFm	_
105-20	17579-17585	showed	_
105-21	17586-17597	significant	_
105-22	17598-17602	rsFC	_
105-23	17603-17614	differences	_
105-24	17615-17616	(	_
105-25	17616-17617	P	_
105-26	17617-17618	 	_
105-27	17618-17619	<	_
105-28	17619-17620	 	_
105-29	17620-17624	0.05	_
105-30	17624-17625	/	_
105-31	17625-17627	11	_
105-32	17627-17628	 	_
105-33	17628-17629	=	_
105-34	17629-17630	 	_
105-35	17630-17636	0.0045	_
105-36	17636-17637	,	_
105-37	17638-17641	FDR	_
105-38	17642-17651	corrected	_
105-39	17651-17652	,	_
105-40	17653-17663	two-tailed	_
105-41	17663-17664	)	_
105-42	17665-17672	between	_
105-43	17673-17676	the	_
105-44	17677-17680	two	_
105-45	17681-17687	groups	_
105-46	17688-17689	(	_
105-47	17689-17692	Fig	_
105-48	17692-17693	.	_
105-49	17694-17696	3A	_
105-50	17696-17697	)	_
105-51	17697-17698	.	_

#Text=Compared with healthy controls, schizophrenia patients exhibited increased rsFC between the left PFm and the bilateral sensorimotor cortices.
106-1	17699-17707	Compared	_
106-2	17708-17712	with	_
106-3	17713-17720	healthy	_
106-4	17721-17729	controls	_
106-5	17729-17730	,	_
106-6	17731-17744	schizophrenia	_
106-7	17745-17753	patients	_
106-8	17754-17763	exhibited	_
106-9	17764-17773	increased	_
106-10	17774-17778	rsFC	_
106-11	17779-17786	between	_
106-12	17787-17790	the	_
106-13	17791-17795	left	_
106-14	17796-17799	PFm	_
106-15	17800-17803	and	_
106-16	17804-17807	the	_
106-17	17808-17817	bilateral	_
106-18	17818-17830	sensorimotor	_
106-19	17831-17839	cortices	_
106-20	17839-17840	.	_

#Text=To reduce type II error, we also used a lenient statistical threshold (P < 0.01, FDR corrected, two-tailed).
107-1	17841-17843	To	_
107-2	17844-17850	reduce	_
107-3	17851-17855	type	_
107-4	17856-17858	II	_
107-5	17859-17864	error	_
107-6	17864-17865	,	_
107-7	17866-17868	we	_
107-8	17869-17873	also	_
107-9	17874-17878	used	_
107-10	17879-17880	a	_
107-11	17881-17888	lenient	_
107-12	17889-17900	statistical	_
107-13	17901-17910	threshold	_
107-14	17911-17912	(	_
107-15	17912-17913	P	_
107-16	17913-17914	 	_
107-17	17914-17915	<	_
107-18	17915-17916	 	_
107-19	17916-17920	0.01	_
107-20	17920-17921	,	_
107-21	17922-17925	FDR	_
107-22	17926-17935	corrected	_
107-23	17935-17936	,	_
107-24	17937-17947	two-tailed	_
107-25	17947-17948	)	_
107-26	17948-17949	.	_

#Text=Among the 11 IPL subregions, only the bilateral PFm subregions showed significant rsFCs differences between the two groups (Table 2, Fig. 3B and C).
108-1	17950-17955	Among	_
108-2	17956-17959	the	_
108-3	17960-17962	11	_
108-4	17963-17966	IPL	_
108-5	17967-17977	subregions	_
108-6	17977-17978	,	_
108-7	17979-17983	only	_
108-8	17984-17987	the	_
108-9	17988-17997	bilateral	_
108-10	17998-18001	PFm	_
108-11	18002-18012	subregions	_
108-12	18013-18019	showed	_
108-13	18020-18031	significant	_
108-14	18032-18037	rsFCs	_
108-15	18038-18049	differences	_
108-16	18050-18057	between	_
108-17	18058-18061	the	_
108-18	18062-18065	two	_
108-19	18066-18072	groups	_
108-20	18073-18074	(	_
108-21	18074-18079	Table	_
108-22	18080-18081	2	_
108-23	18081-18082	,	_
108-24	18083-18086	Fig	_
108-25	18086-18087	.	_
108-26	18088-18090	3B	_
108-27	18091-18094	and	_
108-28	18095-18096	C	_
108-29	18096-18097	)	_
108-30	18097-18098	.	_

#Text=Compared with healthy controls, schizophrenia patients exhibited increased rsFC between the left PFm and the bilateral lingual gyri.
109-1	18099-18107	Compared	_
109-2	18108-18112	with	_
109-3	18113-18120	healthy	_
109-4	18121-18129	controls	_
109-5	18129-18130	,	_
109-6	18131-18144	schizophrenia	_
109-7	18145-18153	patients	_
109-8	18154-18163	exhibited	_
109-9	18164-18173	increased	_
109-10	18174-18178	rsFC	_
109-11	18179-18186	between	_
109-12	18187-18190	the	_
109-13	18191-18195	left	_
109-14	18196-18199	PFm	_
109-15	18200-18203	and	_
109-16	18204-18207	the	_
109-17	18208-18217	bilateral	_
109-18	18218-18225	lingual	_
109-19	18226-18230	gyri	_
109-20	18230-18231	.	_

#Text=The right PFm also exhibited increased rsFC with the right lingual and inferior occipital gyri and the bilateral mid-cingulate and sensorimotor cortices.
110-1	18232-18235	The	_
110-2	18236-18241	right	_
110-3	18242-18245	PFm	_
110-4	18246-18250	also	_
110-5	18251-18260	exhibited	_
110-6	18261-18270	increased	_
110-7	18271-18275	rsFC	_
110-8	18276-18280	with	_
110-9	18281-18284	the	_
110-10	18285-18290	right	_
110-11	18291-18298	lingual	_
110-12	18299-18302	and	_
110-13	18303-18311	inferior	_
110-14	18312-18321	occipital	_
110-15	18322-18326	gyri	_
110-16	18327-18330	and	_
110-17	18331-18334	the	_
110-18	18335-18344	bilateral	_
110-19	18345-18358	mid-cingulate	_
110-20	18359-18362	and	_
110-21	18363-18375	sensorimotor	_
110-22	18376-18384	cortices	_
110-23	18384-18385	.	_

#Text=We also compared these rsFCs between the 9 drug-naïve patients and the 86 patients with antipsychotic treatments and did not find any significant intergroup differences (P < 0.05, uncorrected) (Fig.
111-1	18386-18388	We	_
111-2	18389-18393	also	_
111-3	18394-18402	compared	_
111-4	18403-18408	these	_
111-5	18409-18414	rsFCs	_
111-6	18415-18422	between	_
111-7	18423-18426	the	_
111-8	18427-18428	9	_
111-9	18429-18439	drug-naïve	_
111-10	18440-18448	patients	_
111-11	18449-18452	and	_
111-12	18453-18456	the	_
111-13	18457-18459	86	_
111-14	18460-18468	patients	_
111-15	18469-18473	with	_
111-16	18474-18487	antipsychotic	_
111-17	18488-18498	treatments	_
111-18	18499-18502	and	_
111-19	18503-18506	did	_
111-20	18507-18510	not	_
111-21	18511-18515	find	_
111-22	18516-18519	any	_
111-23	18520-18531	significant	_
111-24	18532-18542	intergroup	_
111-25	18543-18554	differences	_
111-26	18555-18556	(	_
111-27	18556-18557	P	_
111-28	18557-18558	 	_
111-29	18558-18559	<	_
111-30	18559-18560	 	_
111-31	18560-18564	0.05	_
111-32	18564-18565	,	_
111-33	18566-18577	uncorrected	_
111-34	18577-18578	)	_
111-35	18579-18580	(	_
111-36	18580-18583	Fig	_
111-37	18583-18584	.	_

#Text=S4).
112-1	18585-18587	S4	_
112-2	18587-18588	)	_
112-3	18588-18589	.	_

#Text=Correlations with clinical parameters
#Text=We extracted rsFCs of the IPL with significant intergroup differences and correlated with clinical parameters, including the illness duration, PANSS scores, and current antipsychotic dosage in chlorpromazine equivalents.
113-1	18590-18602	Correlations	_
113-2	18603-18607	with	_
113-3	18608-18616	clinical	_
113-4	18617-18627	parameters	_
113-5	18628-18630	We	_
113-6	18631-18640	extracted	_
113-7	18641-18646	rsFCs	_
113-8	18647-18649	of	_
113-9	18650-18653	the	_
113-10	18654-18657	IPL	_
113-11	18658-18662	with	_
113-12	18663-18674	significant	_
113-13	18675-18685	intergroup	_
113-14	18686-18697	differences	_
113-15	18698-18701	and	_
113-16	18702-18712	correlated	_
113-17	18713-18717	with	_
113-18	18718-18726	clinical	_
113-19	18727-18737	parameters	_
113-20	18737-18738	,	_
113-21	18739-18748	including	_
113-22	18749-18752	the	_
113-23	18753-18760	illness	_
113-24	18761-18769	duration	_
113-25	18769-18770	,	_
113-26	18771-18776	PANSS	_
113-27	18777-18783	scores	_
113-28	18783-18784	,	_
113-29	18785-18788	and	_
113-30	18789-18796	current	_
113-31	18797-18810	antipsychotic	_
113-32	18811-18817	dosage	_
113-33	18818-18820	in	_
113-34	18821-18835	chlorpromazine	_
113-35	18836-18847	equivalents	_
113-36	18847-18848	.	_

#Text=However, we did not find any significant correlations (P < 0.05, uncorrected).
114-1	18849-18856	However	_
114-2	18856-18857	,	_
114-3	18858-18860	we	_
114-4	18861-18864	did	_
114-5	18865-18868	not	_
114-6	18869-18873	find	_
114-7	18874-18877	any	_
114-8	18878-18889	significant	_
114-9	18890-18902	correlations	_
114-10	18903-18904	(	_
114-11	18904-18905	P	_
114-12	18905-18906	 	_
114-13	18906-18907	<	_
114-14	18907-18908	 	_
114-15	18908-18912	0.05	_
114-16	18912-18913	,	_
114-17	18914-18925	uncorrected	_
114-18	18925-18926	)	_
114-19	18926-18927	.	_

#Text=Discussion
#Text=In this study, we systematically investigated the rsFC changes of the IPL subregions in schizophrenia.
115-1	18928-18938	Discussion	_
115-2	18939-18941	In	_
115-3	18942-18946	this	_
115-4	18947-18952	study	_
115-5	18952-18953	,	_
115-6	18954-18956	we	_
115-7	18957-18971	systematically	_
115-8	18972-18984	investigated	_
115-9	18985-18988	the	_
115-10	18989-18993	rsFC	_
115-11	18994-19001	changes	_
115-12	19002-19004	of	_
115-13	19005-19008	the	_
115-14	19009-19012	IPL	_
115-15	19013-19023	subregions	_
115-16	19024-19026	in	_
115-17	19027-19040	schizophrenia	_
115-18	19040-19041	.	_

#Text=We found that only the PFm had significantly increased rsFC with the visual and sensorimotor regions in schizophrenia patients than in healthy subjects.
116-1	19042-19044	We	_
116-2	19045-19050	found	_
116-3	19051-19055	that	_
116-4	19056-19060	only	_
116-5	19061-19064	the	_
116-6	19065-19068	PFm	_
116-7	19069-19072	had	_
116-8	19073-19086	significantly	_
116-9	19087-19096	increased	_
116-10	19097-19101	rsFC	_
116-11	19102-19106	with	_
116-12	19107-19110	the	_
116-13	19111-19117	visual	_
116-14	19118-19121	and	_
116-15	19122-19134	sensorimotor	_
116-16	19135-19142	regions	_
116-17	19143-19145	in	_
116-18	19146-19159	schizophrenia	_
116-19	19160-19168	patients	_
116-20	19169-19173	than	_
116-21	19174-19176	in	_
116-22	19177-19184	healthy	_
116-23	19185-19193	subjects	_
116-24	19193-19194	.	_

#Text=This finding suggests that the rsFCs of the IPL subregions are selectively involved in schizophrenia.
117-1	19195-19199	This	_
117-2	19200-19207	finding	_
117-3	19208-19216	suggests	_
117-4	19217-19221	that	_
117-5	19222-19225	the	_
117-6	19226-19231	rsFCs	_
117-7	19232-19234	of	_
117-8	19235-19238	the	_
117-9	19239-19242	IPL	_
117-10	19243-19253	subregions	_
117-11	19254-19257	are	_
117-12	19258-19269	selectively	_
117-13	19270-19278	involved	_
117-14	19279-19281	in	_
117-15	19282-19295	schizophrenia	_
117-16	19295-19296	.	_

#Text=The IPL is anatomically highly variable because it is one of the last areas of the human brain to mature.
118-1	19297-19300	The	_
118-2	19301-19304	IPL	_
118-3	19305-19307	is	_
118-4	19308-19320	anatomically	_
118-5	19321-19327	highly	_
118-6	19328-19336	variable	_
118-7	19337-19344	because	_
118-8	19345-19347	it	_
118-9	19348-19350	is	_
118-10	19351-19354	one	_
118-11	19355-19357	of	_
118-12	19358-19361	the	_
118-13	19362-19366	last	_
118-14	19367-19372	areas	_
118-15	19373-19375	of	_
118-16	19376-19379	the	_
118-17	19380-19385	human	_
118-18	19386-19391	brain	_
118-19	19392-19394	to	_
118-20	19395-19401	mature	_
118-21	19401-19402	.	_

#Text=Moreover, the IPL is among the most highly lateralized areas of the brain.
119-1	19403-19411	Moreover	_
119-2	19411-19412	,	_
119-3	19413-19416	the	_
119-4	19417-19420	IPL	_
119-5	19421-19423	is	_
119-6	19424-19429	among	_
119-7	19430-19433	the	_
119-8	19434-19438	most	_
119-9	19439-19445	highly	_
119-10	19446-19457	lateralized	_
119-11	19458-19463	areas	_
119-12	19464-19466	of	_
119-13	19467-19470	the	_
119-14	19471-19476	brain	_
119-15	19476-19477	.	_

#Text=These may explain why the left IPL is parcellated into 6 subregions but the right IPL is parcellated into 5 subregions based on diffusion MRI data.
120-1	19478-19483	These	_
120-2	19484-19487	may	_
120-3	19488-19495	explain	_
120-4	19496-19499	why	_
120-5	19500-19503	the	_
120-6	19504-19508	left	_
120-7	19509-19512	IPL	_
120-8	19513-19515	is	_
120-9	19516-19527	parcellated	_
120-10	19528-19532	into	_
120-11	19533-19534	6	_
120-12	19535-19545	subregions	_
120-13	19546-19549	but	_
120-14	19550-19553	the	_
120-15	19554-19559	right	_
120-16	19560-19563	IPL	_
120-17	19564-19566	is	_
120-18	19567-19578	parcellated	_
120-19	19579-19583	into	_
120-20	19584-19585	5	_
120-21	19586-19596	subregions	_
120-22	19597-19602	based	_
120-23	19603-19605	on	_
120-24	19606-19615	diffusion	_
120-25	19616-19619	MRI	_
120-26	19620-19624	data	_
120-27	19624-19625	.	_

#Text=These factors may be also associated with the differences in the rsFC patterns of some homologous subregions in healthy subjects, for example, the rsFC between the PFop and the occipital and sensorimotor cortices and the rsFC between the PFm and the medial prefrontal cortex (Fig. 2).
121-1	19626-19631	These	_
121-2	19632-19639	factors	_
121-3	19640-19643	may	_
121-4	19644-19646	be	_
121-5	19647-19651	also	_
121-6	19652-19662	associated	_
121-7	19663-19667	with	_
121-8	19668-19671	the	_
121-9	19672-19683	differences	_
121-10	19684-19686	in	_
121-11	19687-19690	the	_
121-12	19691-19695	rsFC	_
121-13	19696-19704	patterns	_
121-14	19705-19707	of	_
121-15	19708-19712	some	_
121-16	19713-19723	homologous	_
121-17	19724-19734	subregions	_
121-18	19735-19737	in	_
121-19	19738-19745	healthy	_
121-20	19746-19754	subjects	_
121-21	19754-19755	,	_
121-22	19756-19759	for	_
121-23	19760-19767	example	_
121-24	19767-19768	,	_
121-25	19769-19772	the	_
121-26	19773-19777	rsFC	_
121-27	19778-19785	between	_
121-28	19786-19789	the	_
121-29	19790-19794	PFop	_
121-30	19795-19798	and	_
121-31	19799-19802	the	_
121-32	19803-19812	occipital	_
121-33	19813-19816	and	_
121-34	19817-19829	sensorimotor	_
121-35	19830-19838	cortices	_
121-36	19839-19842	and	_
121-37	19843-19846	the	_
121-38	19847-19851	rsFC	_
121-39	19852-19859	between	_
121-40	19860-19863	the	_
121-41	19864-19867	PFm	_
121-42	19868-19871	and	_
121-43	19872-19875	the	_
121-44	19876-19882	medial	_
121-45	19883-19893	prefrontal	_
121-46	19894-19900	cortex	_
121-47	19901-19902	(	_
121-48	19902-19905	Fig	_
121-49	19905-19906	.	_
121-50	19907-19908	2	_
121-51	19908-19909	)	_
121-52	19909-19910	.	_

#Text=Although the IPL is highly variable and lateralized, we found that the PFm was the only IPL subregion that exhibited significant rsFC changes in schizophrenia.
122-1	19911-19919	Although	_
122-2	19920-19923	the	_
122-3	19924-19927	IPL	_
122-4	19928-19930	is	_
122-5	19931-19937	highly	_
122-6	19938-19946	variable	_
122-7	19947-19950	and	_
122-8	19951-19962	lateralized	_
122-9	19962-19963	,	_
122-10	19964-19966	we	_
122-11	19967-19972	found	_
122-12	19973-19977	that	_
122-13	19978-19981	the	_
122-14	19982-19985	PFm	_
122-15	19986-19989	was	_
122-16	19990-19993	the	_
122-17	19994-19998	only	_
122-18	19999-20002	IPL	_
122-19	20003-20012	subregion	_
122-20	20013-20017	that	_
122-21	20018-20027	exhibited	_
122-22	20028-20039	significant	_
122-23	20040-20044	rsFC	_
122-24	20045-20052	changes	_
122-25	20053-20055	in	_
122-26	20056-20069	schizophrenia	_
122-27	20069-20070	.	_

#Text=The selective involvement of the PFm connectivity in schizophrenia may shed light on the neural mechanisms of the disorder.
123-1	20071-20074	The	_
123-2	20075-20084	selective	_
123-3	20085-20096	involvement	_
123-4	20097-20099	of	_
123-5	20100-20103	the	_
123-6	20104-20107	PFm	_
123-7	20108-20120	connectivity	_
123-8	20121-20123	in	_
123-9	20124-20137	schizophrenia	_
123-10	20138-20141	may	_
123-11	20142-20146	shed	_
123-12	20147-20152	light	_
123-13	20153-20155	on	_
123-14	20156-20159	the	_
123-15	20160-20166	neural	_
123-16	20167-20177	mechanisms	_
123-17	20178-20180	of	_
123-18	20181-20184	the	_
123-19	20185-20193	disorder	_
123-20	20193-20194	.	_

#Text=The most important finding of this study is that we found significantly increased rsFC between the PFm and the visual and sensorimotor regions in schizophrenia.
124-1	20195-20198	The	_
124-2	20199-20203	most	_
124-3	20204-20213	important	_
124-4	20214-20221	finding	_
124-5	20222-20224	of	_
124-6	20225-20229	this	_
124-7	20230-20235	study	_
124-8	20236-20238	is	_
124-9	20239-20243	that	_
124-10	20244-20246	we	_
124-11	20247-20252	found	_
124-12	20253-20266	significantly	_
124-13	20267-20276	increased	_
124-14	20277-20281	rsFC	_
124-15	20282-20289	between	_
124-16	20290-20293	the	_
124-17	20294-20297	PFm	_
124-18	20298-20301	and	_
124-19	20302-20305	the	_
124-20	20306-20312	visual	_
124-21	20313-20316	and	_
124-22	20317-20329	sensorimotor	_
124-23	20330-20337	regions	_
124-24	20338-20340	in	_
124-25	20341-20354	schizophrenia	_
124-26	20354-20355	.	_

#Text=Moreover, although being not significant in intergroup comparisons, under the same statistical threshold, the rsFCs of the right PFop and the bilateal PGa with the visual and sensorimotor regions were only significant in schizophrenia patients (Fig. 2).
125-1	20356-20364	Moreover	_
125-2	20364-20365	,	_
125-3	20366-20374	although	_
125-4	20375-20380	being	_
125-5	20381-20384	not	_
125-6	20385-20396	significant	_
125-7	20397-20399	in	_
125-8	20400-20410	intergroup	_
125-9	20411-20422	comparisons	_
125-10	20422-20423	,	_
125-11	20424-20429	under	_
125-12	20430-20433	the	_
125-13	20434-20438	same	_
125-14	20439-20450	statistical	_
125-15	20451-20460	threshold	_
125-16	20460-20461	,	_
125-17	20462-20465	the	_
125-18	20466-20471	rsFCs	_
125-19	20472-20474	of	_
125-20	20475-20478	the	_
125-21	20479-20484	right	_
125-22	20485-20489	PFop	_
125-23	20490-20493	and	_
125-24	20494-20497	the	_
125-25	20498-20506	bilateal	_
125-26	20507-20510	PGa	_
125-27	20511-20515	with	_
125-28	20516-20519	the	_
125-29	20520-20526	visual	_
125-30	20527-20530	and	_
125-31	20531-20543	sensorimotor	_
125-32	20544-20551	regions	_
125-33	20552-20556	were	_
125-34	20557-20561	only	_
125-35	20562-20573	significant	_
125-36	20574-20576	in	_
125-37	20577-20590	schizophrenia	_
125-38	20591-20599	patients	_
125-39	20600-20601	(	_
125-40	20601-20604	Fig	_
125-41	20604-20605	.	_
125-42	20606-20607	2	_
125-43	20607-20608	)	_
125-44	20608-20609	.	_

#Text=Because the IPL plays an important role in multi-sensory and sensorimotor integration, these abnormal increased rsFCs may be associated with the disorders in multi-sensory integration and sensorimotor integration in schizophrenia, which has been repeatedly reported in this disorder.
126-1	20610-20617	Because	_
126-2	20618-20621	the	_
126-3	20622-20625	IPL	_
126-4	20626-20631	plays	_
126-5	20632-20634	an	_
126-6	20635-20644	important	_
126-7	20645-20649	role	_
126-8	20650-20652	in	_
126-9	20653-20666	multi-sensory	_
126-10	20667-20670	and	_
126-11	20671-20683	sensorimotor	_
126-12	20684-20695	integration	_
126-13	20695-20696	,	_
126-14	20697-20702	these	_
126-15	20703-20711	abnormal	_
126-16	20712-20721	increased	_
126-17	20722-20727	rsFCs	_
126-18	20728-20731	may	_
126-19	20732-20734	be	_
126-20	20735-20745	associated	_
126-21	20746-20750	with	_
126-22	20751-20754	the	_
126-23	20755-20764	disorders	_
126-24	20765-20767	in	_
126-25	20768-20781	multi-sensory	_
126-26	20782-20793	integration	_
126-27	20794-20797	and	_
126-28	20798-20810	sensorimotor	_
126-29	20811-20822	integration	_
126-30	20823-20825	in	_
126-31	20826-20839	schizophrenia	_
126-32	20839-20840	,	_
126-33	20841-20846	which	_
126-34	20847-20850	has	_
126-35	20851-20855	been	_
126-36	20856-20866	repeatedly	_
126-37	20867-20875	reported	_
126-38	20876-20878	in	_
126-39	20879-20883	this	_
126-40	20884-20892	disorder	_
126-41	20892-20893	.	_

#Text=The failure of the IPL to provide accurately integrated sensory and motor information for subsequent cognitive processing may finally affect the cognitive performance.
127-1	20894-20897	The	_
127-2	20898-20905	failure	_
127-3	20906-20908	of	_
127-4	20909-20912	the	_
127-5	20913-20916	IPL	_
127-6	20917-20919	to	_
127-7	20920-20927	provide	_
127-8	20928-20938	accurately	_
127-9	20939-20949	integrated	_
127-10	20950-20957	sensory	_
127-11	20958-20961	and	_
127-12	20962-20967	motor	_
127-13	20968-20979	information	_
127-14	20980-20983	for	_
127-15	20984-20994	subsequent	_
127-16	20995-21004	cognitive	_
127-17	21005-21015	processing	_
127-18	21016-21019	may	_
127-19	21020-21027	finally	_
127-20	21028-21034	affect	_
127-21	21035-21038	the	_
127-22	21039-21048	cognitive	_
127-23	21049-21060	performance	_
127-24	21060-21061	.	_

#Text=As the transition zone between the SMG and AG of the IPL, the PFm is functionally connected to multiple cognitive-related brain regions, which supports its role in multiple cognitive functions, such as decision-making, behavioral switching, recognition memory, and declarative memory.
128-1	21062-21064	As	_
128-2	21065-21068	the	_
128-3	21069-21079	transition	_
128-4	21080-21084	zone	_
128-5	21085-21092	between	_
128-6	21093-21096	the	_
128-7	21097-21100	SMG	_
128-8	21101-21104	and	_
128-9	21105-21107	AG	_
128-10	21108-21110	of	_
128-11	21111-21114	the	_
128-12	21115-21118	IPL	_
128-13	21118-21119	,	_
128-14	21120-21123	the	_
128-15	21124-21127	PFm	_
128-16	21128-21130	is	_
128-17	21131-21143	functionally	_
128-18	21144-21153	connected	_
128-19	21154-21156	to	_
128-20	21157-21165	multiple	_
128-21	21166-21183	cognitive-related	_
128-22	21184-21189	brain	_
128-23	21190-21197	regions	_
128-24	21197-21198	,	_
128-25	21199-21204	which	_
128-26	21205-21213	supports	_
128-27	21214-21217	its	_
128-28	21218-21222	role	_
128-29	21223-21225	in	_
128-30	21226-21234	multiple	_
128-31	21235-21244	cognitive	_
128-32	21245-21254	functions	_
128-33	21254-21255	,	_
128-34	21256-21260	such	_
128-35	21261-21263	as	_
128-36	21264-21279	decision-making	_
128-37	21279-21280	,	_
128-38	21281-21291	behavioral	_
128-39	21292-21301	switching	_
128-40	21301-21302	,	_
128-41	21303-21314	recognition	_
128-42	21315-21321	memory	_
128-43	21321-21322	,	_
128-44	21323-21326	and	_
128-45	21327-21338	declarative	_
128-46	21339-21345	memory	_
128-47	21345-21346	.	_

#Text=Most of these functions are impaired in schizophrenia, for example, the impaired decision-making has been thought to be a stable and independent psychopathology in schizophrenia, which has been attributed to the dysfunction of the right PFm.
129-1	21347-21351	Most	_
129-2	21352-21354	of	_
129-3	21355-21360	these	_
129-4	21361-21370	functions	_
129-5	21371-21374	are	_
129-6	21375-21383	impaired	_
129-7	21384-21386	in	_
129-8	21387-21400	schizophrenia	_
129-9	21400-21401	,	_
129-10	21402-21405	for	_
129-11	21406-21413	example	_
129-12	21413-21414	,	_
129-13	21415-21418	the	_
129-14	21419-21427	impaired	_
129-15	21428-21443	decision-making	_
129-16	21444-21447	has	_
129-17	21448-21452	been	_
129-18	21453-21460	thought	_
129-19	21461-21463	to	_
129-20	21464-21466	be	_
129-21	21467-21468	a	_
129-22	21469-21475	stable	_
129-23	21476-21479	and	_
129-24	21480-21491	independent	_
129-25	21492-21507	psychopathology	_
129-26	21508-21510	in	_
129-27	21511-21524	schizophrenia	_
129-28	21524-21525	,	_
129-29	21526-21531	which	_
129-30	21532-21535	has	_
129-31	21536-21540	been	_
129-32	21541-21551	attributed	_
129-33	21552-21554	to	_
129-34	21555-21558	the	_
129-35	21559-21570	dysfunction	_
129-36	21571-21573	of	_
129-37	21574-21577	the	_
129-38	21578-21583	right	_
129-39	21584-21587	PFm	_
129-40	21587-21588	.	_

#Text=In addition, patients with lesions involving the PFm have shown impairment in recognition of pictures and sounds.
130-1	21589-21591	In	_
130-2	21592-21600	addition	_
130-3	21600-21601	,	_
130-4	21602-21610	patients	_
130-5	21611-21615	with	_
130-6	21616-21623	lesions	_
130-7	21624-21633	involving	_
130-8	21634-21637	the	_
130-9	21638-21641	PFm	_
130-10	21642-21646	have	_
130-11	21647-21652	shown	_
130-12	21653-21663	impairment	_
130-13	21664-21666	in	_
130-14	21667-21678	recognition	_
130-15	21679-21681	of	_
130-16	21682-21690	pictures	_
130-17	21691-21694	and	_
130-18	21695-21701	sounds	_
130-19	21701-21702	.	_

#Text=Although we did not find any rsFC abnormality between PFm and cognitive-related brain regions that directly accounts for cognitive dysfunction, we found abnormal rsFC between the PFm and the visual and sensorimotor regions.
131-1	21703-21711	Although	_
131-2	21712-21714	we	_
131-3	21715-21718	did	_
131-4	21719-21722	not	_
131-5	21723-21727	find	_
131-6	21728-21731	any	_
131-7	21732-21736	rsFC	_
131-8	21737-21748	abnormality	_
131-9	21749-21756	between	_
131-10	21757-21760	PFm	_
131-11	21761-21764	and	_
131-12	21765-21782	cognitive-related	_
131-13	21783-21788	brain	_
131-14	21789-21796	regions	_
131-15	21797-21801	that	_
131-16	21802-21810	directly	_
131-17	21811-21819	accounts	_
131-18	21820-21823	for	_
131-19	21824-21833	cognitive	_
131-20	21834-21845	dysfunction	_
131-21	21845-21846	,	_
131-22	21847-21849	we	_
131-23	21850-21855	found	_
131-24	21856-21864	abnormal	_
131-25	21865-21869	rsFC	_
131-26	21870-21877	between	_
131-27	21878-21881	the	_
131-28	21882-21885	PFm	_
131-29	21886-21889	and	_
131-30	21890-21893	the	_
131-31	21894-21900	visual	_
131-32	21901-21904	and	_
131-33	21905-21917	sensorimotor	_
131-34	21918-21925	regions	_
131-35	21925-21926	.	_

#Text=These findings suggest that the abnormal integration of sensory and motor information in the PFm may indirectly affect cognitive processing in patients with schizophrenia.
132-1	21927-21932	These	_
132-2	21933-21941	findings	_
132-3	21942-21949	suggest	_
132-4	21950-21954	that	_
132-5	21955-21958	the	_
132-6	21959-21967	abnormal	_
132-7	21968-21979	integration	_
132-8	21980-21982	of	_
132-9	21983-21990	sensory	_
132-10	21991-21994	and	_
132-11	21995-22000	motor	_
132-12	22001-22012	information	_
132-13	22013-22015	in	_
132-14	22016-22019	the	_
132-15	22020-22023	PFm	_
132-16	22024-22027	may	_
132-17	22028-22038	indirectly	_
132-18	22039-22045	affect	_
132-19	22046-22055	cognitive	_
132-20	22056-22066	processing	_
132-21	22067-22069	in	_
132-22	22070-22078	patients	_
132-23	22079-22083	with	_
132-24	22084-22097	schizophrenia	_
132-25	22097-22098	.	_

#Text=Several limitations should be noted when one interprets our findings.
133-1	22099-22106	Several	_
133-2	22107-22118	limitations	_
133-3	22119-22125	should	_
133-4	22126-22128	be	_
133-5	22129-22134	noted	_
133-6	22135-22139	when	_
133-7	22140-22143	one	_
133-8	22144-22154	interprets	_
133-9	22155-22158	our	_
133-10	22159-22167	findings	_
133-11	22167-22168	.	_

#Text=First, most of the schizophrenia patients participating in this study have received antipsychotic drugs with different time periods.
134-1	22169-22174	First	_
134-2	22174-22175	,	_
134-3	22176-22180	most	_
134-4	22181-22183	of	_
134-5	22184-22187	the	_
134-6	22188-22201	schizophrenia	_
134-7	22202-22210	patients	_
134-8	22211-22224	participating	_
134-9	22225-22227	in	_
134-10	22228-22232	this	_
134-11	22233-22238	study	_
134-12	22239-22243	have	_
134-13	22244-22252	received	_
134-14	22253-22266	antipsychotic	_
134-15	22267-22272	drugs	_
134-16	22273-22277	with	_
134-17	22278-22287	different	_
134-18	22288-22292	time	_
134-19	22293-22300	periods	_
134-20	22300-22301	.	_

#Text=Although we did not find any significant correlations between the rsFC changes of the IPL subregions and the antipsychotic dosages in these patients and significant differences in the rsFCs of the bilateral PFm between the 9 drug-naïve patients and the 86 patients with antipsychotic treatments, we cannot absolutely exclude the possible influence of the various antipsychotic medications on our results.
135-1	22302-22310	Although	_
135-2	22311-22313	we	_
135-3	22314-22317	did	_
135-4	22318-22321	not	_
135-5	22322-22326	find	_
135-6	22327-22330	any	_
135-7	22331-22342	significant	_
135-8	22343-22355	correlations	_
135-9	22356-22363	between	_
135-10	22364-22367	the	_
135-11	22368-22372	rsFC	_
135-12	22373-22380	changes	_
135-13	22381-22383	of	_
135-14	22384-22387	the	_
135-15	22388-22391	IPL	_
135-16	22392-22402	subregions	_
135-17	22403-22406	and	_
135-18	22407-22410	the	_
135-19	22411-22424	antipsychotic	_
135-20	22425-22432	dosages	_
135-21	22433-22435	in	_
135-22	22436-22441	these	_
135-23	22442-22450	patients	_
135-24	22451-22454	and	_
135-25	22455-22466	significant	_
135-26	22467-22478	differences	_
135-27	22479-22481	in	_
135-28	22482-22485	the	_
135-29	22486-22491	rsFCs	_
135-30	22492-22494	of	_
135-31	22495-22498	the	_
135-32	22499-22508	bilateral	_
135-33	22509-22512	PFm	_
135-34	22513-22520	between	_
135-35	22521-22524	the	_
135-36	22525-22526	9	_
135-37	22527-22537	drug-naïve	_
135-38	22538-22546	patients	_
135-39	22547-22550	and	_
135-40	22551-22554	the	_
135-41	22555-22557	86	_
135-42	22558-22566	patients	_
135-43	22567-22571	with	_
135-44	22572-22585	antipsychotic	_
135-45	22586-22596	treatments	_
135-46	22596-22597	,	_
135-47	22598-22600	we	_
135-48	22601-22607	cannot	_
135-49	22608-22618	absolutely	_
135-50	22619-22626	exclude	_
135-51	22627-22630	the	_
135-52	22631-22639	possible	_
135-53	22640-22649	influence	_
135-54	22650-22652	of	_
135-55	22653-22656	the	_
135-56	22657-22664	various	_
135-57	22665-22678	antipsychotic	_
135-58	22679-22690	medications	_
135-59	22691-22693	on	_
135-60	22694-22697	our	_
135-61	22698-22705	results	_
135-62	22705-22706	.	_

#Text=Further studies are needed to validate our findings in a large sample of drug-naïve patients with first-episode schizophrenia.
136-1	22707-22714	Further	_
136-2	22715-22722	studies	_
136-3	22723-22726	are	_
136-4	22727-22733	needed	_
136-5	22734-22736	to	_
136-6	22737-22745	validate	_
136-7	22746-22749	our	_
136-8	22750-22758	findings	_
136-9	22759-22761	in	_
136-10	22762-22763	a	_
136-11	22764-22769	large	_
136-12	22770-22776	sample	_
136-13	22777-22779	of	_
136-14	22780-22790	drug-naïve	_
136-15	22791-22799	patients	_
136-16	22800-22804	with	_
136-17	22805-22818	first-episode	_
136-18	22819-22832	schizophrenia	_
136-19	22832-22833	.	_

#Text=Second, because most of patients were chronic patients with schizophrenia, we cannot determine whether our findings can be generalized to all stages of schizophrenia.
137-1	22834-22840	Second	_
137-2	22840-22841	,	_
137-3	22842-22849	because	_
137-4	22850-22854	most	_
137-5	22855-22857	of	_
137-6	22858-22866	patients	_
137-7	22867-22871	were	_
137-8	22872-22879	chronic	_
137-9	22880-22888	patients	_
137-10	22889-22893	with	_
137-11	22894-22907	schizophrenia	_
137-12	22907-22908	,	_
137-13	22909-22911	we	_
137-14	22912-22918	cannot	_
137-15	22919-22928	determine	_
137-16	22929-22936	whether	_
137-17	22937-22940	our	_
137-18	22941-22949	findings	_
137-19	22950-22953	can	_
137-20	22954-22956	be	_
137-21	22957-22968	generalized	_
137-22	22969-22971	to	_
137-23	22972-22975	all	_
137-24	22976-22982	stages	_
137-25	22983-22985	of	_
137-26	22986-22999	schizophrenia	_
137-27	22999-23000	.	_

#Text=Third, we did not collect neuropsychological data on multiple sensory integration, sensorimotor integration, and IPL-related cognitive processing.
138-1	23001-23006	Third	_
138-2	23006-23007	,	_
138-3	23008-23010	we	_
138-4	23011-23014	did	_
138-5	23015-23018	not	_
138-6	23019-23026	collect	_
138-7	23027-23045	neuropsychological	_
138-8	23046-23050	data	_
138-9	23051-23053	on	_
138-10	23054-23062	multiple	_
138-11	23063-23070	sensory	_
138-12	23071-23082	integration	_
138-13	23082-23083	,	_
138-14	23084-23096	sensorimotor	_
138-15	23097-23108	integration	_
138-16	23108-23109	,	_
138-17	23110-23113	and	_
138-18	23114-23125	IPL-related	_
138-19	23126-23135	cognitive	_
138-20	23136-23146	processing	_
138-21	23146-23147	.	_

#Text=The lack of these behavioral data prevents us from drawing a definite conclusion on our findings.
139-1	23148-23151	The	_
139-2	23152-23156	lack	_
139-3	23157-23159	of	_
139-4	23160-23165	these	_
139-5	23166-23176	behavioral	_
139-6	23177-23181	data	_
139-7	23182-23190	prevents	_
139-8	23191-23193	us	_
139-9	23194-23198	from	_
139-10	23199-23206	drawing	_
139-11	23207-23208	a	_
139-12	23209-23217	definite	_
139-13	23218-23228	conclusion	_
139-14	23229-23231	on	_
139-15	23232-23235	our	_
139-16	23236-23244	findings	_
139-17	23244-23245	.	_

#Text=Finally, we selected asymmetric seed regions for the two hemispheric IPLs, preventing us from accurately comparing connectivity patterns and differences between the two hemispheres.
140-1	23246-23253	Finally	_
140-2	23253-23254	,	_
140-3	23255-23257	we	_
140-4	23258-23266	selected	_
140-5	23267-23277	asymmetric	_
140-6	23278-23282	seed	_
140-7	23283-23290	regions	_
140-8	23291-23294	for	_
140-9	23295-23298	the	_
140-10	23299-23302	two	_
140-11	23303-23314	hemispheric	_
140-12	23315-23319	IPLs	_
140-13	23319-23320	,	_
140-14	23321-23331	preventing	_
140-15	23332-23334	us	_
140-16	23335-23339	from	_
140-17	23340-23350	accurately	_
140-18	23351-23360	comparing	_
140-19	23361-23373	connectivity	_
140-20	23374-23382	patterns	_
140-21	23383-23386	and	_
140-22	23387-23398	differences	_
140-23	23399-23406	between	_
140-24	23407-23410	the	_
140-25	23411-23414	two	_
140-26	23415-23426	hemispheres	_
140-27	23426-23427	.	_

#Text=Conclusion
#Text=By systematically investigating the rsFC changes of the IPL subregions in schizophrenia, we found that only the PFm had significantly increased rsFC with the visual and sensorimotor regions in schizophrenia patients.
141-1	23428-23438	Conclusion	_
141-2	23439-23441	By	_
141-3	23442-23456	systematically	_
141-4	23457-23470	investigating	_
141-5	23471-23474	the	_
141-6	23475-23479	rsFC	_
141-7	23480-23487	changes	_
141-8	23488-23490	of	_
141-9	23491-23494	the	_
141-10	23495-23498	IPL	_
141-11	23499-23509	subregions	_
141-12	23510-23512	in	_
141-13	23513-23526	schizophrenia	_
141-14	23526-23527	,	_
141-15	23528-23530	we	_
141-16	23531-23536	found	_
141-17	23537-23541	that	_
141-18	23542-23546	only	_
141-19	23547-23550	the	_
141-20	23551-23554	PFm	_
141-21	23555-23558	had	_
141-22	23559-23572	significantly	_
141-23	23573-23582	increased	_
141-24	23583-23587	rsFC	_
141-25	23588-23592	with	_
141-26	23593-23596	the	_
141-27	23597-23603	visual	_
141-28	23604-23607	and	_
141-29	23608-23620	sensorimotor	_
141-30	23621-23628	regions	_
141-31	23629-23631	in	_
141-32	23632-23645	schizophrenia	_
141-33	23646-23654	patients	_
141-34	23654-23655	.	_

#Text=This finding suggests that the rsFCs of the IPL subregions are selectively involved in schizophrenia.
142-1	23656-23660	This	_
142-2	23661-23668	finding	_
142-3	23669-23677	suggests	_
142-4	23678-23682	that	_
142-5	23683-23686	the	_
142-6	23687-23692	rsFCs	_
142-7	23693-23695	of	_
142-8	23696-23699	the	_
142-9	23700-23703	IPL	_
142-10	23704-23714	subregions	_
142-11	23715-23718	are	_
142-12	23719-23730	selectively	_
142-13	23731-23739	involved	_
142-14	23740-23742	in	_
142-15	23743-23756	schizophrenia	_
142-16	23756-23757	.	_

#Text=Moreover, the abnormally increased rsFC between the PFm and the sensorimotor-related regions may indicate abnormalities in multi-sensory integration and sensorimotor integration in schizophrenia, which may further interfere the cognitive processing of the PFm of the IPL.
143-1	23758-23766	Moreover	_
143-2	23766-23767	,	_
143-3	23768-23771	the	_
143-4	23772-23782	abnormally	_
143-5	23783-23792	increased	_
143-6	23793-23797	rsFC	_
143-7	23798-23805	between	_
143-8	23806-23809	the	_
143-9	23810-23813	PFm	_
143-10	23814-23817	and	_
143-11	23818-23821	the	_
143-12	23822-23842	sensorimotor-related	_
143-13	23843-23850	regions	_
143-14	23851-23854	may	_
143-15	23855-23863	indicate	_
143-16	23864-23877	abnormalities	_
143-17	23878-23880	in	_
143-18	23881-23894	multi-sensory	_
143-19	23895-23906	integration	_
143-20	23907-23910	and	_
143-21	23911-23923	sensorimotor	_
143-22	23924-23935	integration	_
143-23	23936-23938	in	_
143-24	23939-23952	schizophrenia	_
143-25	23952-23953	,	_
143-26	23954-23959	which	_
143-27	23960-23963	may	_
143-28	23964-23971	further	_
143-29	23972-23981	interfere	_
143-30	23982-23985	the	_
143-31	23986-23995	cognitive	_
143-32	23996-24006	processing	_
143-33	24007-24009	of	_
143-34	24010-24013	the	_
143-35	24014-24017	PFm	_
143-36	24018-24020	of	_
143-37	24021-24024	the	_
143-38	24025-24028	IPL	_
143-39	24028-24029	.	_

#Text=Future studies should investigate selective functional connectivity alterations of the parietal lobe in subjects at ultra-high risk of psychosis, which may improve the prediction of psychosis risk.
144-1	24030-24036	Future	_
144-2	24037-24044	studies	_
144-3	24045-24051	should	_
144-4	24052-24063	investigate	_
144-5	24064-24073	selective	_
144-6	24074-24084	functional	_
144-7	24085-24097	connectivity	_
144-8	24098-24109	alterations	_
144-9	24110-24112	of	_
144-10	24113-24116	the	_
144-11	24117-24125	parietal	_
144-12	24126-24130	lobe	_
144-13	24131-24133	in	_
144-14	24134-24142	subjects	_
144-15	24143-24145	at	_
144-16	24146-24156	ultra-high	_
144-17	24157-24161	risk	_
144-18	24162-24164	of	_
144-19	24165-24174	psychosis	_
144-20	24174-24175	,	_
144-21	24176-24181	which	_
144-22	24182-24185	may	_
144-23	24186-24193	improve	_
144-24	24194-24197	the	_
144-25	24198-24208	prediction	_
144-26	24209-24211	of	_
144-27	24212-24221	psychosis	_
144-28	24222-24226	risk	_
144-29	24226-24227	.	_

#Text=Conflict of interest
#Text=The authors declare no conflict of interests.
145-1	24228-24236	Conflict	_
145-2	24237-24239	of	_
145-3	24240-24248	interest	_
145-4	24249-24252	The	_
145-5	24253-24260	authors	_
145-6	24261-24268	declare	_
145-7	24269-24271	no	_
145-8	24272-24280	conflict	_
145-9	24281-24283	of	_
145-10	24284-24293	interests	_
145-11	24293-24294	.	_

#Text=Reference
#Text=The contribution of the inferior parietal lobe to auditory spatial working memory
#Text=Disrupted modularity and local connectivity of brain functional networks in childhood-onset schizophrenia
#Text=Intentional maps in posterior parietal cortex
#Text=Neural correlates of the attention network test in schizophrenia
#Text=The body in the brain: neural bases of corporeal awareness
#Text=Grey matter and cognitive deficits in young relatives of schizophrenia patients
#Text=Functional connectivity in the motor cortex of resting human brain using echo-planar MRI
#Text=How green is the grass on the other side?
146-1	24295-24304	Reference	_
146-2	24305-24308	The	_
146-3	24309-24321	contribution	_
146-4	24322-24324	of	_
146-5	24325-24328	the	_
146-6	24329-24337	inferior	_
146-7	24338-24346	parietal	_
146-8	24347-24351	lobe	_
146-9	24352-24354	to	_
146-10	24355-24363	auditory	_
146-11	24364-24371	spatial	_
146-12	24372-24379	working	_
146-13	24380-24386	memory	_
146-14	24387-24396	Disrupted	_
146-15	24397-24407	modularity	_
146-16	24408-24411	and	_
146-17	24412-24417	local	_
146-18	24418-24430	connectivity	_
146-19	24431-24433	of	_
146-20	24434-24439	brain	_
146-21	24440-24450	functional	_
146-22	24451-24459	networks	_
146-23	24460-24462	in	_
146-24	24463-24478	childhood-onset	_
146-25	24479-24492	schizophrenia	_
146-26	24493-24504	Intentional	_
146-27	24505-24509	maps	_
146-28	24510-24512	in	_
146-29	24513-24522	posterior	_
146-30	24523-24531	parietal	_
146-31	24532-24538	cortex	_
146-32	24539-24545	Neural	_
146-33	24546-24556	correlates	_
146-34	24557-24559	of	_
146-35	24560-24563	the	_
146-36	24564-24573	attention	_
146-37	24574-24581	network	_
146-38	24582-24586	test	_
146-39	24587-24589	in	_
146-40	24590-24603	schizophrenia	_
146-41	24604-24607	The	_
146-42	24608-24612	body	_
146-43	24613-24615	in	_
146-44	24616-24619	the	_
146-45	24620-24625	brain	_
146-46	24625-24626	:	_
146-47	24627-24633	neural	_
146-48	24634-24639	bases	_
146-49	24640-24642	of	_
146-50	24643-24652	corporeal	_
146-51	24653-24662	awareness	_
146-52	24663-24667	Grey	_
146-53	24668-24674	matter	_
146-54	24675-24678	and	_
146-55	24679-24688	cognitive	_
146-56	24689-24697	deficits	_
146-57	24698-24700	in	_
146-58	24701-24706	young	_
146-59	24707-24716	relatives	_
146-60	24717-24719	of	_
146-61	24720-24733	schizophrenia	_
146-62	24734-24742	patients	_
146-63	24743-24753	Functional	_
146-64	24754-24766	connectivity	_
146-65	24767-24769	in	_
146-66	24770-24773	the	_
146-67	24774-24779	motor	_
146-68	24780-24786	cortex	_
146-69	24787-24789	of	_
146-70	24790-24797	resting	_
146-71	24798-24803	human	_
146-72	24804-24809	brain	_
146-73	24810-24815	using	_
146-74	24816-24827	echo-planar	_
146-75	24828-24831	MRI	_
146-76	24832-24835	How	_
146-77	24836-24841	green	_
146-78	24842-24844	is	_
146-79	24845-24848	the	_
146-80	24849-24854	grass	_
146-81	24855-24857	on	_
146-82	24858-24861	the	_
146-83	24862-24867	other	_
146-84	24868-24872	side	_
146-85	24872-24873	?	_

#Text=Frontopolar cortex and the evidence in favor of alternative courses of action
#Text=
#Text=Meta-analysis of neuroimaging studies of the Wisconsin card-sorting task and component processes
#Text=The parietal cortex and episodic memory: an attentional account
#Text=Defective spatial imagery with pure Gerstmann's syndrome
#Text=The human inferior parietal cortex: cytoarchitectonic parcellation and interindividual variability
#Text=The human inferior parietal lobule in stereotaxic space
#Text=Probabilistic fibre tract analysis of cytoarchitectonically defined human inferior parietal lobule areas reveals similarities to macaques
#Text=Perisylvian language networks of the human brain
#Text=The role of inferior frontal gyrus and inferior parietal lobule in semantic processing of Chinese characters
#Text=Neurological soft signs in first-episode psychosis: a systematic review
#Text=Inferior parietal lobule.
147-1	24874-24885	Frontopolar	_
147-2	24886-24892	cortex	_
147-3	24893-24896	and	_
147-4	24897-24900	the	_
147-5	24901-24909	evidence	_
147-6	24910-24912	in	_
147-7	24913-24918	favor	_
147-8	24919-24921	of	_
147-9	24922-24933	alternative	_
147-10	24934-24941	courses	_
147-11	24942-24944	of	_
147-12	24945-24951	action	_
147-13	24953-24966	Meta-analysis	_
147-14	24967-24969	of	_
147-15	24970-24982	neuroimaging	_
147-16	24983-24990	studies	_
147-17	24991-24993	of	_
147-18	24994-24997	the	_
147-19	24998-25007	Wisconsin	_
147-20	25008-25020	card-sorting	_
147-21	25021-25025	task	_
147-22	25026-25029	and	_
147-23	25030-25039	component	_
147-24	25040-25049	processes	_
147-25	25050-25053	The	_
147-26	25054-25062	parietal	_
147-27	25063-25069	cortex	_
147-28	25070-25073	and	_
147-29	25074-25082	episodic	_
147-30	25083-25089	memory	_
147-31	25089-25090	:	_
147-32	25091-25093	an	_
147-33	25094-25105	attentional	_
147-34	25106-25113	account	_
147-35	25114-25123	Defective	_
147-36	25124-25131	spatial	_
147-37	25132-25139	imagery	_
147-38	25140-25144	with	_
147-39	25145-25149	pure	_
147-40	25150-25161	Gerstmann's	_
147-41	25162-25170	syndrome	_
147-42	25171-25174	The	_
147-43	25175-25180	human	_
147-44	25181-25189	inferior	_
147-45	25190-25198	parietal	_
147-46	25199-25205	cortex	_
147-47	25205-25206	:	_
147-48	25207-25224	cytoarchitectonic	_
147-49	25225-25237	parcellation	_
147-50	25238-25241	and	_
147-51	25242-25257	interindividual	_
147-52	25258-25269	variability	_
147-53	25270-25273	The	_
147-54	25274-25279	human	_
147-55	25280-25288	inferior	_
147-56	25289-25297	parietal	_
147-57	25298-25304	lobule	_
147-58	25305-25307	in	_
147-59	25308-25319	stereotaxic	_
147-60	25320-25325	space	_
147-61	25326-25339	Probabilistic	_
147-62	25340-25345	fibre	_
147-63	25346-25351	tract	_
147-64	25352-25360	analysis	_
147-65	25361-25363	of	_
147-66	25364-25385	cytoarchitectonically	_
147-67	25386-25393	defined	_
147-68	25394-25399	human	_
147-69	25400-25408	inferior	_
147-70	25409-25417	parietal	_
147-71	25418-25424	lobule	_
147-72	25425-25430	areas	_
147-73	25431-25438	reveals	_
147-74	25439-25451	similarities	_
147-75	25452-25454	to	_
147-76	25455-25463	macaques	_
147-77	25464-25475	Perisylvian	_
147-78	25476-25484	language	_
147-79	25485-25493	networks	_
147-80	25494-25496	of	_
147-81	25497-25500	the	_
147-82	25501-25506	human	_
147-83	25507-25512	brain	_
147-84	25513-25516	The	_
147-85	25517-25521	role	_
147-86	25522-25524	of	_
147-87	25525-25533	inferior	_
147-88	25534-25541	frontal	_
147-89	25542-25547	gyrus	_
147-90	25548-25551	and	_
147-91	25552-25560	inferior	_
147-92	25561-25569	parietal	_
147-93	25570-25576	lobule	_
147-94	25577-25579	in	_
147-95	25580-25588	semantic	_
147-96	25589-25599	processing	_
147-97	25600-25602	of	_
147-98	25603-25610	Chinese	_
147-99	25611-25621	characters	_
147-100	25622-25634	Neurological	_
147-101	25635-25639	soft	_
147-102	25640-25645	signs	_
147-103	25646-25648	in	_
147-104	25649-25662	first-episode	_
147-105	25663-25672	psychosis	_
147-106	25672-25673	:	_
147-107	25674-25675	a	_
147-108	25676-25686	systematic	_
147-109	25687-25693	review	_
147-110	25694-25702	Inferior	_
147-111	25703-25711	parietal	_
147-112	25712-25718	lobule	_
147-113	25718-25719	.	_

#Text=Divergent architectonic asymmetries in the human brain
#Text=Parietal lobe: from action organization to intention understanding
#Text=Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis
#Text=The human brain is intrinsically organized into dynamic, anticorrelated functional networks
#Text=Sex differences in the inferior parietal lobule
#Text=Disconnexion syndromes in animals and man
#Text=Functional connectivity in the resting brain: a network analysis of the default mode hypothesis
#Text=Key functional circuitry altered in schizophrenia involves parietal regions associated with sense of self
#Text=The posterior parietal cortex in recognition memory: a neuropsychological study
#Text=Serial organization of human behavior in the inferior parietal cortex
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Mapping longitudinal hemispheric structural asymmetries of the human cerebral cortex from birth to 2 years of age
#Text=Abnormal regional spontaneous neural activity in first-episode, treatment-naive patients with late-life depression: a resting-state fMRI study
#Text=Multivariate classification of social anxiety disorder using whole brain functional connectivity
#Text=Characterization of post-traumatic stress disorder using resting-state fMRI with a multi-level parametric classification approach
#Text=A method for removal of global effects from fMRI time series
#Text=Mapping the functional connectivity of anterior cingulate cortex
#Text=Diffusion-weighted imaging tractography-based parcellation of the human parietal cortex and comparison with human and macaque resting-state functional connectivity
#Text=Reduced left angular gyrus volume in first-episode schizophrenia
#Text=The inferior parietal lobule and recognition memory: expectancy violation or successful retrieval?
148-1	25720-25729	Divergent	_
148-2	25730-25743	architectonic	_
148-3	25744-25755	asymmetries	_
148-4	25756-25758	in	_
148-5	25759-25762	the	_
148-6	25763-25768	human	_
148-7	25769-25774	brain	_
148-8	25775-25783	Parietal	_
148-9	25784-25788	lobe	_
148-10	25788-25789	:	_
148-11	25790-25794	from	_
148-12	25795-25801	action	_
148-13	25802-25814	organization	_
148-14	25815-25817	to	_
148-15	25818-25827	intention	_
148-16	25828-25841	understanding	_
148-17	25842-25852	Functional	_
148-18	25853-25868	dysconnectivity	_
148-19	25869-25871	of	_
148-20	25872-25887	corticostriatal	_
148-21	25888-25897	circuitry	_
148-22	25898-25900	as	_
148-23	25901-25902	a	_
148-24	25903-25907	risk	_
148-25	25908-25917	phenotype	_
148-26	25918-25921	for	_
148-27	25922-25931	psychosis	_
148-28	25932-25935	The	_
148-29	25936-25941	human	_
148-30	25942-25947	brain	_
148-31	25948-25950	is	_
148-32	25951-25964	intrinsically	_
148-33	25965-25974	organized	_
148-34	25975-25979	into	_
148-35	25980-25987	dynamic	_
148-36	25987-25988	,	_
148-37	25989-26003	anticorrelated	_
148-38	26004-26014	functional	_
148-39	26015-26023	networks	_
148-40	26024-26027	Sex	_
148-41	26028-26039	differences	_
148-42	26040-26042	in	_
148-43	26043-26046	the	_
148-44	26047-26055	inferior	_
148-45	26056-26064	parietal	_
148-46	26065-26071	lobule	_
148-47	26072-26084	Disconnexion	_
148-48	26085-26094	syndromes	_
148-49	26095-26097	in	_
148-50	26098-26105	animals	_
148-51	26106-26109	and	_
148-52	26110-26113	man	_
148-53	26114-26124	Functional	_
148-54	26125-26137	connectivity	_
148-55	26138-26140	in	_
148-56	26141-26144	the	_
148-57	26145-26152	resting	_
148-58	26153-26158	brain	_
148-59	26158-26159	:	_
148-60	26160-26161	a	_
148-61	26162-26169	network	_
148-62	26170-26178	analysis	_
148-63	26179-26181	of	_
148-64	26182-26185	the	_
148-65	26186-26193	default	_
148-66	26194-26198	mode	_
148-67	26199-26209	hypothesis	_
148-68	26210-26213	Key	_
148-69	26214-26224	functional	_
148-70	26225-26234	circuitry	_
148-71	26235-26242	altered	_
148-72	26243-26245	in	_
148-73	26246-26259	schizophrenia	_
148-74	26260-26268	involves	_
148-75	26269-26277	parietal	_
148-76	26278-26285	regions	_
148-77	26286-26296	associated	_
148-78	26297-26301	with	_
148-79	26302-26307	sense	_
148-80	26308-26310	of	_
148-81	26311-26315	self	_
148-82	26316-26319	The	_
148-83	26320-26329	posterior	_
148-84	26330-26338	parietal	_
148-85	26339-26345	cortex	_
148-86	26346-26348	in	_
148-87	26349-26360	recognition	_
148-88	26361-26367	memory	_
148-89	26367-26368	:	_
148-90	26369-26370	a	_
148-91	26371-26389	neuropsychological	_
148-92	26390-26395	study	_
148-93	26396-26402	Serial	_
148-94	26403-26415	organization	_
148-95	26416-26418	of	_
148-96	26419-26424	human	_
148-97	26425-26433	behavior	_
148-98	26434-26436	in	_
148-99	26437-26440	the	_
148-100	26441-26449	inferior	_
148-101	26450-26458	parietal	_
148-102	26459-26465	cortex	_
148-103	26466-26469	The	_
148-104	26470-26478	positive	_
148-105	26479-26482	and	_
148-106	26483-26491	negative	_
148-107	26492-26500	syndrome	_
148-108	26501-26506	scale	_
148-109	26507-26508	(	_
148-110	26508-26513	PANSS	_
148-111	26513-26514	)	_
148-112	26515-26518	for	_
148-113	26519-26532	schizophrenia	_
148-114	26533-26540	Mapping	_
148-115	26541-26553	longitudinal	_
148-116	26554-26565	hemispheric	_
148-117	26566-26576	structural	_
148-118	26577-26588	asymmetries	_
148-119	26589-26591	of	_
148-120	26592-26595	the	_
148-121	26596-26601	human	_
148-122	26602-26610	cerebral	_
148-123	26611-26617	cortex	_
148-124	26618-26622	from	_
148-125	26623-26628	birth	_
148-126	26629-26631	to	_
148-127	26632-26633	2	_
148-128	26633-26634	 	_
148-129	26634-26639	years	_
148-130	26640-26642	of	_
148-131	26643-26646	age	_
148-132	26647-26655	Abnormal	_
148-133	26656-26664	regional	_
148-134	26665-26676	spontaneous	_
148-135	26677-26683	neural	_
148-136	26684-26692	activity	_
148-137	26693-26695	in	_
148-138	26696-26709	first-episode	_
148-139	26709-26710	,	_
148-140	26711-26726	treatment-naive	_
148-141	26727-26735	patients	_
148-142	26736-26740	with	_
148-143	26741-26750	late-life	_
148-144	26751-26761	depression	_
148-145	26761-26762	:	_
148-146	26763-26764	a	_
148-147	26765-26778	resting-state	_
148-148	26779-26783	fMRI	_
148-149	26784-26789	study	_
148-150	26790-26802	Multivariate	_
148-151	26803-26817	classification	_
148-152	26818-26820	of	_
148-153	26821-26827	social	_
148-154	26828-26835	anxiety	_
148-155	26836-26844	disorder	_
148-156	26845-26850	using	_
148-157	26851-26856	whole	_
148-158	26857-26862	brain	_
148-159	26863-26873	functional	_
148-160	26874-26886	connectivity	_
148-161	26887-26903	Characterization	_
148-162	26904-26906	of	_
148-163	26907-26921	post-traumatic	_
148-164	26922-26928	stress	_
148-165	26929-26937	disorder	_
148-166	26938-26943	using	_
148-167	26944-26957	resting-state	_
148-168	26958-26962	fMRI	_
148-169	26963-26967	with	_
148-170	26968-26969	a	_
148-171	26970-26981	multi-level	_
148-172	26982-26992	parametric	_
148-173	26993-27007	classification	_
148-174	27008-27016	approach	_
148-175	27017-27018	A	_
148-176	27019-27025	method	_
148-177	27026-27029	for	_
148-178	27030-27037	removal	_
148-179	27038-27040	of	_
148-180	27041-27047	global	_
148-181	27048-27055	effects	_
148-182	27056-27060	from	_
148-183	27061-27065	fMRI	_
148-184	27066-27070	time	_
148-185	27071-27077	series	_
148-186	27078-27085	Mapping	_
148-187	27086-27089	the	_
148-188	27090-27100	functional	_
148-189	27101-27113	connectivity	_
148-190	27114-27116	of	_
148-191	27117-27125	anterior	_
148-192	27126-27135	cingulate	_
148-193	27136-27142	cortex	_
148-194	27143-27161	Diffusion-weighted	_
148-195	27162-27169	imaging	_
148-196	27170-27188	tractography-based	_
148-197	27189-27201	parcellation	_
148-198	27202-27204	of	_
148-199	27205-27208	the	_
148-200	27209-27214	human	_
148-201	27215-27223	parietal	_
148-202	27224-27230	cortex	_
148-203	27231-27234	and	_
148-204	27235-27245	comparison	_
148-205	27246-27250	with	_
148-206	27251-27256	human	_
148-207	27257-27260	and	_
148-208	27261-27268	macaque	_
148-209	27269-27282	resting-state	_
148-210	27283-27293	functional	_
148-211	27294-27306	connectivity	_
148-212	27307-27314	Reduced	_
148-213	27315-27319	left	_
148-214	27320-27327	angular	_
148-215	27328-27333	gyrus	_
148-216	27334-27340	volume	_
148-217	27341-27343	in	_
148-218	27344-27357	first-episode	_
148-219	27358-27371	schizophrenia	_
148-220	27372-27375	The	_
148-221	27376-27384	inferior	_
148-222	27385-27393	parietal	_
148-223	27394-27400	lobule	_
148-224	27401-27404	and	_
148-225	27405-27416	recognition	_
148-226	27417-27423	memory	_
148-227	27423-27424	:	_
148-228	27425-27435	expectancy	_
148-229	27436-27445	violation	_
148-230	27446-27448	or	_
148-231	27449-27459	successful	_
148-232	27460-27469	retrieval	_
148-233	27469-27470	?	_

#Text=Dissociable morphometric differences of the inferior parietal lobule in schizophrenia
#Text=Trait contributions of complex dysregulated behavioral organization in schizophrenic patients
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Regional grey matter volumetric changes in forensic schizophrenia patients: an MRI study comparing the brain structure of patients who have seriously and violently offended with that of patients who have not
#Text=Functional connectivity of the human amygdala using resting state fMRI
#Text=Connectivity architecture and subdivision of the human inferior parietal cortex revealed by diffusion MRI
#Text=The enigma of Gerstmann's syndrome revisited: a telling tale of the vicissitudes of neuropsychology
#Text=Neural basis of global resting-state fMRI activity
#Text=Multisensory maps in parietal cortex
#Text=Sensorimotor integration for speech motor learning involves the inferior parietal cortex
#Text=The functional role of the inferior parietal lobe in the dorsal and ventral stream dichotomy
#Text=Parcellation of human inferior parietal lobule based on diffusion MRI
#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
#Text=Schizophrenia and the inferior parietal lobule
#Text=A systematic review of multisensory cognitive-affective integration in schizophrenia
#Text=rTMS to the right inferior parietal lobule disrupts self-other discrimination
#Text=Spatial neglect, Balint-Homes' and Gerstmann's syndrome, and other spatial disorders
#Text=
#Text=Parietal lobe contributions to episodic memory retrieval
#Text=Tractography-based parcellation of the human left inferior parietal lobule
#Text=Dysfunctional striatal systems in treatment-resistant schizophrenia
#Text=Functional heterogeneity of inferior parietal cortex during mathematical cognition assessed with cytoarchitectonic probability maps
#Text=Parietal lobes in schizophrenia: do they matter?
149-1	27471-27482	Dissociable	_
149-2	27483-27495	morphometric	_
149-3	27496-27507	differences	_
149-4	27508-27510	of	_
149-5	27511-27514	the	_
149-6	27515-27523	inferior	_
149-7	27524-27532	parietal	_
149-8	27533-27539	lobule	_
149-9	27540-27542	in	_
149-10	27543-27556	schizophrenia	_
149-11	27557-27562	Trait	_
149-12	27563-27576	contributions	_
149-13	27577-27579	of	_
149-14	27580-27587	complex	_
149-15	27588-27600	dysregulated	_
149-16	27601-27611	behavioral	_
149-17	27612-27624	organization	_
149-18	27625-27627	in	_
149-19	27628-27641	schizophrenic	_
149-20	27642-27650	patients	_
149-21	27651-27659	Spurious	_
149-22	27660-27663	but	_
149-23	27664-27674	systematic	_
149-24	27675-27687	correlations	_
149-25	27688-27690	in	_
149-26	27691-27701	functional	_
149-27	27702-27714	connectivity	_
149-28	27715-27718	MRI	_
149-29	27719-27727	networks	_
149-30	27728-27733	arise	_
149-31	27734-27738	from	_
149-32	27739-27746	subject	_
149-33	27747-27753	motion	_
149-34	27754-27762	Regional	_
149-35	27763-27767	grey	_
149-36	27768-27774	matter	_
149-37	27775-27785	volumetric	_
149-38	27786-27793	changes	_
149-39	27794-27796	in	_
149-40	27797-27805	forensic	_
149-41	27806-27819	schizophrenia	_
149-42	27820-27828	patients	_
149-43	27828-27829	:	_
149-44	27830-27832	an	_
149-45	27833-27836	MRI	_
149-46	27837-27842	study	_
149-47	27843-27852	comparing	_
149-48	27853-27856	the	_
149-49	27857-27862	brain	_
149-50	27863-27872	structure	_
149-51	27873-27875	of	_
149-52	27876-27884	patients	_
149-53	27885-27888	who	_
149-54	27889-27893	have	_
149-55	27894-27903	seriously	_
149-56	27904-27907	and	_
149-57	27908-27917	violently	_
149-58	27918-27926	offended	_
149-59	27927-27931	with	_
149-60	27932-27936	that	_
149-61	27937-27939	of	_
149-62	27940-27948	patients	_
149-63	27949-27952	who	_
149-64	27953-27957	have	_
149-65	27958-27961	not	_
149-66	27962-27972	Functional	_
149-67	27973-27985	connectivity	_
149-68	27986-27988	of	_
149-69	27989-27992	the	_
149-70	27993-27998	human	_
149-71	27999-28007	amygdala	_
149-72	28008-28013	using	_
149-73	28014-28021	resting	_
149-74	28022-28027	state	_
149-75	28028-28032	fMRI	_
149-76	28033-28045	Connectivity	_
149-77	28046-28058	architecture	_
149-78	28059-28062	and	_
149-79	28063-28074	subdivision	_
149-80	28075-28077	of	_
149-81	28078-28081	the	_
149-82	28082-28087	human	_
149-83	28088-28096	inferior	_
149-84	28097-28105	parietal	_
149-85	28106-28112	cortex	_
149-86	28113-28121	revealed	_
149-87	28122-28124	by	_
149-88	28125-28134	diffusion	_
149-89	28135-28138	MRI	_
149-90	28139-28142	The	_
149-91	28143-28149	enigma	_
149-92	28150-28152	of	_
149-93	28153-28164	Gerstmann's	_
149-94	28165-28173	syndrome	_
149-95	28174-28183	revisited	_
149-96	28183-28184	:	_
149-97	28185-28186	a	_
149-98	28187-28194	telling	_
149-99	28195-28199	tale	_
149-100	28200-28202	of	_
149-101	28203-28206	the	_
149-102	28207-28219	vicissitudes	_
149-103	28220-28222	of	_
149-104	28223-28238	neuropsychology	_
149-105	28239-28245	Neural	_
149-106	28246-28251	basis	_
149-107	28252-28254	of	_
149-108	28255-28261	global	_
149-109	28262-28275	resting-state	_
149-110	28276-28280	fMRI	_
149-111	28281-28289	activity	_
149-112	28290-28302	Multisensory	_
149-113	28303-28307	maps	_
149-114	28308-28310	in	_
149-115	28311-28319	parietal	_
149-116	28320-28326	cortex	_
149-117	28327-28339	Sensorimotor	_
149-118	28340-28351	integration	_
149-119	28352-28355	for	_
149-120	28356-28362	speech	_
149-121	28363-28368	motor	_
149-122	28369-28377	learning	_
149-123	28378-28386	involves	_
149-124	28387-28390	the	_
149-125	28391-28399	inferior	_
149-126	28400-28408	parietal	_
149-127	28409-28415	cortex	_
149-128	28416-28419	The	_
149-129	28420-28430	functional	_
149-130	28431-28435	role	_
149-131	28436-28438	of	_
149-132	28439-28442	the	_
149-133	28443-28451	inferior	_
149-134	28452-28460	parietal	_
149-135	28461-28465	lobe	_
149-136	28466-28468	in	_
149-137	28469-28472	the	_
149-138	28473-28479	dorsal	_
149-139	28480-28483	and	_
149-140	28484-28491	ventral	_
149-141	28492-28498	stream	_
149-142	28499-28508	dichotomy	_
149-143	28509-28521	Parcellation	_
149-144	28522-28524	of	_
149-145	28525-28530	human	_
149-146	28531-28539	inferior	_
149-147	28540-28548	parietal	_
149-148	28549-28555	lobule	_
149-149	28556-28561	based	_
149-150	28562-28564	on	_
149-151	28565-28574	diffusion	_
149-152	28575-28578	MRI	_
149-153	28579-28592	Dysconnection	_
149-154	28593-28595	in	_
149-155	28596-28609	schizophrenia	_
149-156	28609-28610	:	_
149-157	28611-28615	from	_
149-158	28616-28624	abnormal	_
149-159	28625-28633	synaptic	_
149-160	28634-28644	plasticity	_
149-161	28645-28647	to	_
149-162	28648-28656	failures	_
149-163	28657-28659	of	_
149-164	28660-28675	self-monitoring	_
149-165	28676-28689	Schizophrenia	_
149-166	28690-28693	and	_
149-167	28694-28697	the	_
149-168	28698-28706	inferior	_
149-169	28707-28715	parietal	_
149-170	28716-28722	lobule	_
149-171	28723-28724	A	_
149-172	28725-28735	systematic	_
149-173	28736-28742	review	_
149-174	28743-28745	of	_
149-175	28746-28758	multisensory	_
149-176	28759-28778	cognitive-affective	_
149-177	28779-28790	integration	_
149-178	28791-28793	in	_
149-179	28794-28807	schizophrenia	_
149-180	28808-28812	rTMS	_
149-181	28813-28815	to	_
149-182	28816-28819	the	_
149-183	28820-28825	right	_
149-184	28826-28834	inferior	_
149-185	28835-28843	parietal	_
149-186	28844-28850	lobule	_
149-187	28851-28859	disrupts	_
149-188	28860-28870	self-other	_
149-189	28871-28885	discrimination	_
149-190	28886-28893	Spatial	_
149-191	28894-28901	neglect	_
149-192	28901-28902	,	_
149-193	28903-28915	Balint-Homes	_
149-194	28915-28916	'	_
149-195	28917-28920	and	_
149-196	28921-28932	Gerstmann's	_
149-197	28933-28941	syndrome	_
149-198	28941-28942	,	_
149-199	28943-28946	and	_
149-200	28947-28952	other	_
149-201	28953-28960	spatial	_
149-202	28961-28970	disorders	_
149-203	28972-28980	Parietal	_
149-204	28981-28985	lobe	_
149-205	28986-28999	contributions	_
149-206	29000-29002	to	_
149-207	29003-29011	episodic	_
149-208	29012-29018	memory	_
149-209	29019-29028	retrieval	_
149-210	29029-29047	Tractography-based	_
149-211	29048-29060	parcellation	_
149-212	29061-29063	of	_
149-213	29064-29067	the	_
149-214	29068-29073	human	_
149-215	29074-29078	left	_
149-216	29079-29087	inferior	_
149-217	29088-29096	parietal	_
149-218	29097-29103	lobule	_
149-219	29104-29117	Dysfunctional	_
149-220	29118-29126	striatal	_
149-221	29127-29134	systems	_
149-222	29135-29137	in	_
149-223	29138-29157	treatment-resistant	_
149-224	29158-29171	schizophrenia	_
149-225	29172-29182	Functional	_
149-226	29183-29196	heterogeneity	_
149-227	29197-29199	of	_
149-228	29200-29208	inferior	_
149-229	29209-29217	parietal	_
149-230	29218-29224	cortex	_
149-231	29225-29231	during	_
149-232	29232-29244	mathematical	_
149-233	29245-29254	cognition	_
149-234	29255-29263	assessed	_
149-235	29264-29268	with	_
149-236	29269-29286	cytoarchitectonic	_
149-237	29287-29298	probability	_
149-238	29299-29303	maps	_
149-239	29304-29312	Parietal	_
149-240	29313-29318	lobes	_
149-241	29319-29321	in	_
149-242	29322-29335	schizophrenia	_
149-243	29335-29336	:	_
149-244	29337-29339	do	_
149-245	29340-29344	they	_
149-246	29345-29351	matter	_
149-247	29351-29352	?	_

#Text=Disrupted axonal fiber connectivity in schizophrenia
#Text=Gerstmann's syndrome in acute stroke patients
#Text=Supplementary data
#Text=Supplementary Figures
#Text=Supplementary figures
#Text=Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nicl.2016.05.021.
150-1	29353-29362	Disrupted	_
150-2	29363-29369	axonal	_
150-3	29370-29375	fiber	_
150-4	29376-29388	connectivity	_
150-5	29389-29391	in	_
150-6	29392-29405	schizophrenia	_
150-7	29406-29417	Gerstmann's	_
150-8	29418-29426	syndrome	_
150-9	29427-29429	in	_
150-10	29430-29435	acute	_
150-11	29436-29442	stroke	_
150-12	29443-29451	patients	_
150-13	29452-29465	Supplementary	_
150-14	29466-29470	data	_
150-15	29471-29484	Supplementary	_
150-16	29485-29492	Figures	_
150-17	29493-29506	Supplementary	_
150-18	29507-29514	figures	_
150-19	29515-29528	Supplementary	_
150-20	29529-29533	data	_
150-21	29534-29536	to	_
150-22	29537-29541	this	_
150-23	29542-29549	article	_
150-24	29550-29553	can	_
150-25	29554-29556	be	_
150-26	29557-29562	found	_
150-27	29563-29569	online	_
150-28	29570-29572	at	_
150-29	29573-29577	http	_
150-30	29577-29578	:	_
150-31	29578-29579	/	_
150-32	29579-29580	/	_
150-33	29580-29590	dx.doi.org	_
150-34	29590-29591	/	_
150-35	29591-29598	10.1016	_
150-36	29598-29599	/	_
150-37	29599-29605	j.nicl	_
150-38	29605-29617	.2016.05.021	_
150-39	29617-29618	.	_

#Text=Illustration of subregions of the inferior parietal lobule.
151-1	29619-29631	Illustration	_
151-2	29632-29634	of	_
151-3	29635-29645	subregions	_
151-4	29646-29648	of	_
151-5	29649-29652	the	_
151-6	29653-29661	inferior	_
151-7	29662-29670	parietal	_
151-8	29671-29677	lobule	_
151-9	29677-29678	.	_

#Text=Fig. 1
#Text=The rsFC map of each IPL subregion within each group.
152-1	29679-29682	Fig	_
152-2	29682-29683	.	_
152-3	29684-29685	1	_
152-4	29686-29689	The	_
152-5	29690-29694	rsFC	_
152-6	29695-29698	map	_
152-7	29699-29701	of	_
152-8	29702-29706	each	_
152-9	29707-29710	IPL	_
152-10	29711-29720	subregion	_
152-11	29721-29727	within	_
152-12	29728-29732	each	_
152-13	29733-29738	group	_
152-14	29738-29739	.	_

#Text=Only the positive rsFC map of each subregion of the IPL of each group is depicted (P < 0.01, FDR corrected, two-tailed).
153-1	29740-29744	Only	_
153-2	29745-29748	the	_
153-3	29749-29757	positive	_
153-4	29758-29762	rsFC	_
153-5	29763-29766	map	_
153-6	29767-29769	of	_
153-7	29770-29774	each	_
153-8	29775-29784	subregion	_
153-9	29785-29787	of	_
153-10	29788-29791	the	_
153-11	29792-29795	IPL	_
153-12	29796-29798	of	_
153-13	29799-29803	each	_
153-14	29804-29809	group	_
153-15	29810-29812	is	_
153-16	29813-29821	depicted	_
153-17	29822-29823	(	_
153-18	29823-29824	P	_
153-19	29824-29825	 	_
153-20	29825-29826	<	_
153-21	29826-29827	 	_
153-22	29827-29831	0.01	_
153-23	29831-29832	,	_
153-24	29833-29836	FDR	_
153-25	29837-29846	corrected	_
153-26	29846-29847	,	_
153-27	29848-29858	two-tailed	_
153-28	29858-29859	)	_
153-29	29859-29860	.	_

#Text=Abbreviations: FDR, false discovery rate; HC, healthy controls; IPL, inferior parietal lobule; L, left; R, right; rsFC, resting-state functional connectivity; SZ, schizophrenia patients.
154-1	29861-29874	Abbreviations	_
154-2	29874-29875	:	_
154-3	29876-29879	FDR	_
154-4	29879-29880	,	_
154-5	29881-29886	false	_
154-6	29887-29896	discovery	_
154-7	29897-29901	rate	_
154-8	29901-29902	;	_
154-9	29903-29905	HC	_
154-10	29905-29906	,	_
154-11	29907-29914	healthy	_
154-12	29915-29923	controls	_
154-13	29923-29924	;	_
154-14	29925-29928	IPL	_
154-15	29928-29929	,	_
154-16	29930-29938	inferior	_
154-17	29939-29947	parietal	_
154-18	29948-29954	lobule	_
154-19	29954-29955	;	_
154-20	29956-29957	L	_
154-21	29957-29958	,	_
154-22	29959-29963	left	_
154-23	29963-29964	;	_
154-24	29965-29966	R	_
154-25	29966-29967	,	_
154-26	29968-29973	right	_
154-27	29973-29974	;	_
154-28	29975-29979	rsFC	_
154-29	29979-29980	,	_
154-30	29981-29994	resting-state	_
154-31	29995-30005	functional	_
154-32	30006-30018	connectivity	_
154-33	30018-30019	;	_
154-34	30020-30022	SZ	_
154-35	30022-30023	,	_
154-36	30024-30037	schizophrenia	_
154-37	30038-30046	patients	_
154-38	30046-30047	.	_

#Text=Fig. 2
#Text=The rsFC differences of the IPL subregions between schizophrenia patients and healthy controls.
155-1	30048-30051	Fig	_
155-2	30051-30052	.	_
155-3	30053-30054	2	_
155-4	30055-30058	The	_
155-5	30059-30063	rsFC	_
155-6	30064-30075	differences	_
155-7	30076-30078	of	_
155-8	30079-30082	the	_
155-9	30083-30086	IPL	_
155-10	30087-30097	subregions	_
155-11	30098-30105	between	_
155-12	30106-30119	schizophrenia	_
155-13	30120-30128	patients	_
155-14	30129-30132	and	_
155-15	30133-30140	healthy	_
155-16	30141-30149	controls	_
155-17	30149-30150	.	_

#Text=Column A shows results using a threshold of P < 0.05/11 = 0.0045 (FDR corrected, two-tailed).
156-1	30151-30157	Column	_
156-2	30158-30159	A	_
156-3	30160-30165	shows	_
156-4	30166-30173	results	_
156-5	30174-30179	using	_
156-6	30180-30181	a	_
156-7	30182-30191	threshold	_
156-8	30192-30194	of	_
156-9	30195-30196	P	_
156-10	30196-30197	 	_
156-11	30197-30198	<	_
156-12	30198-30199	 	_
156-13	30199-30203	0.05	_
156-14	30203-30204	/	_
156-15	30204-30206	11	_
156-16	30206-30207	 	_
156-17	30207-30208	=	_
156-18	30208-30209	 	_
156-19	30209-30215	0.0045	_
156-20	30216-30217	(	_
156-21	30217-30220	FDR	_
156-22	30221-30230	corrected	_
156-23	30230-30231	,	_
156-24	30232-30242	two-tailed	_
156-25	30242-30243	)	_
156-26	30243-30244	.	_

#Text=Columns B and C show results using P < 0.01 (FDR corrected, two-tailed).
157-1	30245-30252	Columns	_
157-2	30253-30254	B	_
157-3	30255-30258	and	_
157-4	30259-30260	C	_
157-5	30261-30265	show	_
157-6	30266-30273	results	_
157-7	30274-30279	using	_
157-8	30280-30281	P	_
157-9	30281-30282	 	_
157-10	30282-30283	<	_
157-11	30283-30284	 	_
157-12	30284-30288	0.01	_
157-13	30289-30290	(	_
157-14	30290-30293	FDR	_
157-15	30294-30303	corrected	_
157-16	30303-30304	,	_
157-17	30305-30315	two-tailed	_
157-18	30315-30316	)	_
157-19	30316-30317	.	_

#Text=Abbreviations: B, bilateral; FDR, false discovery rate; HC, healthy controls; IOG, inferior occipital gyrus; L, left; LG, lingual gyrus; MCC, mid-cingulate cortex; R, right; SMC, sensorimotor cortex; SZ, schizophrenia patients.
158-1	30318-30331	Abbreviations	_
158-2	30331-30332	:	_
158-3	30333-30334	B	_
158-4	30334-30335	,	_
158-5	30336-30345	bilateral	_
158-6	30345-30346	;	_
158-7	30347-30350	FDR	_
158-8	30350-30351	,	_
158-9	30352-30357	false	_
158-10	30358-30367	discovery	_
158-11	30368-30372	rate	_
158-12	30372-30373	;	_
158-13	30374-30376	HC	_
158-14	30376-30377	,	_
158-15	30378-30385	healthy	_
158-16	30386-30394	controls	_
158-17	30394-30395	;	_
158-18	30396-30399	IOG	_
158-19	30399-30400	,	_
158-20	30401-30409	inferior	_
158-21	30410-30419	occipital	_
158-22	30420-30425	gyrus	_
158-23	30425-30426	;	_
158-24	30427-30428	L	_
158-25	30428-30429	,	_
158-26	30430-30434	left	_
158-27	30434-30435	;	_
158-28	30436-30438	LG	_
158-29	30438-30439	,	_
158-30	30440-30447	lingual	_
158-31	30448-30453	gyrus	_
158-32	30453-30454	;	_
158-33	30455-30458	MCC	_
158-34	30458-30459	,	_
158-35	30460-30473	mid-cingulate	_
158-36	30474-30480	cortex	_
158-37	30480-30481	;	_
158-38	30482-30483	R	_
158-39	30483-30484	,	_
158-40	30485-30490	right	_
158-41	30490-30491	;	_
158-42	30492-30495	SMC	_
158-43	30495-30496	,	_
158-44	30497-30509	sensorimotor	_
158-45	30510-30516	cortex	_
158-46	30516-30517	;	_
158-47	30518-30520	SZ	_
158-48	30520-30521	,	_
158-49	30522-30535	schizophrenia	_
158-50	30536-30544	patients	_
158-51	30544-30545	.	_

#Text=Fig. 3
#Text=Demographic and clinical information for subjects.
159-1	30546-30549	Fig	_
159-2	30549-30550	.	_
159-3	30551-30552	3	_
159-4	30553-30564	Demographic	_
159-5	30565-30568	and	_
159-6	30569-30577	clinical	_
159-7	30578-30589	information	_
159-8	30590-30593	for	_
159-9	30594-30602	subjects	_
159-10	30602-30603	.	_

#Text=Table 1\t \t
#Text=\tSchizophrenia patients (n = 95)\tHealthy controls (n = 104)\tt/χ2\tP value\t \tAge (years)\t34.1 ± 9.2\t33.8 ± 10.9\tt = 0.22\t0.83\t \tGender (male/female)\t53/42\t46/58\tχ2 = 2.65\t0.10\t \tDuration of illness (months)\t123.0 ± 103.6\t–\t\t–\t \tPNSS\t\t\t\t\t \t Positive subscore\t16.83 ± 7.83\t–\t\t–\t \t Negative subscore\t20.20 ± 8.74\t–\t\t–\t \t General subscore\t70.04 ± 22.77\t–\t\t–\t \tCurrent antipsychotic dosage (chlorpromazine equivalents) (mg/d)\t452.97 ± 361.40\t\t\t–\t \t
#Text=Data are shown as mean ± SD.
160-1	30604-30609	Table	_
160-2	30610-30611	1	_
160-3	30616-30629	Schizophrenia	_
160-4	30630-30638	patients	_
160-5	30639-30640	(	_
160-6	30640-30641	n	_
160-7	30641-30642	 	_
160-8	30642-30643	=	_
160-9	30643-30644	 	_
160-10	30644-30646	95	_
160-11	30646-30647	)	_
160-12	30648-30655	Healthy	_
160-13	30656-30664	controls	_
160-14	30665-30666	(	_
160-15	30666-30667	n	_
160-16	30667-30668	 	_
160-17	30668-30669	=	_
160-18	30669-30670	 	_
160-19	30670-30673	104	_
160-20	30673-30674	)	_
160-21	30675-30676	t	_
160-22	30676-30677	/	_
160-23	30677-30679	χ2	_
160-24	30680-30681	P	_
160-25	30682-30687	value	_
160-26	30690-30693	Age	_
160-27	30694-30695	(	_
160-28	30695-30700	years	_
160-29	30700-30701	)	_
160-30	30702-30706	34.1	_
160-31	30706-30707	 	_
160-32	30707-30708	±	_
160-33	30708-30709	 	_
160-34	30709-30712	9.2	_
160-35	30713-30717	33.8	_
160-36	30717-30718	 	_
160-37	30718-30719	±	_
160-38	30719-30720	 	_
160-39	30720-30724	10.9	_
160-40	30725-30726	t	_
160-41	30726-30727	 	_
160-42	30727-30728	=	_
160-43	30728-30729	 	_
160-44	30729-30733	0.22	_
160-45	30734-30738	0.83	_
160-46	30741-30747	Gender	_
160-47	30748-30749	(	_
160-48	30749-30753	male	_
160-49	30753-30754	/	_
160-50	30754-30760	female	_
160-51	30760-30761	)	_
160-52	30762-30764	53	_
160-53	30764-30765	/	_
160-54	30765-30767	42	_
160-55	30768-30770	46	_
160-56	30770-30771	/	_
160-57	30771-30773	58	_
160-58	30774-30776	χ2	_
160-59	30776-30777	 	_
160-60	30777-30778	=	_
160-61	30778-30779	 	_
160-62	30779-30783	2.65	_
160-63	30784-30788	0.10	_
160-64	30791-30799	Duration	_
160-65	30800-30802	of	_
160-66	30803-30810	illness	_
160-67	30811-30812	(	_
160-68	30812-30818	months	_
160-69	30818-30819	)	_
160-70	30820-30825	123.0	_
160-71	30825-30826	 	_
160-72	30826-30827	±	_
160-73	30827-30828	 	_
160-74	30828-30833	103.6	_
160-75	30834-30835	–	_
160-76	30837-30838	–	_
160-77	30841-30845	PNSS	_
160-78	30852-30853	 	_
160-79	30853-30861	Positive	_
160-80	30862-30870	subscore	_
160-81	30871-30876	16.83	_
160-82	30876-30877	 	_
160-83	30877-30878	±	_
160-84	30878-30879	 	_
160-85	30879-30883	7.83	_
160-86	30884-30885	–	_
160-87	30887-30888	–	_
160-88	30891-30892	 	_
160-89	30892-30900	Negative	_
160-90	30901-30909	subscore	_
160-91	30910-30915	20.20	_
160-92	30915-30916	 	_
160-93	30916-30917	±	_
160-94	30917-30918	 	_
160-95	30918-30922	8.74	_
160-96	30923-30924	–	_
160-97	30926-30927	–	_
160-98	30930-30931	 	_
160-99	30931-30938	General	_
160-100	30939-30947	subscore	_
160-101	30948-30953	70.04	_
160-102	30953-30954	 	_
160-103	30954-30955	±	_
160-104	30955-30956	 	_
160-105	30956-30961	22.77	_
160-106	30962-30963	–	_
160-107	30965-30966	–	_
160-108	30969-30976	Current	_
160-109	30977-30990	antipsychotic	_
160-110	30991-30997	dosage	_
160-111	30998-30999	(	_
160-112	30999-31013	chlorpromazine	_
160-113	31014-31025	equivalents	_
160-114	31025-31026	)	_
160-115	31027-31028	(	_
160-116	31028-31030	mg	_
160-117	31030-31031	/	_
160-118	31031-31032	d	_
160-119	31032-31033	)	_
160-120	31034-31040	452.97	_
160-121	31040-31041	 	_
160-122	31041-31042	±	_
160-123	31042-31043	 	_
160-124	31043-31049	361.40	_
160-125	31052-31053	–	_
160-126	31057-31061	Data	_
160-127	31062-31065	are	_
160-128	31066-31071	shown	_
160-129	31072-31074	as	_
160-130	31075-31079	mean	_
160-131	31079-31080	 	_
160-132	31080-31081	±	_
160-133	31081-31082	 	_
160-134	31082-31084	SD	_
160-135	31084-31085	.	_

#Text=Abbreviations: PNSS, positive and negative syndrome scale.
161-1	31086-31099	Abbreviations	_
161-2	31099-31100	:	_
161-3	31101-31105	PNSS	_
161-4	31105-31106	,	_
161-5	31107-31115	positive	_
161-6	31116-31119	and	_
161-7	31120-31128	negative	_
161-8	31129-31137	syndrome	_
161-9	31138-31143	scale	_
161-10	31143-31144	.	_

#Text=Brain regions with increased rsFC with the IPL subregions in schizophrenia patients.
162-1	31145-31150	Brain	_
162-2	31151-31158	regions	_
162-3	31159-31163	with	_
162-4	31164-31173	increased	_
162-5	31174-31178	rsFC	_
162-6	31179-31183	with	_
162-7	31184-31187	the	_
162-8	31188-31191	IPL	_
162-9	31192-31202	subregions	_
162-10	31203-31205	in	_
162-11	31206-31219	schizophrenia	_
162-12	31220-31228	patients	_
162-13	31228-31229	.	_

#Text=Table 2\t \t
#Text=Seed regions\tConnected regions\tMNI coordinates\tP < 0.05/5 = 0.01 (FDR correction)\tP < 0.05/11 = 0.0045 (FDR correction)\t \tx\ty\tz\tPeak t value\tCluster size (voxels)\tPeak t value\tCluster size (voxels)\t \tL.
163-1	31230-31235	Table	_
163-2	31236-31237	2	_
163-3	31241-31245	Seed	_
163-4	31246-31253	regions	_
163-5	31254-31263	Connected	_
163-6	31264-31271	regions	_
163-7	31272-31275	MNI	_
163-8	31276-31287	coordinates	_
163-9	31288-31289	P	_
163-10	31289-31290	 	_
163-11	31290-31291	<	_
163-12	31291-31292	 	_
163-13	31292-31296	0.05	_
163-14	31296-31297	/	_
163-15	31297-31298	5	_
163-16	31298-31299	 	_
163-17	31299-31300	=	_
163-18	31300-31301	 	_
163-19	31301-31305	0.01	_
163-20	31306-31307	(	_
163-21	31307-31310	FDR	_
163-22	31311-31321	correction	_
163-23	31321-31322	)	_
163-24	31323-31324	P	_
163-25	31324-31325	 	_
163-26	31325-31326	<	_
163-27	31326-31327	 	_
163-28	31327-31331	0.05	_
163-29	31331-31332	/	_
163-30	31332-31334	11	_
163-31	31334-31335	 	_
163-32	31335-31336	=	_
163-33	31336-31337	 	_
163-34	31337-31343	0.0045	_
163-35	31344-31345	(	_
163-36	31345-31348	FDR	_
163-37	31349-31359	correction	_
163-38	31359-31360	)	_
163-39	31363-31364	x	_
163-40	31365-31366	y	_
163-41	31367-31368	z	_
163-42	31369-31373	Peak	_
163-43	31374-31375	t	_
163-44	31376-31381	value	_
163-45	31382-31389	Cluster	_
163-46	31390-31394	size	_
163-47	31395-31396	(	_
163-48	31396-31402	voxels	_
163-49	31402-31403	)	_
163-50	31404-31408	Peak	_
163-51	31409-31410	t	_
163-52	31411-31416	value	_
163-53	31417-31424	Cluster	_
163-54	31425-31429	size	_
163-55	31430-31431	(	_
163-56	31431-31437	voxels	_
163-57	31437-31438	)	_
163-58	31441-31442	L	_
163-59	31442-31443	.	_

#Text=PFm\tL.
164-1	31444-31447	PFm	_
164-2	31448-31449	L	_
164-3	31449-31450	.	_

#Text=LG\t− 15\t− 48\t− 12\t4.95\t57\t–\t–\t \tR.
165-1	31451-31453	LG	_
165-2	31454-31455	−	_
165-3	31455-31456	 	_
165-4	31456-31458	15	_
165-5	31459-31460	−	_
165-6	31460-31461	 	_
165-7	31461-31463	48	_
165-8	31464-31465	−	_
165-9	31465-31466	 	_
165-10	31466-31468	12	_
165-11	31469-31473	4.95	_
165-12	31474-31476	57	_
165-13	31477-31478	–	_
165-14	31479-31480	–	_
165-15	31483-31484	R	_
165-16	31484-31485	.	_

#Text=LG\t6\t− 60\t− 3\t4.63\t52\t–\t–\t \tR.
166-1	31486-31488	LG	_
166-2	31489-31490	6	_
166-3	31491-31492	−	_
166-4	31492-31493	 	_
166-5	31493-31495	60	_
166-6	31496-31497	−	_
166-7	31497-31498	 	_
166-8	31498-31499	3	_
166-9	31500-31504	4.63	_
166-10	31505-31507	52	_
166-11	31508-31509	–	_
166-12	31510-31511	–	_
166-13	31514-31515	R	_
166-14	31515-31516	.	_

#Text=PFm\tR.
167-1	31517-31520	PFm	_
167-2	31521-31522	R	_
167-3	31522-31523	.	_

#Text=LG\t18\t− 57\t− 9\t4.82\t75\t–\t–\t \tR.
168-1	31524-31526	LG	_
168-2	31527-31529	18	_
168-3	31530-31531	−	_
168-4	31531-31532	 	_
168-5	31532-31534	57	_
168-6	31535-31536	−	_
168-7	31536-31537	 	_
168-8	31537-31538	9	_
168-9	31539-31543	4.82	_
168-10	31544-31546	75	_
168-11	31547-31548	–	_
168-12	31549-31550	–	_
168-13	31553-31554	R	_
168-14	31554-31555	.	_

#Text=IOG\t30\t− 87\t0\t4.98\t69\t–\t–\t \tB.
169-1	31556-31559	IOG	_
169-2	31560-31562	30	_
169-3	31563-31564	−	_
169-4	31564-31565	 	_
169-5	31565-31567	87	_
169-6	31568-31569	0	_
169-7	31570-31574	4.98	_
169-8	31575-31577	69	_
169-9	31578-31579	–	_
169-10	31580-31581	–	_
169-11	31584-31585	B	_
169-12	31585-31586	.	_

#Text=MCC\t− 6\t− 3\t39\t4.24\t37\t–\t–\t \tB.
170-1	31587-31590	MCC	_
170-2	31591-31592	−	_
170-3	31592-31593	 	_
170-4	31593-31594	6	_
170-5	31595-31596	−	_
170-6	31596-31597	 	_
170-7	31597-31598	3	_
170-8	31599-31601	39	_
170-9	31602-31606	4.24	_
170-10	31607-31609	37	_
170-11	31610-31611	–	_
170-12	31612-31613	–	_
170-13	31616-31617	B	_
170-14	31617-31618	.	_

#Text=SMC\t3\t− 30\t60\t5.57\t507\t5.57\t60\t \t
#Text=Abbreviations: B, bilateral; FDR, false discovery rate; IPL, inferior parietal lobe; L, left; LG, Lingual gyrus; IOG, inferior occipital gyrus, MCC, mid-cingulate cortex; MNI, Montreal Neurological Institute; R, right; rsFC, resting-state functional connectivity; SMC, sensorimotor cortex
171-1	31619-31622	SMC	_
171-2	31623-31624	3	_
171-3	31625-31626	−	_
171-4	31626-31627	 	_
171-5	31627-31629	30	_
171-6	31630-31632	60	_
171-7	31633-31637	5.57	_
171-8	31638-31641	507	_
171-9	31642-31646	5.57	_
171-10	31647-31649	60	_
171-11	31653-31666	Abbreviations	_
171-12	31666-31667	:	_
171-13	31668-31669	B	_
171-14	31669-31670	,	_
171-15	31671-31680	bilateral	_
171-16	31680-31681	;	_
171-17	31682-31685	FDR	_
171-18	31685-31686	,	_
171-19	31687-31692	false	_
171-20	31693-31702	discovery	_
171-21	31703-31707	rate	_
171-22	31707-31708	;	_
171-23	31709-31712	IPL	_
171-24	31712-31713	,	_
171-25	31714-31722	inferior	_
171-26	31723-31731	parietal	_
171-27	31732-31736	lobe	_
171-28	31736-31737	;	_
171-29	31738-31739	L	_
171-30	31739-31740	,	_
171-31	31741-31745	left	_
171-32	31745-31746	;	_
171-33	31747-31749	LG	_
171-34	31749-31750	,	_
171-35	31751-31758	Lingual	_
171-36	31759-31764	gyrus	_
171-37	31764-31765	;	_
171-38	31766-31769	IOG	_
171-39	31769-31770	,	_
171-40	31771-31779	inferior	_
171-41	31780-31789	occipital	_
171-42	31790-31795	gyrus	_
171-43	31795-31796	,	_
171-44	31797-31800	MCC	_
171-45	31800-31801	,	_
171-46	31802-31815	mid-cingulate	_
171-47	31816-31822	cortex	_
171-48	31822-31823	;	_
171-49	31824-31827	MNI	_
171-50	31827-31828	,	_
171-51	31829-31837	Montreal	_
171-52	31838-31850	Neurological	_
171-53	31851-31860	Institute	_
171-54	31860-31861	;	_
171-55	31862-31863	R	_
171-56	31863-31864	,	_
171-57	31865-31870	right	_
171-58	31870-31871	;	_
171-59	31872-31876	rsFC	_
171-60	31876-31877	,	_
171-61	31878-31891	resting-state	_
171-62	31892-31902	functional	_
171-63	31903-31915	connectivity	_
171-64	31915-31916	;	_
171-65	31917-31920	SMC	_
171-66	31920-31921	,	_
171-67	31922-31934	sensorimotor	_
171-68	31935-31941	cortex	_
